CUMULATIVE SUPPLEMENT 7
July 2012



APPROVED DRUG PRODUCTS

WITH THERAPEUTIC EQUIVALENCE EVALUATIONS

32nd EDITION

Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research
Office of Generic Drugs

2012

Prepared By
Office of Generic Drugs
Center for Drug Evaluation and Research
Food and Drug Administration

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

32nd EDITION

Cumulative Supplement 7

July 2012

CONTENTS

PAGE

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

32nd EDITION

CUMULATIVE SUPPLEMENT 7
July 2012

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 30th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; over-the-counter (OTC) drug products that require approved applications as a condition of marketing; drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research; and products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, or have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of the 32nd Edition List will then be added to the "Discontinued Drug Product List" appearing in the 33rd Edition. The current Edition Section 2., How To Use The Drug Product Lists, describes the layout and usage of the List.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >**A**>. The Patent and Exclusivity List new additions are indicated by the symbol **>A>** to the left of Patent Number or Exclusivity Code. The **>A>** symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol **>D>** (DELETE) to the left of the line. The information line with the **>D>** symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month’s second work week (e.g., November’s supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.

- All product changes received and processed as of the date of publication.
  - o Refer to CS Section 1.8 Cumulative Supplement Legend for types of changes
  - o Discontinued products will be processed as of the date of publication. There will be circumstances where a product is discontinued in one month, however, it will be reported in a different month's CS. For example, the Orange Book Staff received a letter November 7 that the product has been discontinued from manufacturing and marketing. The Orange Book subsequently publishes the October CS on November 14. The product will show in the October CS that it is discontinued even though the date of discontinuance is the day that the Orange Book Staff receives notification (November 7).

- New Drug Application (NDA) approvals (20,000 and 50,000 series) appear in the CS month they were approved.

- Patent information, also updated daily in the EOB, is current to the date of publication.

- Exclusivity information is updated monthly and current to the date of publication.

Every effort is made to ensure the Cumulative Supplement is current and accurate. Applicant holders are requested to inform the FDA Orange Book Staff (OBS) of any changes or corrections. The OBS can be contacted by email at drugproducts@fda.hhs.gov. Send Changes by FAX: 240-276-8974; mail to:

FDA/CDER Orange Book Staff
Office of Generic Drugs, HFD-610
7620 Standish Place
Rockville, MD 20855-2773

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)	NEW APPLICANT NAME (NEW ABBREVIATED NAME)
ALCON UNIVERSAL LTD (ALCON UNIVERSAL)	ALCON PHARMACEUTICALS LTD (ALCON PHARMS LTD)
OVATION PHARMACEUTICALS INC (OVATION PHARMS)	OAK PHARMACEUTICALS INC (OAK PHARMS)

1.4 LEVOTHYROXINE SODIUM

Because there are multiple reference listed drugs of levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character TE codes may be potentially confusing and inadequate for these drug products. Accordingly, FDA provides the following explanation and chart of therapeutic equivalence evaluations for levothyroxine sodium drug products.

Levothyroxine Sodium (Mylan ANDA 76187) and Levo-T (Alara NDA 21342) tablets have been determined to be therapeutically equivalent to corresponding strengths of Unithroid (Jerome Stevens NDA 021210) tablets. Levo-T (Alara NDA 021342), Levothyroxine Sodium (Mylan ANDA 76187), Unithroid (Jerome Stevens NDA 021210), and Levothyroxine Sodium (Merck KGAA ANDA 76752)tablets have been determined to be therapeutically equivalent to corresponding strengths of Synthroid (Abbott NDA 021402) tablets.

Levo-T (Alara NDA 021342), Unithroid (Jerome Stevens NDA 021210), Levothyroxine Sodium (Mylan ANDA 076187), and Levothyroxine Sodium (Merck KGAA ANDA 76752) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levoxyl (King Pharms NDA 021301) tablets.

Levothyroxine Sodium (Mylan ANDA 76187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levothroid (Lloyd NDA 021116) tablets.

The chart outlines TE codes for all 0.025mg products. Other product strengths may be similar. Therapeutic equivalence has been established between products that have the same AB+number TE code. More than one TE code may apply to some products. One common TE code indicates therapeutic equivalence between products.

Trade Name	Applicant	Potency	TE Code	Appl No	Product No
UNITHROID	STEVENS J	0.025MG	AB1	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB1	76187	001
LEVOXYL	KING PHARMS	0.025MG	AB1	21301	001
SYNTHROID	ABBOTT	0.025MG	AB1	21402	001
LEVO-T	ALARA PHARM	0.025MG	AB1	21342	001
SYNTHROID	ABBOTT	0.025MG	AB2	21402	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB2	76187	001
LEVO-T	ALARA PHARM	0.025MG	AB2	21342	001
UNITHROID	STEVENS J	0.025MG	AB2	21210	001
LEVOTHYROXINE SODIUM	MERCK KGAA	0.025MG	AB2	76752	001
LEVOXYL	KUNG PHARMS	0.025MG	AB3	21301	001
LEVO-T	ALARA PHARM	0.025MG	AB3	21342	001
UNITHROID	STEVENS J	0.025MG	AB3	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB3	76187	001
LEVOTHYROXINE SODIUM	MERCK KGAA	0.025MG	AB3	76752	001
LEVOTHROID	LLOYD	0.025MG	AB4	21116	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB4	76187	001

1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: http://bookstore.gpo.gov; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, http://www.fda.gov/opacom/morechoices/fdaforms/default.html.

The current listing of the Orphan Product Designations and Approvals is available at http://www.fda.gov/orphan/designat/list.htm.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 2011) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use

in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST
COUNTS CUMULATIVE BY QUARTER

CATEGORIES COUNTED	DEC 2011	MAR 2012	JUN 2012	SEPT 2012	DEC 2012
DRUG PRODUCTS LISTED	14480	14711	14834		
SINGLE SOURCE	2451 (16.9%)	2446 (16.6%)	2428 (16.4%)		
MULTISOURCE	11953 (82.5%)	12187 (82.8%)	12328 (83.1%)		
THERAPEUTICALLY EQUIVALENT	11792 (81.4%)	12037 (81.8%)	12187 (82.2%)		
NOT THERAPEUTICALLY EQUIVALENT	161 (1.1%)	150 (1.0%)	141 (1.0%)		
EXCEPTIONS[1]	76 (0.5%)	78 (0.5%)	78 (0.5%)		
NEW MOLECULAR ENTITIES APPROVED	6	8	7		
NUMBER OF APPLICANTS	810	826	826		

[1]Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route and then by trade name.

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by “N” is a New Drug Application (NDA or innovator). The application number preceded by an “A” is an Abbreviated New Drug Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form; route(s), new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be proceeded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN	Applicant holder firm name has changed.
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.

CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.

ABACAVIR SULFATE

TABLET; ORAL

		ABACAVIR SULFATE						
AB		MYLAN PHARMS INC	EQ 300MG BASE	A091294	001	Jun 18, 2012	Jun	NEWA
		ZIAGEN						
AB	+	VIIV HLTHCARE	EQ 300MG BASE	N020977	001	Dec 17, 1998	Jun	CFTG

ACARBOSE

TABLET; ORAL

		ACARBOSE						
AB		EMCURE PHARMS LTD	25MG	A202271	001	Feb 07, 2012	Jan	NEWA
AB			50MG	A202271	002	Feb 07, 2012	Jan	NEWA
AB			100MG	A202271	003	Feb 07, 2012	Jan	NEWA

ACETAMINOPHEN; BUTALBITAL

TABLET; ORAL

		BUTAPAP						
	+	MIKART	325MG;50MG	A089987	001	Oct 26, 1992	Jun	CRLD
		PHRENILIN						
		@ VALEANT	325MG;50MG	A087811	001	Jun 19, 1985	Jun	DISC

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL

		BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE						
>A>		NEXGEN PHARMA INC	300MG;50MG;40MG;30MG	A076560	002	Jul 19, 2012	Jul	NEWA

ACETAMINOPHEN; CODEINE PHOSPHATE

SOLUTION; ORAL

		ACETAMINOPHEN AND CODEINE PHOSPHATE						
AA	+	PHARM ASSOC	120MG/5ML;12MG/5ML	A087508	001		Jan	CRLD

SUSPENSION; ORAL

		CAPITAL AND CODEINE						
	+	VALEANT	120MG/5ML;12MG/5ML	A086024	001		Jan	CTEC
	+	VALEANT PHARMS LLC	120MG/5ML;12MG/5ML	A086024	001		Jun	CAHN

ACETAMINOPHEN; HYDROCODONE BITARTRATE

SOLUTION; ORAL

		HYDROCODONE BITARTRATE AND ACETAMINOPHEN						
		@ NESHER PHARMS	500MG/15ML;7.5MG/15ML	A040366	001	Jan 23, 2002	Jun	DISC
AA		VISTAPHARM	325MG/15ML;7.5MG/15ML	A200343	001	Jan 25, 2012	Jan	NEWA

TABLET; ORAL

		HYDROCODONE BITARTRATE AND ACETAMINOPHEN						
AA		AUROLIFE PHARMA LLC	325MG;5MG	A201013	001	Apr 11, 2012	Mar	NEWA
AA			325MG;7.5MG	A201013	002	Apr 11, 2012	Mar	NEWA
AA			325MG;10MG	A201013	003	Apr 11, 2012	Mar	NEWA

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

TABLET; ORAL

		OXYCODONE AND ACETAMINOPHEN						
AA		ACTAVIS TOTOWA	325MG;7.5MG	A040800	001	Apr 03, 2012	Mar	NEWA
AA			325MG;10MG	A040800	002	Apr 03, 2012	Mar	NEWA
>A> AA		ALVOGEN INC	325MG;7.5MG	A202677	001	Jul 26, 2012	Jul	NEWA
>A> AA			325MG;10MG	A202677	002	Jul 26, 2012	Jul	NEWA

ACETAMINOPHEN; TRAMADOL HYDROCHLORIDE

TABLET; ORAL
TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN

AB		ALVOGEN INC	325MG;37.5MG	A202076	001	Mar 30, 2012	Mar	NEWA

ACETAZOLAMIDE SODIUM

INJECTABLE; INJECTION
ACETAZOLAMIDE SODIUM

AP		SAGENT STRIDES	EQ 500MG BASE/VIAL	A200880	001	May 09, 2012	Apr	NEWA
AP	+	X GEN PHARMS	EQ 500MG BASE/VIAL	A040784	001	Dec 10, 2008	Apr	CRLD

DIAMOX

	@	TEVA WOMENS	EQ 500MG BASE/VIAL	N009388	001	Dec 05, 1990	Apr	DISC

ACETYLCYSTEINE

SOLUTION; INHALATION, ORAL
ACETYLCYSTEINE

AN		INNOPHARMA INC	20%	A203853	001	Jun 21, 2012	Jun	NEWA

>A> ACLIDINIUM BROMIDE

>A> POWDER, METERED; INHALATION
>A> TUDORZA PRESSAIR

>A>	+	FOREST LABS INC	0.375MG/INH	N202450	001	Jul 23, 2012	Jul	NEWA

ACYCLOVIR

CAPSULE; ORAL
ACYCLOVIR

	@	HERITAGE PHARMS INC	200MG	A074889	001	Oct 31, 1997	May	CAHN

TABLET; ORAL
ACYCLOVIR

	@	HERITAGE PHARMS INC	400MG	A074891	001	Oct 31, 1997	May	CAHN
	@		800MG	A074891	002	Oct 31, 1997	May	CAHN

ADAPALENE

CREAM; TOPICAL
ADAPALENE

AB		FOUGERA PHARMS	0.1%	A090824	001	Jun 30, 2010	Jan	CAHN

GEL; TOPICAL
ADAPALENE

AB		TOLMAR	0.3%	A200298	001	Jun 14, 2012	Jun	NEWA

DIFFERIN

AB	+	GALDERMA LABS LP	0.3%	N021753	001	Jun 19, 2007	Jun	CFTG

LOTION; TOPICAL
DIFFERIN

	+	GALDERMA LABS LP	0.1%	N022502	001	Mar 17, 2010	Apr	CAHN

ADENOSINE

INJECTABLE; INJECTION
ADENOSINE

	@	TEVA PARENTERAL	3MG/ML	A078676	001	Jul 31, 2008	Mar	DISC
	@		3MG/ML	A076564	001	Jun 16, 2004	Jan	DISC

ALBUTEROL SULFATE; IPRATROPIUM BROMIDE

SOLUTION; INHALATION
ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE

	@	SANDOZ INC	EQ 0.083% BASE;0.017%	A076867	001	Dec 21, 2006	Apr	DISC

ALCLOMETASONE DIPROPIONATE

CREAM; TOPICAL
ALCLOMETASONE DIPROPIONATE

	AB		FOUGERA PHARMS	0.05%	A076973	001	Jul 12, 2005	Jan	CAHN

OINTMENT; TOPICAL
ALCLOMETASONE DIPROPIONATE

	AB		FOUGERA PHARMS	0.05%	A076884	001	Jul 18, 2005	Jan	CAHN

ALENDRONATE SODIUM

TABLET, EFFERVESCENT; ORAL
BINOSTO

		+	MISSION PHARMA	EQ 70MG BASE	N202344	001	Mar 12, 2012	Mar	NEWA

ALFUZOSIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
ALFUZOSIN HYDROCHLORIDE

	AB		INVAGEN PHARMS	10MG	A090284	001	Jan 17, 2012	Jan	NEWA
>A>	AB		WOCKHARDT LTD	10MG	A090221	001	Aug 10, 2012	Jul	NEWA

ALGLUCERASE

INJECTABLE; INJECTION
CEREDASE

			@ GENZYME	80 UNITS/ML	N020057	003	Apr 05, 1991	Mar	DISC

ALPRAZOLAM

TABLET, EXTENDED RELEASE; ORAL
ALPRAZOLAM

			@ SANDOZ INC	0.5MG	A077777	001	Jun 30, 2006	Mar	DISC
			@	1MG	A077777	002	Jun 30, 2006	Mar	DISC
			@	2MG	A077777	003	Jun 30, 2006	Mar	DISC
			@	3MG	A077777	004	Jun 30, 2006	Mar	DISC
>D>	AB		VINTAGE	0.5MG	A078442	001	Oct 15, 2007	Jul	DISC
>D>	AB			1MG	A078442	002	Oct 15, 2007	Jul	DISC
>D>	AB			2MG	A078442	003	Oct 15, 2007	Jul	DISC
>D>	AB			3MG	A078442	004	Oct 15, 2007	Jul	DISC
>A>			@ VINTAGE PHARMS	0.5MG	A078442	001	Oct 15, 2007	Jul	DISC
>A>			@	1MG	A078442	002	Oct 15, 2007	Jul	DISC
>A>			@	2MG	A078442	003	Oct 15, 2007	Jul	DISC
>A>			@	3MG	A078442	004	Oct 15, 2007	Jul	DISC

TABLET, ORALLY DISINTEGRATING; ORAL
NIRAVAM

	AB		UCB INC	0.25MG	N021726	001	Jan 19, 2005	Jan	CAHN
	AB			0.5MG	N021726	002	Jan 19, 2005	Jan	CAHN
	AB	+		1MG	N021726	003	Jan 19, 2005	Jan	CAHN
	AB			2MG	N021726	004	Jan 19, 2005	Jan	CAHN

ALVIMOPAN

CAPSULE; ORAL
ENTEREG

		+	CUBIST PHARMS	12MG	N021775	001	May 20, 2008	Feb	CAHN

AMCINONIDE

CREAM; TOPICAL
AMCINONIDE

	AB	+	FOUGERA PHARMS	0.1%	A076065	001	May 15, 2003	Jan	CAHN

	LOTION; TOPICAL							
	AMCINONIDE							
	+ FOUGERA PHARMS	0.1%	A076329	001	Nov 06, 2002	Jan	CAHN	
	OINTMENT; TOPICAL							
	AMCINONIDE							
AB	+ FOUGERA PHARMS	0.1%	A076096	001	Nov 19, 2002	Jan	CAHN	
	AMIKACIN SULFATE							
	INJECTABLE; INJECTION							
	AMIKACIN SULFATE							
	@ HOSPIRA	EQ 50MG BASE/ML	A063263	001	Nov 30, 1994	Jun	DISC	
	AMINO ACIDS							
	INJECTABLE; INJECTION							
	AMINO ACIDS							
	B BRAUN	15%(300GM/2000ML)	A091112	002	Apr 13, 2012	Mar	NEWA	
		15%(150GM/1000ML)	A091112	001	Apr 13, 2012	Mar	NEWA	
	CLINISOL 15% SULFITE FREE IN PLASTIC CONTAINER							
	BAXTER HLTHCARE	15% (15GM/100ML)	A020512	001	Aug 30, 1996	Jun	CAHN	
	NOVAMINE 15%							
	@ HOSPIRA INC	15% (75GM/500ML)	N017957	004	Nov 28, 1986	Mar	CPOT	
	AMINOCAPROIC ACID							
	INJECTABLE; INJECTION							
	AMICAR							
	@ CLOVER PHARMS	250MG/ML	N015229	002		Mar	CAHN	
	SYRUP; ORAL							
	AMICAR							
AA	+ CLOVER PHARMS	1.25GM/5ML	N015230	002		Mar	CAHN	
	TABLET; ORAL							
	AMICAR							
AB	CLOVER PHARMS	500MG	N015197	001		Mar	CAHN	
	+	1GM	N015197	002	Jun 24, 2004	Mar	CAHN	
	AMIODARONE HYDROCHLORIDE							
	INJECTABLE; INJECTION							
	AMIODARONE HYDROCHLORIDE							
	@ BEDFORD	50MG/ML	A076018	001	Oct 15, 2002	Jun	DISC	
	@ BEDFORD LABS	50MG/ML	A076299	001	Oct 24, 2002	Jun	DISC	
	@ TEVA PARENTERAL	50MG/ML	A076163	001	Sep 05, 2003	Jan	DISC	
	TABLET; ORAL							
	AMIODARONE HYDROCHLORIDE							
AB	MURTY PHARMS	200MG	A077069	001	Apr 08, 2005	May	CAHN	
AB		400MG	A077069	002	Apr 08, 2005	May	CAHN	
	AMITRIPTYLINE HYDROCHLORIDE							
	TABLET; ORAL							
	AMITRIPTYLINE HYDROCHLORIDE							
AB	CARACO	10MG	A040816	002	Jun 27, 2008	Apr	NEWA	
AB		50MG	A040816	003	Jun 27, 2008	Apr	NEWA	
AB		75MG	A040816	004	Jun 27, 2008	Apr	NEWA	
AB		100MG	A040816	005	Jun 27, 2008	Apr	NEWA	
AB		150MG	A040816	006	Jun 27, 2008	Apr	NEWA	

AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE

TABLET; ORAL

CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE

		MYLAN PHARMS INC	EQ 12.5MG BASE;5MG	A071297	002	Dec 10, 1986	Feb	CTEC
	+		EQ 25MG BASE;10MG	A071297	001	Dec 10, 1986	Feb	CRLD

LIMBITROL

	@	VALEANT PHARM INTL	EQ 12.5MG BASE;5MG	N016949	001		Feb	DISC

LIMBITROL DS

	@	VALEANT PHARM INTL	EQ 25MG BASE;10MG	N016949	002		Feb	DISC

AMLODIPINE BESYLATE

TABLET; ORAL

AMLODIPINE BESYLATE

AB		MACLEODS PHARMS LTD	EQ 5MG BASE	A201380	001	Apr 13, 2012	Mar	NEWA
AB			EQ 10MG BASE	A201380	002	Apr 13, 2012	Mar	NEWA

AMOXICILLIN

TABLET, FOR SUSPENSION; ORAL

DISPERMOX

	@	RANBAXY LABS LTD	600MG	A065159	001	Dec 04, 2003	Apr	DISC

AMOXICILLIN; CLAVULANATE POTASSIUM

FOR SUSPENSION; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

>D>	AB	LEK PHARMS	200MG/5ML;EQ 28.5MG BASE/5ML	A065098	001	Dec 16, 2002	Jul	CAHN
>D>	AB		400MG/5ML;EQ 57MG BASE/5ML	A065098	002	Dec 16, 2002	Jul	CAHN
>D>	AB	LEK PHARMS DD	600MG/5ML;EQ 42.9MG BASE/5ML	A065358	001	Aug 13, 2007	Jul	CAHN
>A>	AB	SANDOZ INC	200MG/5ML;EQ 28.5MG BASE/5ML	A065098	001	Dec 16, 2002	Jul	CAHN
>A>	AB		400MG/5ML;EQ 57MG BASE/5ML	A065098	002	Dec 16, 2002	Jul	CAHN
>A>	AB		600MG/5ML;EQ 42.9MG BASE/5ML	A065358	001	Aug 13, 2007	Jul	CAHN

TABLET; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

AB		AUROBINDO PHARMA LTD	250MG;EQ 125MG BASE	A091569	001	Jan 20, 2012	Jan	NEWA
AB			500MG;EQ 125MG BASE	A091569	002	Jan 20, 2012	Jan	NEWA
AB			875MG;EQ 125MG BASE	A091568	001	Jan 20, 2012	Jan	NEWA
>D>	AB	LEK PHARMS	500MG;EQ 125MG BASE	A065117	001	Nov 27, 2002	Jul	CAHN
>D>	AB		875MG;EQ 125MG BASE	A065093	001	Nov 21, 2002	Jul	CAHN
>A>	AB	SANDOZ INC	500MG;EQ 125MG BASE	A065117	001	Nov 27, 2002	Jul	CAHN
>A>	AB		875MG;EQ 125MG BASE	A065093	001	Nov 21, 2002	Jul	CAHN

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

ADDERALL XR 10

AB		SHIRE	2.5MG;2.5MG;2.5MG;2.5MG	N021303	001	Oct 11, 2001	Jun	CFTG

ADDERALL XR 15

AB		SHIRE	3.75MG;3.75MG;3.75MG;3.75MG	N021303	006	May 22, 2002	Jun	CFTG

ADDERALL XR 20

AB		SHIRE	5MG;5MG;5MG;5MG	N021303	002	Oct 11, 2001	Jun	CFTG

ADDERALL XR 25

AB		SHIRE	6.25MG;6.25MG;6.25MG;6.25MG	N021303	004	May 22, 2002	Jun	CFTG

ADDERALL XR 30

AB	+	SHIRE	7.5MG;7.5MG;7.5MG;7.5MG	N021303	003	Oct 11, 2001	Jun	CFTG

ADDERALL XR 5

AB		SHIRE	1.25MG;1.25MG;1.25MG;1.25MG	N021303	005	May 22, 2002	Jun	CFTG

CAPSULE, EXTENDED RELEASE; ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB	ACTAVIS ELIZABETH	1.25MG;1.25MG;1.25MG;1.25MG	A077302	001	Jun 22, 2012	Jun	NEWA
AB		2.5MG;2.5MG;2.5MG;2.5MG	A077302	002	Jun 22, 2012	Jun	NEWA
AB		3.75MG;3.75MG;3.75MG;3.75MG	A077302	003	Jun 22, 2012	Jun	NEWA
AB		5MG;5MG;5MG;5MG	A077302	004	Jun 22, 2012	Jun	NEWA
AB		6.25MG;6.25MG;6.25MG;6.25MG	A077302	005	Jun 22, 2012	Jun	NEWA
AB		7.5MG;7.5MG;7.5MG;7.5MG	A077302	006	Jun 22, 2012	Jun	NEWA

AMPHETAMINE SULFATE

TABLET; ORAL

AMPHETAMINE SULFATE

>A>		INDEPENDENCE PHARMS	5MG	A200166	001	Aug 09, 2012	Jul	NEWA
>A>	+		10MG	A200166	002	Aug 09, 2012	Jul	NEWA

AMPHOTERICIN B

INJECTABLE, LIPID COMPLEX; INJECTION

AMPHOTEC

	+	ALKOPHARMA USA	50MG/VIAL	N050729	001	Nov 22, 1996	May	CAHN
	+		100MG/VIAL	N050729	002	Nov 22, 1996	May	CAHN

ANAGRELIDE HYDROCHLORIDE

CAPSULE; ORAL

AGRYLIN

AB		SHIRE LLC	EQ 0.5MG BASE	N020333	001	Mar 14, 1997	Jan	CAHN

ANAGRELIDE HYDROCHLORIDE

	@	SANDOZ INC	EQ 0.5MG BASE	A076683	001	Apr 18, 2005	Mar	DISC
	@		EQ 1MG BASE	A076683	002	Apr 18, 2005	Mar	DISC

ANASTROZOLE

TABLET; ORAL

ANASTROZOLE

AB		APOTEX INC	1MG	A200654	001	May 11, 2012	Apr	NEWA
AB		IMPAX LABS INC	1MG	A091242	001	May 31, 2012	May	NEWA

APROTININ

INJECTABLE; INJECTION

TRASYLOL

	@	BAYER HLTHCARE	10,000KIU/ML	N020304	001	Dec 29, 1993	May	DISC

ARGATROBAN

INJECTABLE; INJECTION

ACOVA

AP	+	PFIZER	250MG/2.5ML (100MG/ML)	N020883	001	Jun 30, 2000	Jan	CTNA

ARGATROBAN

AP		HIKMA PHARM CO LTD	250MG/2.5ML (100MG/ML)	N203049	001	Jan 05, 2012	Jan	NEWA

ARMODAFINIL

TABLET; ORAL

ARMODAFINIL

AB		MYLAN PHARMS INC	50MG	A200043	001	Jun 01, 2012	May	NEWA
AB			150MG	A200043	002	Jun 01, 2012	May	NEWA
AB			250MG	A200043	003	Jun 01, 2012	May	NEWA

NUVIGIL

AB		CEPHALON	50MG	N021875	001	Jun 15, 2007	May	CFTG
AB			150MG	N021875	003	Jun 15, 2007	May	CFTG

		TABLET; ORAL							
		NUVIGIL							
AB	+	CEPHALON	250MG	N021875	004	Jun 15, 2007	May		CFTG

ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE

		FOR SOLUTION; ORAL							
		ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE							
AA		NOVEL LABS INC	4.7GM;100GM;1.015GM;5.9MG;2.691GM;7.5GM	A090145	001	Jan 25, 2012	Jan		NEWA
		MOVIPREP							
AA	+	SALIX PHARMS	4.7GM;100GM;1.015GM;5.9GM;2.691GM;7.5GM	N021881	001	Aug 02, 2006	Jan		CFTG

ASENAPINE MALEATE

		TABLET; SUBLINGUAL							
		SAPHRIS							
>A>		ORGANON SUB MERCK	EQ 5MG BASE	N022117	001	Aug 13, 2009	Jul		CAHN
>A>	+		EQ 10MG BASE	N022117	002	Aug 13, 2009	Jul		CAHN
>D>		ORGANON USA INC	EQ 5MG BASE	N022117	001	Aug 13, 2009	Jul		CAHN
>D>	+		EQ 10MG BASE	N022117	002	Aug 13, 2009	Jul		CAHN

ASPIRIN; CARISOPRODOL

		TABLET; ORAL							
		CARISOPRODOL AND ASPIRIN							
AB		PROSAM LABS	325MG;200MG	A040252	001	Dec 10, 1997	Feb		CAHN

ASPIRIN; CARISOPRODOL; CODEINE PHOSPHATE

		TABLET; ORAL							
		CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE							
AB		PROSAM LABS	325MG;200MG;16MG	A040283	001	Dec 29, 1998	Feb		CAHN

ATOMOXETINE HYDROCHLORIDE

		CAPSULE; ORAL							
		ATOMOXETINE HYDROCHLORIDE							
		@ ZYDUS PHARMS USA INC	18MG	A079017	001	Sep 17, 2010	Jun		DISC
		@	25MG	A079017	002	Sep 17, 2010	Jun		DISC
		@	40MG	A079017	003	Sep 17, 2010	Jun		DISC
		@	60MG	A079017	004	Sep 17, 2010	Jun		DISC
		@	80MG	A079017	005	Sep 17, 2010	Jun		DISC
		@	100MG	A079017	006	Sep 17, 2010	Jun		DISC
		STRATTERA							
		LILLY	10MG	N021411	002	Nov 26, 2002	Jun		CTEC
			18MG	N021411	003	Nov 26, 2002	Jun		CTEC
			25MG	N021411	004	Nov 26, 2002	Jun		CTEC
			40MG	N021411	005	Nov 26, 2002	Jun		CTEC
	+		60MG	N021411	006	Nov 26, 2002	Jun		CTEC
			80MG	N021411	007	Feb 14, 2005	Jun		CTEC
			100MG	N021411	008	Feb 14, 2005	Jun		CTEC

ATORVASTATIN CALCIUM

		TABLET; ORAL							
		ATORVASTATIN CALCIUM							
AB		APOTEX INC	EQ 10MG BASE	A090548	001	May 29, 2012	May		NEWA
AB			EQ 20MG BASE	A090548	002	May 29, 2012	May		NEWA
AB			EQ 40MG BASE	A090548	003	May 29, 2012	May		NEWA

TABLET; ORAL
ATORVASTATIN CALCIUM

	AB	APOTEX INC	EQ 80MG BASE	A090548	004	May 29, 2012	May	NEWA
>A>	AB	DR REDDYS LABS LTD	EQ 10MG BASE	A091650	001	Jul 17, 2012	Jul	NEWA
>A>	AB		EQ 20MG BASE	A091650	002	Jul 17, 2012	Jul	NEWA
>A>	AB		EQ 40MG BASE	A091650	003	Jul 17, 2012	Jul	NEWA
>A>	AB		EQ 80MG BASE	A202357	001	Jul 17, 2012	Jul	NEWA
	AB	MYLAN PHARMS INC	EQ 10MG BASE	A091226	001	May 29, 2012	May	NEWA
	AB		EQ 20MG BASE	A091226	002	May 29, 2012	May	NEWA
	AB		EQ 40MG BASE	A091226	003	May 29, 2012	May	NEWA
	AB		EQ 80MG BASE	A091226	004	May 29, 2012	May	NEWA
	AB	SANDOZ INC	EQ 10MG BASE	A077575	001	May 29, 2012	May	NEWA
	AB		EQ 20MG BASE	A077575	002	May 29, 2012	May	NEWA
	AB		EQ 40MG BASE	A077575	003	May 29, 2012	May	NEWA
	AB		EQ 80MG BASE	A077575	004	May 29, 2012	May	NEWA
	AB	TEVA PHARMS	EQ 10MG BASE	A078773	001	May 29, 2012	May	NEWA
	AB		EQ 20MG BASE	A078773	002	May 29, 2012	May	NEWA
	AB		EQ 40MG BASE	A078773	003	May 29, 2012	May	NEWA
	AB		EQ 80MG BASE	A078773	004	May 29, 2012	May	NEWA

ATRACURIUM BESYLATE

INJECTABLE; INJECTION
ATRACURIUM BESYLATE

	AP	+ BEDFORD	10MG/ML	A074901	001	Jul 18, 1997	Feb	CTEC
	AP	SAGENT PHARMS	10MG/ML	A091489	001	Feb 17, 2012	Feb	NEWA

ATRACURIUM BESYLATE PRESERVATIVE FREE

	AP	+ BEDFORD	10MG/ML	A074900	001	Jul 18, 1997	Feb	CTEC
	AP	SAGENT PHARMS	10MG/ML	A091488	001	Feb 17, 2012	Feb	NEWA

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

SOLUTION; ORAL
DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

	AA	+ ROXANE	0.025MG/5ML;2.5MG/5ML	A087708	001	May 03, 1982	Apr	CRLD

LOMOTIL

		@ GD SEARLE LLC	0.025MG/5ML;2.5MG/5ML	N012699	001		Apr	DISC

AVANAFIL

TABLET; ORAL
STENDRA

		VIVUS	50MG	N202276	001	Apr 27, 2012	Apr	NEWA
			100MG	N202276	002	Apr 27, 2012	Apr	NEWA
	+		200MG	N202276	003	Apr 27, 2012	Apr	NEWA

AXITINIB

TABLET; ORAL
INLYTA

		PFIZER	1MG	N202324	001	Jan 27, 2012	Jan	NEWA
	+		5MG	N202324	002	Jan 27, 2012	Jan	NEWA

AZELAIC ACID

GEL; TOPICAL
FINACEA

	+	BAYER HLTHCARE	15%	N021470	001	Dec 24, 2002	Jun	CAHN

AZELASTINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC
AZELASTINE HYDROCHLORIDE

AT	ALCON PHARMA	0.05%	A202305	001	May 31, 2012	May	NEWA	

SPRAY, METERED; NASAL
AZELASTINE HYDROCHLORIDE

AB	SUN PHARMA GLOBAL	EQ 0.125MG BASE/SPRAY	A090423	001	May 23, 2012	May	NEWA	

AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE

SPRAY, METERED; NASAL
DYMISTA

+	MEDA PHARMS	EQ 0.125MG BASE/SPRAY;0.05MG/SPRAY	N202236	001	May 01, 2012	May	NEWA	

AZILSARTAN KAMEDOXOMIL

TABLET; ORAL
EDARBI

	TAKEDA PHARMS USA	EQ 40MG MEDOXOMIL	N200796	001	Feb 25, 2011	Apr	CAHN	
+		EQ 80MG MEDOXOMIL	N200796	002	Feb 25, 2011	Apr	CAHN	

AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE

TABLET; ORAL
EDARBYCLOR

	TAKEDA PHARMS USA	EQ 40MG MEDOXOMIL;12.5MG	N202331	001	Dec 20, 2011	Apr	CAHN	
+		EQ 40MG MEDOXOMIL;25MG	N202331	002	Dec 20, 2011	Apr	CAHN	

AZITHROMYCIN

INJECTABLE; INJECTION
AZITHROMYCIN

>D>	AP	PLIVA HRVATSKA DOO	EQ 500MG BASE/VIAL	A065265	001	Jan 18, 2007	Jul	DISC
>A>		@	EQ 500MG BASE/VIAL	A065265	001	Jan 18, 2007	Jul	DISC
		@ TEVA PARENTERAL	EQ 500MG BASE/VIAL	N050809	001	Dec 19, 2006	Jun	DISC
		@	EQ 2.5GM BASE/VIAL	N050809	002	Dec 19, 2006	Jun	DISC

BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC
NEOMYCIN AND POLYMYXIN B SULFATES, BACITRACIN ZINC AND HYDROCORTISONE

>A>	AT	AKORN	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A065213	001	Jul 25, 2012	Jul	NEWA
>D>		+ BAUSCH AND LOMB	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A064068	001	Oct 30, 1995	Jul	CTEC
>A>	AT	+	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A064068	001	Oct 30, 1995	Jul	CTEC

BACLOFEN

INJECTABLE; INTRATHECAL
GABLOFEN

	CNS THERAPS INC	1MG/ML	N022462	004	Jun 22, 2012	Jun	NEWA	

TABLET; ORAL
BACLOFEN

AB	PROSAM LABS	10MG	A077089	001	Oct 31, 2007	Feb	CAHN	
AB		20MG	A077088	001	Oct 31, 2007	Feb	CAHN	

TABLET, ORALLY DISINTEGRATING; ORAL
KEMSTRO

	@ UCB INC	10MG	N021589	001	Oct 30, 2003	Jan	CAHN	
	@	20MG	N021589	002	Oct 30, 2003	Jan	CAHN	

BALSALAZIDE DISODIUM

TABLET; ORAL
GIAZO

+	SALIX PHARMS	1.1GM	N022205	001	Feb 03, 2012	Feb	NEWA	

BECLOMETHASONE DIPROPIONATE

AEROSOL, METERED; NASAL
QNASL

+	TEVA BRANDED PHARM	0.08MG/ACTIVATION	N202813	001	Mar 23, 2012	Mar	NEWA	

BENZONATATE

CAPSULE; ORAL
BENZONATATE

@	NESHER PHARMS	100MG	A040795	001	Oct 31, 2007	Jun	DISC	
@		200MG	A040795	002	Oct 31, 2007	Jun	DISC	

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE

GEL; TOPICAL
BENZACLIN

BT	+ VALEANT INTL	5%;EQ 1% BASE	N050756	002	Apr 20, 2007	Apr	CAHN	
AB		5%;EQ 1% BASE	N050756	001	Dec 21, 2000	Apr	CAHN	

CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE

AB	PERRIGO ISRAEL	5%;1.2%	A090979	001	Jun 26, 2012	Jun	NEWA	

DUAC

AB	+ STIEFEL	5%;1.2%	N050741	001	Aug 26, 2002	Jun	CFTG	

BENZOYL PEROXIDE; ERYTHROMYCIN

GEL; TOPICAL
BENZAMYCIN

AB	+ VALEANT INTL	5%;3%	N050557	001	Oct 26, 1984	Jan	CAHN	

BENZAMYCIN PAK

+	VALEANT INTL	5%;3%	N050769	001	Nov 27, 2000	Jun	CAHN	

BENZPHETAMINE HYDROCHLORIDE

TABLET; ORAL
BENZPHETAMINE HYDROCHLORIDE

AA	EMCURE PHARMS LTD	50MG	A202061	001	Jan 27, 2012	Jan	NEWA	

BENZTROPINE MESYLATE

INJECTABLE; INJECTION
BENZTROPINE MESYLATE

AP	APP PHARMS LLC	1MG/ML	A090233	001	Jul 28, 2009	May	CAHN	

COGENTIN

AP	+ OAK PHARMS AKORN	1MG/ML	N012015	001		Feb	CAHN	

TABLET; ORAL
BENZTROPINE MESYLATE

@	LANNETT HOLDINGS INC	0.5MG	A088877	001	Apr 11, 1985	Jan	DISC	
@		1MG	A088894	001	Apr 11, 1985	Jan	DISC	
@		2MG	A088895	001	Apr 11, 1985	Jan	DISC	
AA	PROSAM LABS	0.5MG	A040699	001	Feb 14, 2008	Feb	CMFD	
AA		1MG	A040705	001	Feb 14, 2008	Feb	CMFD	
AA		2MG	A040706	001	Feb 14, 2008	Feb	CMFD	
AA	+ USL PHARMA	0.5MG	A040103	001	Dec 12, 1996	Jan	CRLD	
AA	+	1MG	A040103	002	Dec 12, 1996	Jan	CRLD	
AA	+	2MG	A040103	003	Dec 12, 1996	Jan	CRLD	

BETAMETHASONE

SYRUP; ORAL
CELESTONE

	@	SCHERING	0.6MG/5ML	N014215	002		May	DISC

BETAMETHASONE DIPROPIONATE

CREAM; TOPICAL
BETAMETHASONE DIPROPIONATE

AB	+	FOUGERA PHARMS	EQ 0.05% BASE	N019137	001	Jun 26, 1984	Jan	CAHN

CREAM, AUGMENTED; TOPICAL
BETAMETHASONE DIPROPIONATE

AB		FOUGERA PHARMS	EQ 0.05% BASE	A076215	001	Dec 09, 2003	Jan	CAHN

GEL, AUGMENTED; TOPICAL
BETAMETHASONE DIPROPIONATE

AB	+	FOUGERA PHARMS	EQ 0.05% BASE	A075276	001	May 13, 2003	Jan	CAHN

LOTION, AUGMENTED; TOPICAL
BETAMETHASONE DIPROPIONATE

AB		FOUGERA PHARMS	EQ 0.05% BASE	A077111	001	May 21, 2007	Jan	CAHN

OINTMENT, AUGMENTED; TOPICAL
BETAMETHASONE DIPROPIONATE

AB		FOUGERA PHARMS	EQ 0.05% BASE	A075373	001	Jun 22, 1999	Jan	CAHN

BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE

CREAM; TOPICAL
CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE

AB		FOUGERA PHARMS	EQ 0.05% BASE;1%	A075502	001	Jun 05, 2001	Jan	CAHN

LOTION; TOPICAL
CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE

AB		FOUGERA PHARMS	EQ 0.05% BASE;1%	A076516	001	Jun 16, 2005	Jan	CAHN

LOTRISONE

AB	+	SCHERING CORP	EQ 0.05% BASE;1%	N020010	001	Dec 08, 2000	Feb	CAHN

BETAMETHASONE VALERATE

AEROSOL, FOAM; TOPICAL
LUXIQ

	+	STIEFEL	EQ 0.12% BASE	N020934	001	Feb 28, 1999	Jan	CAHN

BISOPROLOL FUMARATE

TABLET; ORAL
ZEBETA

AB		TEVA WOMENS	5MG	N019982	002	Jul 31, 1992	Jan	CAHN
AB	+		10MG	N019982	001	Jul 31, 1992	Jan	CAHN

BOCEPREVIR

CAPSULE; ORAL
VICTRELIS

	+	MERCK SHARP DOHME	200MG	N202258	001	May 13, 2011	Mar	CAHN

BORTEZOMIB

INJECTABLE; INTRAVENOUS, SUBCUTANEOUS
VELCADE

	+	MILLENNIUM PHARMS	3.5MG/VIAL	N021602	001	May 13, 2003	Jan	CDFR

BOSENTAN

TABLET; ORAL
TRACLEER

		ACTELION PHARMS LTD	62.5MG	N021290	001	Nov 20, 2001	May	CAHN
	+		125MG	N021290	002	Nov 20, 2001	May	CAHN

BUDESONIDE

POWDER, METERED; INHALATION
PULMICORT

		@ ASTRAZENECA	0.16MG/INH	N020441	002	Jun 24, 1997	Jun	DISC

SUSPENSION; INHALATION
BUDESONIDE

>A>	AN	WATSON LABS INC	0.25MG/2ML	A078404	001	Jul 31, 2012	Jul	NEWA
>A>	AN		0.5MG/2ML	A078404	002	Jul 31, 2012	Jul	NEWA

BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE

AEROSOL, METERED; INHALATION
SYMBICORT

	+	ASTRAZENECA	0.08MG/INH;0.0045MG/INH	N021929	001	Jul 21, 2006	Jan	CDFR
	+		0.16MG/INH;0.0045MG/INH	N021929	002	Jul 21, 2006	Jan	CDFR

BUPIVACAINE

INJECTABLE, LIPOSOMAL; INJECTION
EXPAREL

>D>	+	PACIRA PHARMS INC	133MG/10ML (13.3MG/ML)	N022496	001	Oct 28, 2011	Jul	DISC
>A>	@		133MG/10ML (13.3MG/ML)	N022496	001	Oct 28, 2011	Jul	DISC

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

FILM; SUBLINGUAL
SUBOXONE

		RECKITT BENCKISER	EQ 2MG BASE;EQ 0.5MG BASE	N022410	001	Aug 30, 2010	Apr	CAIN
	+		EQ 8MG BASE;EQ 2MG BASE	N022410	002	Aug 30, 2010	Apr	CAIN

TABLET; SUBLINGUAL
SUBOXONE

		RECKITT BENCKISER	EQ 2MG BASE;EQ 0.5MG BASE	N020733	001	Oct 08, 2002	Apr	CPOT
	+		EQ 8MG BASE;EQ 2MG BASE	N020733	002	Oct 08, 2002	Apr	CPOT

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
FORFIVO XL

	+	EDGEMONT PHARMS LLC	450MG	N022497	001	Nov 10, 2011	Mar	CAHN

BUSPIRONE HYDROCHLORIDE

TABLET; ORAL
BUSPIRONE HYDROCHLORIDE

		@ APOTEX	5MG	A075521	001	Apr 05, 2002	Mar	DISC
		@	10MG	A075521	002	Apr 05, 2002	Mar	DISC
		@	15MG	A075521	003	Apr 05, 2002	Mar	DISC
		@ EGIS	5MG	A075119	001	Mar 14, 2002	Mar	DISC
		@	10MG	A075119	002	Mar 14, 2002	Mar	DISC
		@	15MG	A075119	003	Jan 23, 2003	Mar	DISC
		@ NESHER PHARMS	5MG	A075572	001	Feb 27, 2002	Jun	DISC
		@	10MG	A075572	002	Feb 27, 2002	Jun	DISC
		@	15MG	A075572	003	Feb 27, 2002	Jun	DISC
		@ PROSAM LABS	5MG	A075388	001	May 09, 2002	Mar	DISC

TABLET; ORAL
BUSPIRONE HYDROCHLORIDE

AB		PROSAM LABS	5MG	A075388	001	May 09, 2002	Feb	CMFD
	@		10MG	A075388	002	May 09, 2002	Mar	DISC
AB			10MG	A075388	002	May 09, 2002	Feb	CMFD
	@		15MG	A075388	003	May 09, 2002	Mar	DISC
AB			15MG	A075388	003	May 09, 2002	Feb	CMFD
AB			30MG	A078302	001	Dec 17, 2007	Feb	CMFD

BUTOCONAZOLE NITRATE

CREAM; VAGINAL
BUTOCONAZOLE NITRATE

	@	PERRIGO ISRAEL	2%	A200923	001	May 18, 2012	Apr	NEWA

CAFFEINE CITRATE

SOLUTION; INTRAVENOUS
CAFCIT

AP	+	BEDFORD LABS	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	N020793	001	Sep 21, 1999	Jan	CAHN

SOLUTION; ORAL
CAFCIT

AA	+	BEDFORD LABS	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	N020793	002	Apr 12, 2000	Jan	CAHN

CALCIPOTRIENE

CREAM; TOPICAL
CALCIPOTRIENE

AB		TOLMAR	0.005%	A200935	001	May 30, 2012	May	NEWA

DOVONEX

AB	+	LEO PHARMA AS	0.005%	N020554	001	Jul 22, 1996	May	CFTG

SOLUTION; TOPICAL
CALCIPOTRIENE

AT		FOUGERA PHARMS	0.005%	A078305	001	May 06, 2008	Jan	CAHN

CALCIUM ACETATE

CAPSULE; ORAL
CALCIUM ACETATE

AB		PADDOCK LLC	EQ 169MG CALCIUM	A091312	001	Jun 01, 2012	May	NEWA

CARBIDOPA; ENTACAPONE; LEVODOPA

TABLET; ORAL
CARBIDOPA, LEVODOPA AND ENTACAPONE

AB		SUN PHARMA GLOBAL	25MG;200MG;100MG	A079085	001	May 10, 2012	Apr	NEWA
AB			37.5MG;200MG;150MG	A079085	002	May 10, 2012	Apr	NEWA

STALEVO 100

AB		ORION PHARMA	25MG;200MG;100MG	N021485	002	Jun 11, 2003	Apr	CFTG

STALEVO 150

AB		ORION PHARMA	37.5MG;200MG;150MG	N021485	003	Jun 11, 2003	Apr	CFTG

CARBIDOPA; LEVODOPA

TABLET, ORALLY DISINTEGRATING; ORAL
PARCOPA

AB		UCB INC	10MG;100MG	A076699	001	Aug 27, 2004	Jan	CAHN
AB			25MG;100MG	A076699	002	Aug 27, 2004	Jan	CAHN
AB	+		25MG;250MG	A076699	003	Aug 27, 2004	Jan	CAHN

CARBOPLATIN

INJECTABLE; INJECTION

CARBOPLATIN

AP	CIPLA LTD	50MG/VIAL	A077383	001	Jan 27, 2006	Mar	CAHN
AP		150MG/VIAL	A077383	002	Jan 27, 2006	Mar	CAHN
AP		450MG/VIAL	A077383	003	Jan 27, 2006	Mar	CAHN
AP	ONCO THERAPIES LTD	50MG/VIAL	A091510	001	May 29, 2012	May	NEWA
AP		150MG/VIAL	A091510	002	May 29, 2012	May	NEWA
AP		450MG/VIAL	A091510	003	May 29, 2012	May	NEWA

PARAPLATIN

@	CORDEN PHARMA	50MG/VIAL	N019880	001	Mar 03, 1989	Feb	CAHN
@		150MG/VIAL	N019880	002	Mar 03, 1989	Feb	CAHN
@		450MG/VIAL	N019880	003	Mar 03, 1989	Feb	CAHN

INJECTABLE; IV (INFUSION)

CARBOPLATIN

AP	ACTAVIS TOTOWA	50MG/5ML (10MG/ML)	A078732	001	Feb 06, 2012	Jan	NEWA
AP		150MG/15ML (10MG/ML)	A078732	002	Feb 06, 2012	Jan	NEWA
AP		450MG/45ML (10MG/ML)	A078732	003	Feb 06, 2012	Jan	NEWA
AP		600MG/60ML (10MG/ML)	A078732	004	Feb 06, 2012	Jan	NEWA
AP	CIPLA LTD	50MG/5ML (10MG/ML)	A077861	001	Jan 18, 2007	Mar	CAHN
AP		150MG/15ML (10MG/ML)	A077861	002	Jan 18, 2007	Mar	CAHN
AP		450MG/45ML (10MG/ML)	A077861	003	Jan 18, 2007	Mar	CAHN
AP		600MG/60ML (10MG/ML)	A077861	004	Jan 18, 2007	Mar	CAHN

>A> CARFILZOMIB

>A> POWDER; INTRAVENOUS

>A> KYPROLIS

>A> +	ONYX PHARMS	60MG/VIAL	N202714	001	Jul 20, 2012	Jul	NEWA

CARISOPRODOL

TABLET; ORAL

CARISOPRODOL

AA	PROSAM LABS	350MG	A040188	001	Mar 07, 1997	Feb	CAHN

CEFACLOR

CAPSULE; ORAL

CEFACLOR

@	RANBAXY	EQ 250MG BASE	A064156	001	Aug 28, 1997	Apr	DISC
@		EQ 500MG BASE	A064156	002	Aug 28, 1997	Apr	DISC

FOR SUSPENSION; ORAL

CEFACLOR

@	RANBAXY	EQ 125MG BASE/5ML	A064166	001	Oct 02, 1997	Apr	DISC
AB +		EQ 125MG BASE/5ML	A064166	001	Oct 02, 1997	Feb	CTEC
@		EQ 187MG BASE/5ML	A064165	001	Oct 02, 1997	Apr	DISC
AB +		EQ 187MG BASE/5ML	A064165	001	Oct 02, 1997	Feb	CTEC
@		EQ 250MG BASE/5ML	A064164	001	Oct 02, 1997	Apr	DISC
AB +		EQ 250MG BASE/5ML	A064164	001	Oct 02, 1997	Feb	CTEC
@		EQ 375MG BASE/5ML	A064155	001	Oct 02, 1997	Apr	DISC
AB +		EQ 375MG BASE/5ML	A064155	001	Oct 02, 1997	Feb	CTEC
AB	YUNG SHIN PHARM	EQ 125MG BASE/5ML	A065412	001	Feb 17, 2012	Feb	NEWA
AB		EQ 187MG BASE/5ML	A065412	002	Feb 17, 2012	Feb	NEWA
AB		EQ 250MG BASE/5ML	A065412	003	Feb 17, 2012	Feb	NEWA
AB		EQ 375MG BASE/5ML	A065412	004	Feb 17, 2012	Feb	NEWA

TABLET, CHEWABLE; ORAL
RANICLOR
@ RANBAXY LABS LTD EQ 125MG BASE A065092 001 Dec 22, 2003 Apr DISC
@ EQ 187MG BASE A065092 002 Dec 22, 2003 Apr DISC
@ EQ 250MG BASE A065092 003 Dec 22, 2003 Apr DISC
@ EQ 375MG BASE A065092 004 Dec 22, 2003 Apr DISC

CEFADROXIL/CEFADROXIL HEMIHYDRATE

CAPSULE; ORAL
CEFADROXIL
@ RANBAXY LABS LTD EQ 500MG BASE A065015 001 Jun 22, 1999 Apr DISC

TABLET; ORAL
CEFADROXIL
@ RANBAXY EQ 1GM BASE A065018 001 Apr 23, 1999 Apr DISC

CEFAZOLIN SODIUM

INJECTABLE; INJECTION
CEFAZOLIN AND DEXTROSE
B BRAUN EQ 2GM BASE/VIAL N050779 003 Jan 13, 2012 May NEWA

CEFDITOREN PIVOXIL

TABLET; ORAL
SPECTRACEF
VANSEN PHARMA 200MG N021222 001 Aug 29, 2001 Mar CAHN
+ 400MG N021222 002 Jul 21, 2008 Mar CAHN

CEFEPIME HYDROCHLORIDE

INJECTABLE; INJECTION
CEFEPIME HYDROCHLORIDE
>A> AP HOSPIRA INC EQ 1GM BASE/VIAL A202268 001 Jul 30, 2012 Jul NEWA
>A> AP EQ 2GM BASE/VIAL A202268 002 Jul 30, 2012 Jul NEWA

CEFIXIME

CAPSULE; ORAL
SUPRAX
+ LUPIN LTD 400MG N203195 001 Jun 01, 2012 Jun NEWA

CEFOTAXIME SODIUM

INJECTABLE; INJECTION
CLAFORAN
AP + SANOFI AVENTIS US EQ 1GM BASE/VIAL A062659 001 Jan 13, 1987 Mar CRLD
AP + EQ 2GM BASE/VIAL A062659 002 Jan 13, 1987 Mar CRLD

>D> CEFOXITIN

>D> INJECTABLE; INJECTION
>D> CEFOXITIN
>D> AP ANTIBIOTICOS BRASIL EQ 1GM BASE/VIAL A065467 001 Aug 31, 2011 Jul CAIN
>D> AP EQ 2GM BASE/VIAL A065467 002 Aug 31, 2011 Jul CAIN
>D> AP EQ 10GM BASE/VIAL A065464 001 Aug 31, 2011 Jul CAIN

>A> CEFOXITIN SODIUM

>A> INJECTABLE; INJECTION
>A> CEFOXITIN
>A> AP ANTIBIOTICOS BRASIL EQ 1GM BASE/VIAL A065467 001 Aug 31, 2011 Jul CAIN
>A> AP EQ 2GM BASE/VIAL A065467 002 Aug 31, 2011 Jul CAIN
>A> AP EQ 10GM BASE/VIAL A065464 001 Aug 31, 2011 Jul CAIN

CEFPROZIL

FOR SUSPENSION; ORAL
CEFPROZIL

AB		APOTEX INC	125MG/5ML	A065351	001	Feb 29, 2012	Feb	NEWA
AB			250MG/5ML	A065351	002	Feb 29, 2012	Feb	NEWA
	@	RANBAXY LABS LTD	125MG/5ML	A065202	001	Jun 30, 2006	Apr	DISC
	@		250MG/5ML	A065202	002	Jun 30, 2006	Apr	DISC

TABLET; ORAL
CEFPROZIL

	@	RANBAXY LABS LTD	250MG	A065198	001	Dec 13, 2006	Apr	DISC
	@		500MG	A065198	002	Dec 13, 2006	Apr	DISC

CEFZIL

	@	CORDEN PHARMA	250MG	N050664	001	Dec 23, 1991	Feb	CAHN
	@		500MG	N050664	002	Dec 23, 1991	Feb	CAHN

CEFTAZIDIME

INJECTABLE; INJECTION
FORTAZ

AP	+	COVIS PHARMA	500MG/VIAL	N050578	001	Jul 19, 1985	Apr	CAHN
AP	+		1GM/VIAL	N050578	002	Jul 19, 1985	Apr	CAHN
AP	+		2GM/VIAL	N050578	003	Jul 19, 1985	Apr	CAHN
AP	+		6GM/VIAL	N050578	004	Jul 19, 1985	Apr	CAHN

CEFTAZIDIME SODIUM

INJECTABLE; INJECTION
FORTAZ IN PLASTIC CONTAINER

	@	COVIS PHARMA	EQ 10MG BASE/ML	N050634	001	Apr 28, 1989	Apr	CAHN
	+		EQ 20MG BASE/ML	N050634	002	Apr 28, 1989	Apr	CAHN
	+		EQ 40MG BASE/ML	N050634	003	Apr 28, 1989	Apr	CAHN

CEFTRIAXONE SODIUM

INJECTABLE; INJECTION
CEFTRIAXONE

AP	+	SANDOZ INC	EQ 1GM BASE/VIAL	A065204	001	May 03, 2005	Mar	CRLD
AP	+		EQ 2GM BASE/VIAL	A065204	002	May 03, 2005	Mar	CRLD

CEFUROXIME AXETIL

TABLET; ORAL
CEFUROXIME AXETIL

	@	RANBAXY LABS LTD	EQ 125MG BASE	A065043	003	Feb 15, 2002	Apr	DISC
	@		EQ 250MG BASE	A065043	002	Feb 15, 2002	Apr	DISC
	@		EQ 500MG BASE	A065043	001	Feb 15, 2002	Apr	DISC

CEFUROXIME SODIUM

INJECTABLE; IM-IV
ZINACEF

AB	+	COVIS PHARMA	EQ 750MG BASE/VIAL	N050558	002	Oct 19, 1983	Apr	CAHN

INJECTABLE; INJECTION
ZINACEF

AP	+	COVIS PHARMA	EQ 1.5GM BASE/VIAL	N050558	003	Oct 19, 1983	Apr	CAHN
AP	+		EQ 7.5GM BASE/VIAL	N050558	004	Oct 23, 1986	Apr	CAHN

ZINACEF IN PLASTIC CONTAINER

	+	COVIS PHARMA	EQ 15MG BASE/ML	N050643	001	Apr 28, 1989	Apr	CAHN
	+		EQ 30MG BASE/ML	N050643	002	Apr 28, 1989	Apr	CAHN

CEPHALEXIN

FOR SUSPENSION; ORAL

KEFLEX

>D>		@ LEX PHARMS	EQ 100MG BASE/ML	N050406	003		Jul	CAHN
>D>		@	EQ 125MG BASE/5ML	N050406	001		Jul	CAHN
>D>		@	EQ 250MG BASE/5ML	N050406	002		Jul	CAHN
>A>		@ SHIONOGI INC	EQ 100MG BASE/ML	N050406	003		Jul	CAHN
>A>		@	EQ 125MG BASE/5ML	N050406	001		Jul	CAHN
>A>		@	EQ 250MG BASE/5ML	N050406	002		Jul	CAHN

CETIRIZINE HYDROCHLORIDE

SYRUP; ORAL

CETIRIZINE HYDROCHLORIDE

>D>	AA	RANBAXY	5MG/5ML	A077472	001	Jun 18, 2008	Jul	DISC
>A>		@ RANBAXY LABS LTD	5MG/5ML	A077472	001	Jun 18, 2008	Jul	DISC
	AA	SILARX	5MG/5ML	A078876	001	May 11, 2012	Apr	NEWA

CHLORAMBUCIL

TABLET; ORAL

LEUKERAN

	+	ASPEN GLOBAL INC	2MG	N010669	002		May	CAHN

CHLORPHENIRAMINE POLISTIREX; HYDROCODONE POLISTIREX

SUSPENSION, EXTENDED RELEASE; ORAL

HYDROCODONE POLISTIREX AND CHLORPHENIRAMNE POLISTIREX

	AB	CORNERSTONE THERAP	EQ 8MG MALEATE/5ML;EQ 10MG BITARTRATE/5ML	A091671	001	Jun 29, 2012	Jun	NEWA

CICLESONIDE

AEROSOL, METERED; INHALATION

ALVESCO

		NYCOMED GMBH	0.08MG/INH	N021658	002	Jan 10, 2008	May	CAHN
	+		0.16MG/INH	N021658	003	Jan 10, 2008	May	CAHN

AEROSOL, METERED; NASAL

ZETONNA

	+	NYCOMED GMBH	0.037MG/INH	N202129	001	Jan 20, 2012	Jan	NEWA

SPRAY, METERED; NASAL

OMNARIS

	+	NYCOMED GMBH	0.05MG/INH	N022004	001	Oct 20, 2006	May	CAHN

CICLOPIROX

CREAM; TOPICAL

CICLOPIROX

	AB	FOUGERA PHARMS	0.77%	A076435	001	Dec 29, 2004	Jan	CAHN

GEL; TOPICAL

CICLOPIROX

	AB	FOUGERA PHARMS	0.77%	A077896	001	Jun 10, 2008	Jan	CAHN
	AB	GLENMARK GENERICS	0.77%	A091595	001	Feb 29, 2012	Feb	NEWA

SHAMPOO; TOPICAL

CICLOPIROX

	AT	FOUGERA PHARMS	1%	A090146	001	May 25, 2010	Jan	CAHN

SOLUTION; TOPICAL

CICLOPIROX

	AT	MYLAN PHARMS INC	8%	A078567	001	Sep 18, 2007	Feb	CAHN

		SUSPENSION; TOPICAL							
		CICLOPIROX							
	AB	FOUGERA PHARMS	0.77%		A076422	001	Aug 06, 2004	Jan	CAHN
		CIDOFOVIR							
		INJECTABLE; INJECTION							
		CIDOFOVIR							
>A>	AP	EMCURE PHARMS LTD	EQ 75MG BASE/ML		A202501	001	Jul 26, 2012	Jul	NEWA
	AP	MYLAN LLC	EQ 75MG BASE/ML		A201276	001	Jun 27, 2012	Jun	NEWA
		VISTIDE							
	AP	+ GILEAD SCIENCES INC	EQ 75MG BASE/ML		N020638	001	Jun 26, 1996	Jun	CFTG
		CIMETIDINE HYDROCHLORIDE							
		INJECTABLE; INJECTION							
		CIMETIDINE HYDROCHLORIDE							
		@ HOSPIRA	EQ 300MG BASE/2ML		A074344	001	Jan 31, 1995	Jun	DISC
		@	EQ 300MG BASE/2ML		A074345	001	Jan 31, 1995	Jun	DISC
		CIPROFLOXACIN							
		INJECTABLE; INJECTION							
		CIPROFLOXACIN							
		@ TEVA PARENTERAL	200MG/20ML (10MG/ML)		A077782	001	Aug 28, 2006	Mar	DISC
		@	400MG/40ML (10MG/ML)		A077782	002	Aug 28, 2006	Jan	DISC
		CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER							
		@ BAXTER HLTHCARE	200MG/100ML		A077888	001	Mar 18, 2008	Jun	DISC
		@	400MG/200ML		A077888	002	Mar 18, 2008	Jun	DISC
		CIPROFLOXACIN HYDROCHLORIDE							
		TABLET; ORAL							
		CIPROFLOXACIN HYDROCHLORIDE							
		@ PLIVA	EQ 100MG BASE		A076426	001	Jun 15, 2005	Jan	DISC
		@	EQ 250MG BASE		A076426	002	Jun 15, 2005	Jan	DISC
		@	EQ 500MG BASE		A076426	003	Jun 15, 2005	Jan	DISC
		@	EQ 750MG BASE		A076426	004	Jun 15, 2005	Jan	DISC
		CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE							
		TABLET, EXTENDED RELEASE; ORAL							
		CIPROFLOXACIN EXTENDED RELEASE							
	AB	DR REDDYS LABS LTD	212.6MG;EQ 287.5MG BASE		A077701	002	Oct 31, 2007	Apr	NEWA
		CISATRACURIUM BESYLATE							
		INJECTABLE; INJECTION							
		CISATRACURIUM BESYLATE							
	AP	SANDOZ INC	EQ 2MG BASE/ML		A200159	001	Feb 03, 2012	Jan	NEWA
		CISATRACURIUM BESYLATE PRESERVATIVE FREE							
	AP	SANDOZ INC	EQ 2MG BASE/ML		A200154	001	Feb 03, 2012	Jan	NEWA
	AP		EQ 10MG BASE/ML		A200154	002	Feb 03, 2012	Jan	NEWA
		NIMBEX							
	AP	+ ABBOTT	EQ 2MG BASE/ML		N020551	001	Dec 15, 1995	Jan	CFTG
		NIMBEX PRESERVATIVE FREE							
	AP	+ ABBOTT	EQ 2MG BASE/ML		N020551	003	Dec 15, 1995	Jan	CFTG
	AP	+	EQ 10MG BASE/ML		N020551	002	Dec 15, 1995	Jan	CFTG

CISPLATIN

INJECTABLE; INJECTION

CISPLATIN

AP		ONCO THERAPIES LTD	1MG/ML	A091062	001	Apr 18, 2012	Apr	NEWA
	@	TEVA PARENTERAL	1MG/ML	A074814	001	May 16, 2000	Mar	DISC

>A> CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE

>A> FOR SOLUTION; ORAL

>A> PREPOPIK

>A>	+	FERRING PHARMS AS	12GM/PACKET;3.5GM/PACKET;10MG/PACKET	N202535	001	Jul 16, 2012	Jul	NEWA

CLARITHROMYCIN

TABLET; ORAL

CLARITHROMYCIN

>A> AB		AUROBINDO	250MG	A065489	001	Jul 25, 2012	Jul	NEWA
>A> AB			500MG	A065489	002	Jul 25, 2012	Jul	NEWA

CLINDAMYCIN PHOSPHATE

CREAM; VAGINAL

CLINDAMYCIN PHOSPHATE

AB		FOUGERA PHARMS	EQ 2% BASE	A065139	001	Dec 27, 2004	Jan	CAHN

GEL; TOPICAL

CLINDAMYCIN PHOSPHATE

AB		FOUGERA PHARMS	EQ 1% BASE	A064160	001	Jan 28, 2000	Jan	CAHN

INJECTABLE; INJECTION

CLEOCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	+	PHARMACIA AND UPJOHN	EQ 6MG BASE/ML	N050639	001	Aug 30, 1989	May	CFTG
AP	+		EQ 12MG BASE/ML	N050639	002	Aug 30, 1989	May	CFTG
AP	+		EQ 18MG BASE/ML	N050639	003	Apr 10, 1991	May	CFTG

CLINDAMYCIN PHOSPHATE IN 5% DEXTROSE IN PLASTIC CONTAINER

AP		SANDOZ INC	EQ 6MG BASE/ML	A201692	001	May 31, 2012	May	NEWA
AP			EQ 12MG BASE/ML	A201692	002	May 31, 2012	May	NEWA
AP			EQ 18MG BASE/ML	A201692	003	May 31, 2012	May	NEWA

LOTION; TOPICAL

CLINDAMYCIN PHOSPHATE

AB		FOUGERA PHARMS	EQ 1% BASE	A065067	001	Jan 31, 2002	Jan	CAHN

SOLUTION; TOPICAL

CLINDAMYCIN PHOSPHATE

AT		FOUGERA PHARMS	EQ 1% BASE	A065254	001	Feb 14, 2006	Jan	CAHN

CLINDAMYCIN PHOSPHATE; TRETINOIN

GEL; TOPICAL

VELTIN

BX	+	STIEFEL GSK	1.2%;0.025%	N050803	001	Jul 16, 2010	May	CRLD

CLOBAZAM

TABLET; ORAL

ONFI

		LUNDBECK LLC	5MG	N202067	001	Oct 21, 2011	Mar	CAHN
			10MG	N202067	002	Oct 21, 2011	Mar	CAHN
	+		20MG	N202067	003	Oct 21, 2011	Mar	CAHN

CLOBETASOL PROPIONATE

AEROSOL, FOAM; TOPICAL
CLOBETASOL PROPIONATE

>D>	AB		PERRIGO ISRAEL	0.05%	A077763	001	Mar 10, 2008	Jul	CTEC
>A>	AB1			0.05%	A077763	001	Mar 10, 2008	Jul	CTEC
>A>	AB2			0.05%	A201402	001	Aug 14, 2012	Jul	NEWA

OLUX

>D>	AB	+	STIEFEL LABS INC	0.05%	N021142	001	May 26, 2000	Jul	CTEC
>A>	AB1	+		0.05%	N021142	001	May 26, 2000	Jul	CTEC

OLUX E

>D>		+	STIEFEL LABS INC	0.05%	N022013	001	Jan 12, 2007	Jul	CFTG
>A>	AB2	+		0.05%	N022013	001	Jan 12, 2007	Jul	CFTG

CREAM; TOPICAL
CLOBETASOL PROPIONATE

			@ G AND W LABS INC	0.05%	A074139	001	Aug 03, 1994	Jun	CAHN

CLOBETASOL PROPIONATE (EMOLLIENT)

	AB2		FOUGERA PHARMS	0.05%	A075430	001	May 26, 1999	Jan	CAHN

TEMOVATE

	AB1	+	FOUGERA PHARMS	0.05%	N019322	001	Dec 27, 1985	Jan	CAHN

GEL; TOPICAL
CLOBETASOL PROPIONATE

	AB		FOUGERA PHARMS	0.05%	A075368	001	Feb 15, 2000	Jan	CAHN

TEMOVATE

	AB	+	FOUGERA PHARMS	0.05%	N020337	001	Apr 29, 1994	Jan	CAHN

LOTION; TOPICAL
CLOBETASOL PROPIONATE

	AB		TARO	0.05%	A200302	001	Jul 02, 2012	Jun	NEWA

OINTMENT; TOPICAL
CLOBETASOL PROPIONATE

	AB		FOUGERA PHARMS	0.05%	A074407	001	Feb 23, 1996	Jan	CAHN

TEMOVATE

	AB	+	FOUGERA PHARMS	0.05%	N019323	001	Dec 27, 1985	Jan	CAHN

SHAMPOO; TOPICAL
CLOBETASOL PROPIONATE

>A>	AB		PERRIGO ISRAEL	0.05%	A090974	001	Aug 09, 2012	Jul	NEWA

SOLUTION; TOPICAL
CLOBETASOL PROPIONATE

	AT		FOUGERA PHARMS	0.05%	A075391	001	Feb 08, 1999	Jan	CAHN
			@ G AND W LABS INC	0.05%	A074331	001	Dec 15, 1995	Jun	CAHN

TEMOVATE

	AT	+	FOUGERA PHARMS	0.05%	N019966	001	Feb 22, 1990	Jan	CAHN

CLONIDINE HYDROCHLORIDE

INJECTABLE; INJECTION
DURACLON

	AP		MYLAN INSTITUTIONAL	1 MG/10 ML (0.1 MG/ML)	N020615	001	Oct 02, 1996	Feb	CAHN
	AP	+		5 MG/10 ML (0.5 MG/ML)	N020615	002	Apr 27, 1999	Feb	CAHN

TABLET, EXTENDED RELEASE; ORAL
KAPVAY

			SHIONOGI INC	0.2MG	N022331	004	Sep 28, 2010	May	CMFD

CLOPIDOGREL BISULFATE

TABLET; ORAL
CLOPIDOGREL BISULFATE

	AB		APOTEX INC	EQ 75MG BASE	A076274	001	May 17, 2012	Apr	NEWA

TABLET; ORAL
CLOPIDOGREL BISULFATE

AB		AUROBINDO PHARMA LTD	EQ 75MG BASE	A090540	001	May 17, 2012	Apr	NEWA
AB		DR REDDYS LABS INC	EQ 75MG BASE	A076273	001	Jan 14, 2008	Mar	CMFD
AB		DR REDDYS LABS LTD	EQ 300MG BASE	A091023	001	May 17, 2012	Apr	NEWA
AB		GATE PHARMS	EQ 300MG BASE	A091216	001	May 17, 2012	Apr	NEWA
AB		MYLAN PHARMS INC	EQ 75MG BASE	A077665	001	May 17, 2012	Apr	NEWA
AB			EQ 300MG BASE	A077665	002	May 17, 2012	Apr	NEWA
AB		ROXANE	EQ 75MG BASE	A078004	001	May 17, 2012	Apr	NEWA
AB		SUN PHARMA GLOBAL	EQ 75MG BASE	A090494	001	May 17, 2012	Apr	NEWA
AB		TEVA	EQ 75MG BASE	A076999	001	May 17, 2012	Apr	NEWA
AB		TEVA PHARMS	EQ 300MG BASE	A090625	001	May 17, 2012	Apr	NEWA
AB		TORRENT PHARMS LTD	EQ 75MG BASE	A090844	001	May 17, 2012	Apr	NEWA
>A> AB		WOCKHARDT LTD	EQ 75MG BASE	A202266	001	Aug 14, 2012	Jul	NEWA

PLAVIX

AB		SANOFI AVENTIS US	EQ 75MG BASE	N020839	001	Nov 17, 1997	Mar	CTEC
AB	+		EQ 300MG BASE	N020839	002	Sep 20, 2007	Apr	CTEC

CLORAZEPATE DIPOTASSIUM

CAPSULE; ORAL
TRANXENE

		@ LUNDBECK LLC	3.75MG	N017105	001		Mar	CAHN
		@	7.5MG	N017105	002		Mar	CAHN
		@	15MG	N017105	003		Mar	CAHN

TABLET; ORAL
TRANXENE

AB		LUNDBECK LLC	3.75MG	N017105	006		Mar	CAHN
AB			7.5MG	N017105	007		Mar	CAHN
AB	+		15MG	N017105	008		Mar	CAHN

TRANXENE SD

		@ LUNDBECK LLC	11.25MG	N017105	005		Mar	CAHN
		@	22.5MG	N017105	004		Mar	CAHN

CLOTRIMAZOLE

CREAM; TOPICAL
CLOTRIMAZOLE

AB		FOUGERA PHARMS	1%	A078338	001	Sep 02, 2008	Jan	CAHN

CLOZAPINE

TABLET, ORALLY DISINTEGRATING; ORAL
FAZACLO ODT

		JAZZ	12.5MG	N021590	004	May 30, 2007	Apr	CAHN
			25MG	N021590	001	Feb 10, 2004	Apr	CAHN
		@	50MG	N021590	003	Jun 03, 2005	Apr	CAHN
	+		100MG	N021590	002	Feb 10, 2004	Apr	CAHN
			150MG	N021590	005	Jul 09, 2010	Apr	CAHN
			200MG	N021590	006	Jul 09, 2010	Apr	CAHN
		JAZZ PHARMS III	12.5MG	N021590	004	May 30, 2007	Jun	CAHN
			25MG	N021590	001	Feb 10, 2004	Jun	CAHN
		@	50MG	N021590	003	Jun 03, 2005	Jun	CAHN
	+		100MG	N021590	002	Feb 10, 2004	Jun	CAHN
			150MG	N021590	005	Jul 09, 2010	Jun	CAHN
			200MG	N021590	006	Jul 09, 2010	Jun	CAHN

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL
PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE

AA		TRIS PHARMA INC	10MG/5ML;6.25MG/5ML	A200386	001	Jun 29, 2012	Jun	NEWA

COPPER

INTRAUTERINE DEVICE; INTRAUTERINE
PARAGARD T 380A

+		TEVA WOMENS	309MG/COPPER	N018680	001	Nov 15, 1984	May	CAHN

COSYNTROPIN

INJECTABLE; INJECTION
COSYNTROPIN

AP		INNOPHARMA INC	0.25MG/VIAL	A202147	001	Jun 29, 2012	Jun	NEWA

CROMOLYN SODIUM

AEROSOL, METERED; INHALATION
INTAL

@		KING PFIZER	0.8MG/INH	N018887	001	Dec 05, 1985	Jun	DISC

CONCENTRATE; ORAL
GASTROCROM

AA	+	JAZZ PHARMS COMMERCL	100MG/5ML	N020479	001	Feb 29, 1996	Mar	CAHN
AA	+	JAZZ PHARMS INTL	100MG/5ML	N020479	001	Feb 29, 1996	Jun	CAHN

CYCLOBENZAPRINE HYDROCHLORIDE

TABLET; ORAL
CYCLOBENZAPRINE HYDROCHLORIDE

>D>	AB		MYLAN	10MG	A073144	001	May 30, 1991	Jul	CRLD
>A>	AB	+	MYLAN PHARMS INC	10MG	A073144	001	May 30, 1991	Jul	CRLD
	AB		PROSAM LABS	5MG	A077291	001	Feb 03, 2006	Feb	CAHN
	AB			10MG	A077209	001	Oct 04, 2005	Feb	CAHN

FLEXERIL

>D>	AB	+	JANSSEN R AND D	10MG	N017821	002		Jul	DISC
>D>	AB		JANSSEN RES AND DEV	5MG	N017821	001		Jul	DISC
>A>		@		5MG	N017821	001		Jul	DISC
>A>		@		10MG	N017821	002		Jul	DISC

CYCLOPHOSPHAMIDE

INJECTABLE; INJECTION
CYTOXAN

AP	+	BAXTER HLTHCARE	500MG/VIAL	N012142	003		Apr	CRLD
AP	+		1GM/VIAL	N012142	004	Aug 30, 1982	Apr	CRLD
AP	+		2GM/VIAL	N012142	005	Aug 30, 1982	Apr	CRLD

CYCLOSPORINE

CAPSULE; ORAL
CYCLOSPORINE

AB1		WATSON LABS INC	25MG	A065044	002	Dec 20, 2000	May	CAHN
AB1			100MG	A065044	001	Dec 20, 2000	May	CAHN

CYTARABINE

INJECTABLE; INJECTION
CYTARABINE

AP		ONCO THERAPIES LTD	100MG/ML	A201784	001	Jan 30, 2012	Jan	NEWA

DACTINOMYCIN

INJECTABLE; INJECTION
COSMEGEN

	AP	+	LUNDBECK LLC	0.5MG/VIAL	N050682	001		Mar	CAHN

DANTROLENE SODIUM

CAPSULE; ORAL
DANTROLENE SODIUM

>D>		@	ACTAVIS TOTOWA	25MG	A076686	001	Oct 24, 2005	Jul	CAHN
>D>		@		50MG	A076686	002	Oct 24, 2005	Jul	CAHN
>D>		@		100MG	A076686	003	Oct 24, 2005	Jul	CAHN
>A>		@	MIKAH PHARMA	25MG	A076686	001	Oct 24, 2005	Jul	CAHN
>A>		@		50MG	A076686	002	Oct 24, 2005	Jul	CAHN
>A>		@		100MG	A076686	003	Oct 24, 2005	Jul	CAHN

DAPIPRAZOLE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC
>A> DAPIPRAZOLE HYDROCHLORIDE

>A>		@	FERA PHARMS	0.5%	N019849	001	Dec 31, 1990	Jul	CTNA

>D> REV-EYES

>D>		@	FERA PHARMS	0.5%	N019849	001	Dec 31, 1990	Jul	CTNA

DARUNAVIR ETHANOLATE

SUSPENSION; ORAL
PREZISTA

		+	JANSSEN PRODS	EQ 100MG BASE/ML	N202895	001	Dec 16, 2011	Feb	CAHN

TABLET; ORAL
PREZISTA

			JANSSEN PRODS	EQ 75MG BASE	N021976	004	Dec 18, 2008	Feb	CAHN
				EQ 150MG BASE	N021976	005	Dec 18, 2008	Feb	CAHN
		@		EQ 300MG BASE	N021976	001	Jun 23, 2006	Feb	CAHN
				EQ 400MG BASE	N021976	003	Oct 21, 2008	Feb	CAHN
		+		EQ 600MG BASE	N021976	002	Feb 25, 2008	Feb	CAHN

DEMECLOCYCLINE HYDROCHLORIDE

TABLET; ORAL
>D> DECLOMYCIN

>D>	AB		COREPHARMA	150MG	N050261	002		Jul	DISC
>A>		@		150MG	N050261	002		Jul	DISC
>D>	AB	+		300MG	N050261	003		Jul	DISC
>A>		@		300MG	N050261	003		Jul	DISC

DEMECLOCYCLINE HYDROCHLORIDE

>D>	AB		AMNEAL PHARM	300MG	A065425	002	Feb 27, 2008	Jul	CRLD
>A>	AB	+		300MG	A065425	002	Feb 27, 2008	Jul	CRLD

DESFLURANE

LIQUID; INHALATION
SUPRANE

>A>		+	BAXTER HLTHCARE	99.9%	N020118	001	Sep 18, 1992	Jul	CAHN
>D>		+	BAXTER HLTHCARE CORP	99.9%	N020118	001	Sep 18, 1992	Jul	CAHN

DESLORATADINE

TABLET; ORAL
DESLORATADINE

	AB		BELCHER PHARMS	5MG	A078355	001	Apr 19, 2012	Apr	NEWA

	TABLET; ORAL								
	DESLORATADINE								
AB	MYLAN PHARMS INC	5MG	A078351	001	Feb 10, 2012	Jan	NEWA		
	DESMOPRESSIN ACETATE								
	SOLUTION; NASAL								
	DDAVP								
AB +	SANOFI AVENTIS US	0.01%	N017922	001		Mar	CFTG		
	DESMOPRESSIN ACETATE								
AB	SUN PHARM INDS	0.01%	A077212	001	Apr 12, 2012	Mar	NEWA		
	DESOGESTREL; ETHINYL ESTRADIOL								
	TABLET; ORAL-28								
	MIRCETTE								
AB +	TEVA BRANDED PHARM	0.15MG,N/A;0.02MG,0.01MG	N020713	001	Apr 22, 1998	Jun	CAHN		
	VIORELE								
AB	GLENMARK GENERICS	.15MG,N/A; 0.02MG,0.01MG	A091346	001	Apr 02, 2012	Mar	NEWA		
	DESONIDE								
	LOTION; TOPICAL								
	DESONIDE								
AB	FOUGERA PHARMS	0.05%	A075860	001	Mar 19, 2002	Jan	CAHN		
	OINTMENT; TOPICAL								
	DESONIDE								
AB	FOUGERA PHARMS	0.05%	A075751	001	Mar 12, 2001	Jan	CAHN		
	DESOXIMETASONE								
	CREAM; TOPICAL								
	DESOXIMETASONE								
AB	FOUGERA PHARMS	0.25%	A078369	001	Jun 29, 2010	Jan	CAHN		
	TOPICORT								
+	TARO	0.05%	A073210	001	Nov 30, 1990	Apr	CTNA		
+		0.25%	A073193	001	Nov 30, 1990	Apr	CTNA		
	@ TARO PHARMS NORTH	0.25%	N017856	001		Apr	DISC		
	TOPICORT LP								
	@ TARO PHARMS NORTH	0.05%	N018309	001		Apr	DISC		
	GEL; TOPICAL								
	TOPICORT								
AB +	TARO	0.05%	A074904	001	Jul 14, 1998	Apr	CTNA		
	@ TARO PHARMS NORTH	0.05%	N018586	001	Mar 29, 1982	Apr	DISC		
	OINTMENT; TOPICAL								
	DESOXIMETASONE								
AB +	TARO	0.25%	A074286	001	Jun 07, 1996	Mar	CRLD		
	TOPICORT								
+	TARO	0.25%	A074286	001	Jun 07, 1996	Apr	CTNA		
	@ TARO PHARMS NORTH	0.25%	N018763	001	Sep 30, 1983	Mar	DISC		
	DEXAMETHASONE SODIUM PHOSPHATE								
	INJECTABLE; INJECTION								
	DEXAMETHASONE SODIUM PHOSPHATE								
AP +	APP PHARMS LLC	EQ 10MG PHOSPHATE/ML	A040572	001	Apr 22, 2005	Feb	CRLD		
	DEXRAZOXANE HYDROCHLORIDE								
	INJECTABLE; INJECTION								
	TOTECT								
+	APRICUS PHARMS	EQ 500MG BASE/VIAL	N022025	001	Sep 06, 2007	Jun	CAHN		

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL
PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE

AA		TRIS PHARMA INC	15MG/5ML;6.25MG/5ML	A091687	001	Jun 28, 2012	Jun	NEWA

DIAZEPAM

INJECTABLE; INJECTION
DIAZEPAM

>D>		@ BAXTER HLTHCARE	5MG/ML	A071309	001	Jul 17, 1987	Jul	CAHN
>D>		@	5MG/ML	A070313	001	Dec 16, 1985	Jul	CAHN
>D>		@	5MG/ML	A070311	001	Dec 16, 1985	Jul	CAHN
>D>		@	5MG/ML	A071308	001	Jul 17, 1987	Jul	CAHN
>D>		@	5MG/ML	A070312	001	Dec 16, 1985	Jul	CAHN
>D>		@	5MG/ML	A071310	001	Jul 17, 1987	Jul	CAHN
>A>		@ HIKMA MAPLE	5MG/ML	A070312	001	Dec 16, 1985	Jul	CAHN
>A>		@	5MG/ML	A070311	001	Dec 16, 1985	Jul	CAHN
>A>		@	5MG/ML	A070313	001	Dec 16, 1985	Jul	CAHN
>A>		@	5MG/ML	A071308	001	Jul 17, 1987	Jul	CAHN
>A>		@	5MG/ML	A071309	001	Jul 17, 1987	Jul	CAHN
>A>		@	5MG/ML	A071310	001	Jul 17, 1987	Jul	CAHN
		@ HOSPIRA	5MG/ML	A071584	001	Oct 13, 1987	Apr	DISC

DICLOFENAC POTASSIUM

CAPSULE; ORAL
ZIPSOR

	+	DEPOMED INC	25MG	N022202	001	Jun 16, 2009	Jun	CAHN

DICLOFENAC SODIUM; MISOPROSTOL

TABLET, DELAYED RELEASE; ORAL
ARTHROTEC

AB		GD SEARLE LLC	50MG;0.2MG	N020607	001	Dec 24, 1997	Jun	CFTG
AB	+		75MG;0.2MG	N020607	002	Dec 24, 1997	Jun	CFTG

DICLOFENAC SODIUM AND MISOPROSTOL

AB		WATSON LABS INC	50MG;0.2MG	A201089	001	Jul 09, 2012	Jun	NEWA
AB			75MG;0.2MG	A201089	002	Jul 09, 2012	Jun	NEWA

DIDANOSINE

TABLET, CHEWABLE; ORAL
DIDANOSINE

>A>								
>A>		AUROBINDO	100MG	A077275	001	Aug 14, 2012	Jul	NEWA
>A>			150MG	A077275	002	Aug 14, 2012	Jul	NEWA
>A>			200MG	A077275	003	Aug 14, 2012	Jul	NEWA

DIFLORASONE DIACETATE

CREAM; TOPICAL
DIFLORASONE DIACETATE

BX	+	FOUGERA PHARMS	0.05%	A076263	001	Dec 20, 2002	Jan	CAHN
AB1	+		0.05%	A075187	001	Mar 30, 1998	Jan	CAHN

OINTMENT; TOPICAL
DIFLORASONE DIACETATE

AB		FOUGERA PHARMS	0.05%	A075374	001	Apr 27, 1999	Jan	CAHN

DIFLUNISAL

TABLET; ORAL

DIFLUNISAL

	AB		EMCURE PHARMS USA	500MG	A202845	001	Mar 08, 2012	Feb	NEWA
	AB	+	TEVA	500MG	A073673	001	Jul 31, 1992	Feb	CTEC

DIGOXIN

INJECTABLE; INJECTION

DIGOXIN

>D>	AP		BAXTER HLTHCARE	0.25MG/ML	A083391	001		Jul	CAHN
>A>	AP		HIKMA MAPLE	0.25MG/ML	A083391	001		Jul	CAHN
		@	HOSPIRA	0.25MG/ML	A040093	001	May 16, 1996	Jun	DISC

TABLET; ORAL

DIGOXIN

>D>		@	ACTAVIS TOTOWA	0.125MG	A040282	001	Dec 23, 1999	Jul	CAHN
>D>		@		0.25MG	A040282	002	Dec 23, 1999	Jul	CAHN
>A>		@	MYLAN PHARMS INC	0.125MG	A040282	001	Dec 23, 1999	Jul	CAHN
>A>		@		0.25MG	A040282	002	Dec 23, 1999	Jul	CAHN

DILTIAZEM HYDROCHLORIDE

INJECTABLE; INJECTION

DILTIAZEM HYDROCHLORIDE

>D>	AP		BAXTER HLTHCARE	5MG/ML	A078538	001	Dec 17, 2008	Jul	CAHN
>A>	AP		HIKMA FARMACEUTICA	5MG/ML	A202651	001	Aug 09, 2012	Jul	NEWA
>A>	AP		HIKMA MAPLE	5MG/ML	A078538	001	Dec 17, 2008	Jul	CAHN
		@	TEVA PARENTERAL	5MG/ML	A074894	001	Aug 26, 1997	Jan	DISC

DINOPROSTONE

INSERT, EXTENDED RELEASE; VAGINAL

CERVIDIL

>D>		+	CONTROLLED THERAP	10MG	N020411	001	Mar 30, 1995	Jul	CAHN
>A>		+	FERRING CONTROLLED	10MG	N020411	001	Mar 30, 1995	Jul	CAHN

DIPHENHYDRAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

BENADRYL

		@	MCNEIL CONS	50MG/ML	N006146	002		Mar	DISC

BENADRYL PRESERVATIVE FREE

		@	MCNEIL CONS	50MG/ML	N009486	001		Mar	DISC

DIPHENHYDRAMINE HYDROCHLORIDE

>D>	AP	+	BAXTER HLTHCARE	50MG/ML	A080817	002		Jul	CAHN
>D>		@		50MG/ML	A083183	001		Jul	CAHN
	AP	+		50MG/ML	A080817	002		Apr	CRLD
>A>	AP	+	HIKMA MAPLE	50MG/ML	A080817	002		Jul	CAHN
>A>		@		50MG/ML	A083183	001		Jul	CAHN

DIPYRIDAMOLE

INJECTABLE; INJECTION

DIPYRIDAMOLE

>D>	AP		BAXTER HLTHCARE	5MG/ML	A074521	001	Oct 18, 1996	Jul	CAHN
>A>	AP		HIKMA MAPLE	5MG/ML	A074521	001	Oct 18, 1996	Jul	CAHN
		@	TEVA PARENTERAL	5MG/ML	A074952	001	Nov 26, 1997	Jan	DISC

TABLET; ORAL

DIPYRIDAMOLE

	AB		PROSAM LABS	25MG	A040542	001	Apr 21, 2006	Feb	CAHN

TABLET; ORAL
DIPYRIDAMOLE

AB		PROSAM LABS	50MG	A040542	002	Apr 21, 2006	Feb	CAHN
AB			75MG	A040542	003	Apr 21, 2006	Feb	CAHN

DISOPYRAMIDE PHOSPHATE

CAPSULE, EXTENDED RELEASE; ORAL
DISOPYRAMIDE PHOSPHATE

		@ NESHER PHARMS	EQ 150MG BASE	A071200	001	Dec 15, 1987	Jun	DISC

DIVALPROEX SODIUM

TABLET, EXTENDED RELEASE; ORAL
DIVALPROEX SODIUM

AB		DR REDDYS LABS LTD	EQ 250MG VALPROIC ACID	A090161	001	Mar 15, 2012	Feb	NEWA
AB		REDDYS	EQ 500MG VALPROIC ACID	A090070	001	Mar 12, 2012	Feb	NEWA

DOCETAXEL

INJECTABLE; INJECTION
DOCETAXEL

AP		ACCORD HLTHCARE	20MG/ML (20MG/ML)	N201195	003	Apr 20, 2012	Apr	NEWA
AP			20MG/0.5ML (40MG/ML)	N201195	001	Jun 08, 2011	Jan	CTEC
AP			80MG/4ML (20MG/ML)	N201195	004	Apr 20, 2012	Apr	NEWA
AP			80MG/2ML (40MG/ML)	N201195	002	Jun 08, 2011	Jan	CTEC
			160MG/8ML (20MG/ML)	N201195	005	Apr 20, 2012	Apr	NEWA
AP		APOTEX INC	20MG/0.5ML (40MG/ML)	N022312	001	Jan 11, 2012	Jan	NEWA
AP			80MG/2ML (40MG/ML)	N022312	002	Jan 11, 2012	Jan	NEWA

TAXOTERE

AP	+	SANOFI AVENTIS US	20MG/ML (20MG/ML)	N020449	003	Aug 03, 2010	Apr	CTEC
AP	+		80MG/4ML (20MG/ML)	N020449	004	Aug 02, 2010	Apr	CTEC

DONEPEZIL HYDROCHLORIDE

TABLET; ORAL
DONEPEZIL HYDROCHLORIDE

>A>	AB	INDICUS PHARMA	5MG	A201634	001	Jun 13, 2012	Jul	NEWA
>A>	AB		10MG	A201634	002	Jun 13, 2012	Jul	NEWA
	AB	PRINSTON INC	5MG	A200292	001	May 31, 2011	Jun	CAHN
	AB		10MG	A200292	002	May 31, 2011	Jun	CAHN

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC
COSOPT PF

	+	MERCK SHARP DOHME	EQ 2% BASE;EQ 0.5% BASE	N202667	001	Feb 01, 2012	Feb	NEWA

DOXAZOSIN MESYLATE

TABLET; ORAL
DOXAZOSIN MESYLATE

		@ NESHER PHARMS	EQ 1MG BASE	A075609	001	Oct 18, 2000	Feb	DISC
		@	EQ 2MG BASE	A075609	002	Oct 18, 2000	Feb	DISC
		@	EQ 4MG BASE	A075609	003	Oct 18, 2000	Feb	DISC
		@	EQ 8MG BASE	A075609	004	Oct 18, 2000	Feb	DISC

DOXEPIN HYDROCHLORIDE

CREAM; TOPICAL
ZONALON

	+	FOUGERA PHARMS	5%	N020126	001	Apr 01, 1994	Jan	CAHN

DOXORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION
DOXORUBICIN HYDROCHLORIDE

	AP		ONCO THERAPIES LTD	2MG/ML	A200901	001	Feb 14, 2012	Jan	NEWA
>A>	AP		SANDOZ INC	2MG/ML	A200146	001	Jul 18, 2012	Jul	NEWA
	AP		SUN PHARM INDS	2MG/ML	A091418	001	Feb 15, 2012	Jan	NEWA

INJECTABLE, LIPOSOMAL; INJECTION
DOXIL

	+		JANSSEN R AND D	20MG/10ML (2MG/ML)	N050718	001	Nov 17, 1995	Jan	CAHN
	+			50MG/25ML (2MG/ML)	N050718	002	Jun 13, 2000	Jan	CAHN

DOXYCYCLINE

CAPSULE; ORAL
DOXYCYCLINE

	AB		MYLAN PHARMS INC	EQ 150MG BASE	A202778	001	Jun 08, 2012	May	NEWA
		@	SANDOZ INC	EQ 50MG BASE	A065032	001	Jun 30, 2000	Mar	DISC
		@		EQ 100MG BASE	A065032	002	Jun 30, 2000	Mar	DISC

MONODOX

>A>	AB		AQUA PHARMS	EQ 50MG BASE	N050641	002	Feb 10, 1992	Jul	CAHN
>A>	AB			EQ 75MG BASE	N050641	003	Oct 18, 2006	Jul	CAHN
>A>	AB	+		EQ 100MG BASE	N050641	001	Dec 29, 1989	Jul	CAHN
>D>	AB		WATSON PHARMS	EQ 50MG BASE	N050641	002	Feb 10, 1992	Jul	CAHN
>D>	AB			EQ 75MG BASE	N050641	003	Oct 18, 2006	Jul	CAHN
>D>	AB	+		EQ 100MG BASE	N050641	001	Dec 29, 1989	Jul	CAHN

TABLET; ORAL
DOXYCYCLINE

		@	SANDOZ INC	EQ 50MG BASE	A065353	001	Nov 27, 2006	Mar	DISC
		@		EQ 75MG BASE	A065353	002	Nov 27, 2006	Mar	DISC
		@		EQ 100MG BASE	A065353	003	Nov 27, 2006	Mar	DISC

DOXYCYCLINE HYCLATE

INJECTABLE; INJECTION
DOXYCYCLINE

>D>		@	BAXTER HLTHCARE	EQ 100MG BASE/VIAL	A062450	001	Oct 27, 1983	Jul	CAHN
>D>		@		EQ 200MG BASE/VIAL	A062450	002	Oct 27, 1983	Jul	CAHN
>A>		@	HIKMA MAPLE	EQ 100MG BASE/VIAL	A062450	001	Oct 27, 1983	Jul	CAHN
>A>		@		EQ 200MG BASE/VIAL	A062450	002	Oct 27, 1983	Jul	CAHN

DOXYCYCLINE HYCLATE

>D>		@	BAXTER HLTHCARE	EQ 100MG BASE/VIAL	A062992	001	Feb 16, 1989	Jul	CAHN
>D>		@		EQ 200MG BASE/VIAL	A062992	002	Feb 16, 1989	Jul	CAHN
>A>		@	HIKMA MAPLE	EQ 100MG BASE/VIAL	A062992	001	Feb 16, 1989	Jul	CAHN
>A>		@		EQ 200MG BASE/VIAL	A062992	002	Feb 16, 1989	Jul	CAHN

TABLET; ORAL
DOXYCYCLINE HYCLATE

	AB		LARKEN LABS	EQ 20MG BASE	A065287	001	Feb 28, 2006	Apr	CMFD

TABLET, DELAYED RELEASE; ORAL
DORYX

	AB	+	MAYNE PHARMA	EQ 150MG BASE	N050795	003	Jun 20, 2008	Jan	CTEC

DOXYCYCLINE HYCLATE

	AB		MYLAN PHARMS INC	EQ 150MG BASE	A091052	001	Feb 08, 2012	Jan	NEWA

DROSPIRENONE; ESTRADIOL

TABLET; ORAL
ANGELIQ

			BAYER HLTHCARE	0.25MG;0.5MG	N021355	001	Feb 29, 2012	Feb	NEWA

ECONAZOLE NITRATE

CREAM; TOPICAL
ECONAZOLE NITRATE

AB	+	FOUGERA PHARMS	1%	A076075	001	Nov 26, 2002	Jan	CAHN

EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE

TABLET; ORAL
COMPLERA

	+	GILEAD SCIENCES INC	200MG;EQ 25MG BASE;300MG	N202123	001	Aug 10, 2011	Apr	CAIN

ENALAPRIL MALEATE

TABLET; ORAL
ENALAPRIL MALEATE

	@	SANDOZ INC	2.5MG	A075621	001	Aug 22, 2000	Feb	DISC
	@		2.5MG	A075496	001	Aug 22, 2000	Jan	DISC
	@		5MG	A075621	002	Aug 22, 2000	Feb	DISC
	@		5MG	A075496	002	Aug 22, 2000	Jan	DISC
	@		10MG	A075621	003	Aug 22, 2000	Feb	DISC
	@		10MG	A075459	001	Aug 22, 2000	Jan	DISC
	@		20MG	A075621	004	Aug 22, 2000	Feb	DISC
	@		20MG	A075459	002	Aug 22, 2000	Jan	DISC

ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL
ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE

	@	SANDOZ INC	5MG;12.5MG	A076116	001	Sep 19, 2001	Mar	DISC
	@		10MG;25MG	A076116	002	Sep 19, 2001	Mar	DISC

ENFLURANE

LIQUID; INHALATION
ETHRANE

>A>	AN	+	BAXTER HLTHCARE	99.9%	N017087	001		Jul	CAHN
>D>	AN	+	BAXTER HLTHCARE CORP	99.9%	N017087	001		Jul	CAHN

ENTACAPONE

TABLET; ORAL
COMTAN

>D>		+	ORION PHARMA	200MG	N020796	001	Oct 19, 1999	Jul	CFTG
>A>	AB	+		200MG	N020796	001	Oct 19, 1999	Jul	CFTG
		+		200MG	N020796	001	Oct 19, 1999	May	CAHN
>A>			ENTACAPONE						
>A>	AB		SUN PHARMA GLOBAL	200MG	A090690	001	Jul 16, 2012	Jul	NEWA
>A>	AB		WOCKHARDT LTD	200MG	A078941	001	Aug 16, 2012	Jul	NEWA

EPINASTINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC
EPINASTINE HYDROCHLORIDE

AT		LUITPOLD	0.05%	A090951	001	Oct 31, 2011	Mar	CAHN

EPINEPHRINE

INJECTABLE; IM-SC
ADRENACLICK

BX	+	COREPHARMA	EQ 0.15MG /DELIVERY	N020800	003	Nov 25, 2009	Mar	CAHN
BX	+		EQ 0.3MG /DELIVERY	N020800	004	Nov 25, 2009	Mar	CAHN

		INJECTABLE; IM-SC							
		TWINJECT 0.15							
BX	+	COREPHARMA	EQ 0.15MG /DELIVERY	N020800	002	May 28, 2004	Mar	CAHN
		TWINJECT 0.3							
BX	+	COREPHARMA	EQ 0.3MG /DELIVERY	N020800	001	May 30, 2003	Mar	CAHN
		EPINEPHRINE; LIDOCAINE HYDROCHLORIDE							
		INJECTABLE; INJECTION							
		OCTOCAINE							
AP	+	SEPTODONT	0.01MG/ML;2%	A084048	001		May	CRLD
		XYLOCAINE DENTAL WITH EPINEPHRINE							
		@ DENTSPLY PHARM	0.01MG/ML;2%	N021381	001		May	DISC
		@	0.02MG/ML;2%	N021381	002		May	DISC
		EPIRUBICIN HYDROCHLORIDE							
		INJECTABLE; INJECTION							
		EPIRUBICIN HYDROCHLORIDE							
AP		CIPLA LTD	50MG/25ML (2MG/ML)	A065361	001	Oct 22, 2007	Mar	CAHN
AP			200MG/100ML (2MG/ML)	A065361	002	Oct 22, 2007	Mar	CAHN
AP		HISUN PHARM HANGZHOU	50MG/25ML (2MG/ML)	A090075	001	Mar 25, 2010	Mar	CAHN
AP			200MG/100ML (2MG/ML)	A090075	002	Mar 25, 2010	Mar	CAHN
AP		ONCO THERAPIES LTD	50MG/25ML (2MG/ML)	A091599	001	Mar 12, 2012	Mar	NEWA
AP			200MG/100ML (2MG/ML)	A091599	002	Mar 12, 2012	Mar	NEWA
		EPOPROSTENOL SODIUM							
		INJECTABLE; INJECTION							
		VELETRI							
		ACTELION PHARMS LTD	EQ 0.5MG BASE/VIAL	N022260	002	Jun 28, 2012	Jun	NEWA
	+		EQ 1.5MG BASE/VIAL	N022260	001	Jun 27, 2008	May	CAHN
		ERYTHROMYCIN							
		CAPSULE, DELAYED REL PELLETS; ORAL							
		ERYC							
AB		WARNER CHILCOTT LLC	250MG	A062338	001		Jun	CAHN
		GEL; TOPICAL							
		E-GLADES							
>D> AT		COREPHARMA	2%	A065009	001	Mar 18, 2002	Jul	DISC
>A>		@	2%	A065009	001	Mar 18, 2002	Jul	DISC
		ERYTHROMYCIN							
AT		FOUGERA PHARMS	2%	A064184	001	Sep 30, 1997	Jan	CAHN
		SOLUTION; TOPICAL							
		C-SOLVE-2							
AT		FOUGERA PHARMS	2%	A062468	001	Jul 03, 1985	Jan	CMFD
		SWAB; TOPICAL							
		ERYCETTE							
		@ JOHNSON AND JOHNSON	2%	N050594	001	Feb 15, 1985	Apr	CAHN
		ERYTHROMYCIN							
AT	+	FOUGERA PHARMS	2%	A065320	001	Jul 25, 2006	Jan	CAHN
		ESCITALOPRAM OXALATE							
		SOLUTION; ORAL							
		ESCITALOPRAM OXALATE							
AA		AMNEAL PHARMS	EQ 5MG BASE/5ML	A202227	001	Mar 14, 2012	Feb	NEWA
AA		AUROBINDO PHARMA LTD	EQ 5MG BASE/5ML	A079062	001	Apr 02, 2012	Mar	NEWA
AA		HETERO LABS LTD III	EQ 5MG BASE/5ML	A202221	001	Jun 12, 2012	May	NEWA
AA		TARO	EQ 5MG BASE/5ML	A079121	001	May 03, 2012	Apr	NEWA

SOLUTION; ORAL
LEXAPRO
AA + FOREST LABS EQ 5MG BASE/5ML N021365 001 Nov 27, 2002 Feb CFTG

TABLET; ORAL
ESCITALOPRAM OXALATE
AB IVAX SUB TEVA PHARMS EQ 5MG BASE A076765 001 Mar 14, 2012 Feb NEWA
AB EQ 10MG BASE A076765 002 Mar 14, 2012 Feb NEWA
AB EQ 20MG BASE A076765 003 Mar 14, 2012 Feb NEWA
LEXAPRO
AB FOREST LABS EQ 5MG BASE N021323 001 Aug 14, 2002 Feb CFTG
AB EQ 10MG BASE N021323 002 Aug 14, 2002 Feb CFTG
AB + EQ 20MG BASE N021323 003 Aug 14, 2002 Feb CFTG

ESMOLOL HYDROCHLORIDE

INJECTABLE; INJECTION
BREVIBLOC
AP + BAXTER HLTHCARE 10MG/ML N019386 006 Feb 25, 2003 Jun CAHN
@ 10MG/ML N019386 003 Aug 15, 1988 Jun CAHN
@ 20MG/ML N019386 007 May 28, 2003 Jun CAHN
BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER
+ BAXTER HLTHCARE 2GM/100ML N019386 005 Jan 27, 2003 Jun CAHN
BREVIBLOC IN PLASTIC CONTAINER
+ BAXTER HLTHCARE 1GM/100ML N019386 004 Feb 16, 2001 Jun CAHN

ESOMEPRAZOLE MAGNESIUM

FOR SUSPENSION, DELAYED RELEASE; ORAL
NEXIUM
ASTRAZENECA EQ 2.5MG BASE/PACKET N021957 003 Dec 15, 2011 Jun NEWA
EQ 5MG BASE/PACKET N021957 004 Dec 15, 2011 Jun NEWA

ESTRADIOL

CREAM; VAGINAL
ESTRACE
+ WARNER CHILCOTT US 0.01% A086069 001 Jan 31, 1984 Jun CAHN

GEL, METERED; TRANSDERMAL
ELESTRIN
+ JAZZ PHARMS COMMERCL 0.06% (0.87GM/ACTIVATION) N021813 001 Dec 15, 2006 Jun CAHN

ESTRADIOL ACETATE

INSERT, EXTENDED RELEASE; VAGINAL
FEMRING
WARNER IRELAND EQ 0.05MG BASE/24HR N021367 001 Mar 20, 2003 May CAHN
+ EQ 0.1MG BASE/24HR N021367 002 Mar 20, 2003 May CAHN

TABLET; ORAL
FEMTRACE
WARNER CHILCOTT LLC 0.45MG N021633 001 Aug 20, 2004 Jun CAHN
0.9MG N021633 002 Aug 20, 2004 Jun CAHN
+ 1.8MG N021633 003 Aug 20, 2004 Jun CAHN

ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL
ESTRADIOL AND NORETHINDRONE ACETATE
AB TEVA PHARMS USA 0.5MG;0.1MG A200747 001 Mar 08, 2012 Feb NEWA

ESTROGENS, CONJUGATED SYNTHETIC A

TABLET; ORAL

			CENESTIN						
			TEVA BRANDED PHARM	0.3MG	N020992	001	Jun 21, 2002	Jun	CAHN
				0.45MG	N020992	005	Feb 05, 2004	Jun	CAHN
				0.625MG	N020992	002	Mar 24, 1999	Jun	CAHN
				0.9MG	N020992	003	Mar 24, 1999	Jun	CAHN
		+		1.25MG	N020992	004	Mar 13, 2000	Jun	CAHN

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL

			LEVONORGESTREL AND ETHINYL ESTRADIOL						
		+	WATSON LABS	0.02MG;0.09MG	A079218	001	Jun 06, 2011	May	CRLD
			LOSEASONIQUE						
	AB		TEVA BRANDED PHARM	0.02MG,0.01MG;0.1MG,N/A	N022262	001	Oct 24, 2008	Jun	CAHN
			LYBREL						
			@ WYETH PHARMS INC	0.02MG;0.09MG	N021864	001	May 22, 2007	May	DISC
			PREVEN EMERGENCY CONTRACEPTIVE KIT						
			@ TEVA BRANDED PHARM	0.05MG;0.25MG	N020946	001	Sep 01, 1998	Jun	CAHN
			SEASONALE						
>D>	AB	+	DURAMED RES	0.03MG;0.15MG	N021544	001	Sep 05, 2003	Jul	CAHN
>A>	AB	+	TEVA BRANDED PHARM	0.03MG;0.15MG	N021544	001	Sep 05, 2003	Jul	CAHN
			SEASONIQUE						
	AB	+	TEVA BRANDED PHARM	0.03MG,0.01MG;0.15MG,N/A	N021840	001	May 25, 2006	Jun	CAHN

TABLET; ORAL-21

			NORDETTE-21						
			@ TEVA BRANDED PHARM	0.03MG;0.15MG	N018668	001	May 10, 1982	Jun	CAHN

TABLET; ORAL-28

			FALMINA						
	AB1		NOVAST LABS LTD	0.02MG;0.1MG	A090721	001	Mar 28, 2012	Mar	NEWA
			MARLISSA						
	AB		GLENMARK GENERICS	0.03MG;0.15MG	A091452	001	Feb 29, 2012	Feb	NEWA
			MYZILRA						
	AB		VINTAGE PHARMS	0.03MG,0.04MG,0.03MG;0.05MG,0.075 MG,0.125MG	A077502	001	Nov 23, 2011	May	CDFR
			NORDETTE-28						
	AB	+	TEVA BRANDED PHARM	0.03MG;0.15MG	N018782	001	Jul 21, 1982	Jun	CAHN

ETHINYL ESTRADIOL; NORELGESTROMIN

FILM, EXTENDED RELEASE; TRANSDERMAL

			ORTHO EVRA						
		+	JANSSEN PHARMS	0.75MG;6MG	N021180	001	Nov 20, 2001	Jun	CPOT

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-28

			ALYACEN 1/35						
	AB		GLENMARK GENERICS	0.035MG;1MG	A091634	001	Jan 19, 2012	Jan	NEWA
			ALYACEN 7/7/7						
	AB		GLENMARK GENERICS	0.035MG,0.035MG,0.035MG;0.5MG,0.7 5MG,1MG	A091636	001	Jan 19, 2012	Jan	NEWA
			OVCON-35						
	AB	+	WARNER CHILCOTT LLC	0.035MG;0.4MG	N017716	001		Jun	CAHN
			OVCON-50						
		+	WARNER CHILCOTT LLC	0.05MG;1MG	N017576	001		Jun	CAHN
			WERA						
	AB		NOVAST LABS LTD	0.035MG;0.5MG	A091204	001	Mar 27, 2012	Mar	NEWA

	TABLET, CHEWABLE; ORAL							
	FEMCON FE							
AB	+ WARNER CHILCOTT LLC	0.035MG;0.4MG	N021490	001	Nov 14, 2003	Jun	CAHN	
	ETHINYL ESTRADIOL; NORETHINDRONE ACETATE							
	TABLET; ORAL							
	FEMHRT							
	WARNER CHILCOTT LLC	0.0025MG;0.5MG	N021065	001	Jan 14, 2005	Jun	CAHN	
AB	+	0.005MG;1MG	N021065	002	Oct 15, 1999	Jun	CAHN	
	LO LOESTRIN FE							
	+ WARNER CHILCOTT LLC	0.01MG,0.01MG;1MG,N/A	N022501	001	Oct 21, 2010	Jun	CAHN	
	TABLET; ORAL-21							
	ESTROSTEP 21							
	@ WARNER CHILCOTT LLC	0.02MG,0.03MG,0.035MG;1MG,1MG,1MG	N020130	001	Oct 09, 1996	Jun	CAHN	
	LOESTRIN 21 1.5/30							
AB	WARNER CHILCOTT LLC	0.03MG;1.5MG	N017875	001		Jun	CAHN	
	LOESTRIN 21 1/20							
AB	WARNER CHILCOTT LLC	0.02MG;1MG	N017876	001		Jun	CAHN	
	TABLET; ORAL-28							
	ESTROSTEP FE							
AB	+ WARNER CHILCOTT LLC	0.02MG,0.03MG,0.035MG;1MG,1MG,1MG	N020130	002	Oct 09, 1996	Jun	CAHN	
	LOESTRIN FE 1.5/30							
AB	+ WARNER CHILCOTT LLC	0.03MG;1.5MG	N017355	001		Jun	CAHN	
	ETHINYL ESTRADIOL; NORGESTIMATE							
	TABLET; ORAL-28							
	MONO-LINYAH							
AB	NOVAST LABS LTD	0.035MG;0.25MG	A090523	001	May 23, 2012	May	NEWA	
	NORGESTIMATE AND ETHINYL ESTRADIOL							
AB	GLENMARK GENERICS	0.035MG;0.25MG	A200538	001	Apr 05, 2012	Mar	NEWA	
AB	LUPIN PHARMS	0.025MG,0.025MG,0.025MG;0.18MG,0.215MG,0.25MG	A200541	001	Jun 25, 2012	Jun	NEWA	
	TRI-LINYAH							
AB	NOVAST LABS LTD	0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG	A090524	001	May 30, 2012	May	NEWA	
	ETHINYL ESTRADIOL; NORGESTREL							
	TABLET; ORAL-28							
	ELINEST							
AB	NOVAST LABS LTD	0.03MG;0.3MG	A091105	001	Mar 28, 2012	Mar	NEWA	
	ETODOLAC							
	TABLET; ORAL							
	ETODOLAC							
AB	PROSAM LABS	400MG	A074819	001	Feb 28, 1997	Feb	CMFD	
AB		500MG	A074819	002	Apr 28, 1998	Feb	CMFD	
	ETOMIDATE							
	INJECTABLE; INJECTION							
	ETOMIDATE							
AP	MYLAN INSTITUTIONAL	2MG/ML	A091297	001	Jun 20, 2012	Jun	NEWA	
	ETOPOSIDE							
	CAPSULE; ORAL							
	VEPESID							
	@ CORDEN PHARMA	50MG	N019557	001	Dec 30, 1986	Feb	CAHN	

CAPSULE; ORAL
VEPESID
@ CORDEN PHARMA 100MG N019557 002 Dec 30, 1986 Feb CAHN

INJECTABLE; INJECTION
ETOPOSIDE
AP + APP PHARMS LLC 20MG/ML A074983 001 Sep 30, 1998 Mar CRLD
AP BEDFORD 20MG/ML A074290 001 Jul 17, 1995 Mar CRLD
VEPESID
@ CORDEN PHARMA 20MG/ML N018768 001 Nov 10, 1983 Feb CAHN

ETRAVIRINE

TABLET; ORAL
INTELENCE
JANSSEN R AND D 25MG N022187 003 Mar 26, 2012 Mar NEWA
100MG N022187 001 Jan 18, 2008 Feb CAHN
+ 200MG N022187 002 Dec 22, 2010 Feb CAHN

EVEROLIMUS

TABLET; ORAL
AFINITOR
NOVARTIS 7.5MG N022334 004 Mar 30, 2012 Apr NEWA

EXENATIDE SYNTHETIC

FOR SUSPENSION, EXTENDED RELEASE; SUBCUTANEOUS
BYDUREON
+ AMYLIN 2MG/VIAL N022200 001 Jan 27, 2012 Jan NEWA

EZETIMIBE

TABLET; ORAL
ZETIA
+ MSD INTL GMBH 10MG N021445 001 Oct 25, 2002 Feb CAHN
+ MSP SINGAPORE 10MG N021445 001 Oct 25, 2002 Jan CAHN

EZETIMIBE; SIMVASTATIN

TABLET; ORAL
VYTORIN
MSD INTL 10MG;10MG N021687 001 Jul 23, 2004 Jan CAHN
10MG;20MG N021687 002 Jul 23, 2004 Jan CAHN
10MG;40MG N021687 003 Jul 23, 2004 Jan CAHN
+ 10MG;80MG N021687 004 Jul 23, 2004 Jan CAHN

EZOGABINE

TABLET; ORAL
POTIGA
GLAXOSMITHKLINE 50MG N022345 001 Jun 10, 2011 May CAHN
200MG N022345 002 Jun 10, 2011 May CAHN
300MG N022345 003 Jun 10, 2011 May CAHN
+ 400MG N022345 004 Jun 10, 2011 May CAHN

FAMCICLOVIR

TABLET; ORAL
FAMCICLOVIR
AB MACLEODS PHARMS LTD 125MG A201022 001 Jan 12, 2012 Jan NEWA
AB 250MG A201022 002 Jan 12, 2012 Jan NEWA
AB 500MG A201022 003 Jan 12, 2012 Jan NEWA

FAMOTIDINE

INJECTABLE; INJECTION

FAMOTIDINE

>D>	AP	+	BAXTER HLTHCARE	10MG/ML	A075488	001	Apr 16, 2001	Jul	CAHN
>D>	AP	+		10MG/ML	A075799	001	Apr 30, 2002	Jul	CAHN
>A>	AP	+	HIKMA MAPLE	10MG/ML	A075488	001	Apr 16, 2001	Jul	CAHN
>A>	AP	+		10MG/ML	A075799	001	Apr 30, 2002	Jul	CAHN

FAMOTIDINE PRESERVATIVE FREE

>D>	AP	+	BAXTER HLTHCARE	10MG/ML	A075789	001	Apr 30, 2002	Jul	CAHN
>D>	AP	+		10MG/ML	A075486	001	Apr 16, 2001	Jul	CAHN
>A>	AP	+	HIKMA MAPLE	10MG/ML	A075486	001	Apr 16, 2001	Jul	CAHN
>A>	AP	+		10MG/ML	A075789	001	Apr 30, 2002	Jul	CAHN

TABLET; ORAL

PEPCID

	AB		MARATHON PHARMS	20MG	N019462	001	Oct 15, 1986	Jan	CAHN
	AB	+		40MG	N019462	002	Oct 15, 1986	Jan	CAHN

TABLET, ORALLY DISINTEGRATING; ORAL

FLUXID

			@ UCB INC	20MG	N021712	001	Sep 24, 2004	Jan	CAHN
			@	40MG	N021712	002	Sep 24, 2004	Jan	CAHN

FEBUXOSTAT

TABLET; ORAL

ULORIC

			TAKEDA PHARMS USA	40MG	N021856	001	Feb 13, 2009	Apr	CAHN
		+		80MG	N021856	002	Feb 13, 2009	Apr	CAHN

FELODIPINE

TABLET, EXTENDED RELEASE; ORAL

FELODIPINE

>A>	AB		WOCKHARDT LTD	2.5MG	A091484	001	Aug 15, 2012	Jul	NEWA
>A>	AB			5MG	A091484	002	Aug 15, 2012	Jul	NEWA
>A>	AB			10MG	A091484	003	Aug 15, 2012	Jul	NEWA

FENOFIBRATE

CAPSULE; ORAL

ANTARA (MICRONIZED)

	AB		LUPIN ATLANTIS	43MG	N021695	001	Nov 30, 2004	Feb	CFTG
	AB	+		130MG	N021695	003	Nov 30, 2004	Feb	CFTG

FENOFIBRATE (MICRONIZED)

	AB		DR REDDYS LABS SA	43MG	A090859	001	Mar 01, 2012	Feb	NEWA
	AB			130MG	A090859	002	Mar 01, 2012	Feb	NEWA

TABLET; ORAL

FENOFIBRATE

	AB		IMPAX LABS	160MG	A076509	002	Mar 26, 2008	May	CRLD
	AB	+		160MG	A076509	002	Mar 26, 2008	Mar	CRLD
	AB		TEVA	54MG	A076433	001	May 13, 2005	May	CMFD
			@	54MG	A076433	001	May 13, 2005	Mar	DISC
	AB	+		160MG	A076433	002	May 13, 2005	May	CMFD
			@	160MG	A076433	002	May 13, 2005	Mar	DISC
	AB		VALEANT INTL	48MG	A090715	001	Apr 05, 2012	Mar	NEWA
	AB			145MG	A090715	002	Apr 05, 2012	Mar	NEWA

FENTANYL

FILM, EXTENDED RELEASE; TRANSDERMAL

FENTANYL-100

AB		AVEVA	100MCG/HR	A077449	004	Oct 20, 2008	Jun	CAHN

FENTANYL-25

AB		AVEVA	25MCG/HR	A077449	001	Oct 20, 2008	Jun	CAHN

FENTANYL-50

AB		AVEVA	50MCG/HR	A077449	002	Oct 20, 2008	Jun	CAHN

FENTANYL-75

AB		AVEVA	75MCG/HR	A077449	003	Oct 20, 2008	Jun	CAHN

SPRAY; SUBLINGUAL

SUBSYS

		INSYS THERAP	0.1MG	N202788	001	Jan 04, 2012	Mar	CPOT
			0.1MCG	N202788	001	Jan 04, 2012	Jan	NEWA
			0.2MG	N202788	002	Jan 04, 2012	Mar	CPOT
			0.2MCG	N202788	002	Jan 04, 2012	Jan	NEWA
	+		0.4MG	N202788	003	Jan 04, 2012	Mar	CPOT
	+		0.4MCG	N202788	003	Jan 04, 2012	Jan	NEWA
			0.6MG	N202788	004	Jan 04, 2012	Mar	CPOT
			0.6MCG	N202788	004	Jan 04, 2012	Jan	NEWA
			0.8MG	N202788	005	Jan 04, 2012	Mar	CPOT
			0.8MCG	N202788	005	Jan 04, 2012	Jan	NEWA

FENTANYL CITRATE

SPRAY, METERED; NASAL

LAZANDA

		ARCHIMEDES	EQ 0.1MG BASE	N022569	001	Jun 30, 2011	Jan	CPOT
	+		EQ 0.4MG BASE	N022569	002	Jun 30, 2011	Jan	CPOT

TROCHE/LOZENGE; TRANSMUCOSAL

FENTANYL CITRATE

AB		PAR PHARM	EQ 0.2MG BASE	A077312	001	Oct 30, 2009	Feb	CAHN
AB			EQ 0.4MG BASE	A077312	002	Oct 30, 2009	Feb	CAHN
AB			EQ 0.6MG BASE	A077312	003	Oct 30, 2009	Feb	CAHN
AB			EQ 0.8MG BASE	A077312	004	Oct 30, 2009	Feb	CAHN
AB			EQ 1.2MG BASE	A077312	005	Oct 30, 2009	Feb	CAHN
AB			EQ 1.6MG BASE	A077312	006	Oct 30, 2009	Feb	CAHN

FERUMOXIDES

INJECTABLE; INJECTION

FERIDEX I.V.

		@ AMAG PHARMS INC	EQ 11.2MG IRON/ML	N020416	001	Aug 30, 1996	Jun	DISC

FEXOFENADINE HYDROCHLORIDE

SUSPENSION; ORAL

ALLEGRA

>D>		+	SANOFI AVENTIS US	30MG/5ML	N021963	001	Oct 16, 2006	Jul	CFTG
>A>	AB	+		30MG/5ML	N021963	001	Oct 16, 2006	Jul	CFTG

>A> FEXOFENADINE HYDROCHLORIDE

>A>	AB		ACTAVIS MID ATLANTIC	30MG/5ML	A201311	001	Jul 25, 2012	Jul	NEWA

FLORBETAPIR F-18

SOLUTION; INTRAVENOUS

AMYVID

+		AVID RADIOPHARMS INC	10-50ML (13.5-51MCI/ML)	N202008	003	Apr 06, 2012	Jun	CPOT
+			10-50ML (13.5-51CMI/ML)	N202008	003	Apr 06, 2012	Apr	NEWA

		SOLUTION; INTRAVENOUS							
		AMYVID							
		+ AVID RADIOPHARMS INC	10-30ML (13.5-51MCI/ML)	N202008	002	Apr 06, 2012	Apr	NEWA
		+	10ML (13.5-51MCI/ML)	N202008	001	Apr 06, 2012	Apr	NEWA
		FLUCONAZOLE							
		INJECTABLE; INJECTION							
		FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER							
	AP	HIKMA FARMACEUTICA	200MG/100ML (2MG/ML)	A078764	001	Jan 30, 2012	Jan	NEWA
	AP		400MG/200ML (2MG/ML)	A078764	002	Jan 30, 2012	Jan	NEWA
		FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER							
	AP	HIKMA FARMACEUTICA	200MG/100ML (2MG/ML)	A078698	001	Jan 30, 2012	Jan	NEWA
	AP		400MG/200ML (2MG/ML)	A078698	002	Jan 30, 2012	Jan	NEWA
		TABLET; ORAL							
		FLUCONAZOLE							
>D>	AB	AMNEAL PHARM	50MG	A078423	001	Mar 07, 2011	Jul	CAHN
>D>	AB		100MG	A078423	002	Mar 07, 2011	Jul	CAHN
>D>	AB		150MG	A078423	003	Mar 07, 2011	Jul	CAHN
>D>	AB		200MG	A078423	004	Mar 07, 2011	Jul	CAHN
>A>	AB	HARRIS PHARM	50MG	A078423	001	Mar 07, 2011	Jul	CAHN
>A>	AB		100MG	A078423	002	Mar 07, 2011	Jul	CAHN
>A>	AB		150MG	A078423	003	Mar 07, 2011	Jul	CAHN
>A>	AB		200MG	A078423	004	Mar 07, 2011	Jul	CAHN
		@ PLIVA	50MG	A076424	001	Jul 29, 2004	Feb	DISC
		@	100MG	A076424	002	Jul 29, 2004	Feb	DISC
		@	150MG	A076424	003	Jul 29, 2004	Feb	DISC
		@	200MG	A076424	004	Jul 29, 2004	Feb	DISC
		@ RANBAXY LABS LTD	50MG	A076386	001	Jul 29, 2004	Apr	DISC
		@	100MG	A076386	002	Jul 29, 2004	Apr	DISC
		@	150MG	A076386	003	Jul 29, 2004	Apr	DISC
		@	200MG	A076386	004	Jul 29, 2004	Apr	DISC
		FLUDARABINE PHOSPHATE							
		INJECTABLE; INJECTION							
		FLUDARA							
		@ GENZYME CORP	50MG/VIAL	N020038	001	Apr 18, 1991	Mar	DISC
		FLUDARABINE PHOSPHATE							
	AP	+ HOSPIRA	50MG/VIAL	A077790	001	Apr 06, 2007	Mar	CRLD
		TABLET; ORAL							
		OFORTA							
		@ SANOFI AVENTIS US	10MG	N022273	001	Dec 18, 2008	May	DISC
		FLUMAZENIL							
		INJECTABLE; INJECTION							
		FLUMAZENIL							
>D>	AP	BAXTER HLTHCARE	0.5MG/5ML (0.1MG/ML)	A076787	002	Oct 12, 2004	Jul	CAHN
>D>	AP		1MG/10ML (0.1MG/ML)	A076787	001	Oct 12, 2004	Jul	CAHN
>A>	AP	HIKMA MAPLE	0.5MG/5ML (0.1MG/ML)	A076787	002	Oct 12, 2004	Jul	CAHN
>A>	AP		1MG/10ML (0.1MG/ML)	A076787	001	Oct 12, 2004	Jul	CAHN
		@ TEVA PARENTERAL	0.5MG/5ML (0.1MG/ML)	A076589	002	Oct 12, 2004	Jan	DISC
		@	1MG/10ML (0.1MG/ML)	A076589	001	Oct 12, 2004	Jan	DISC
		FLUNISOLIDE							
		AEROSOL, METERED; INHALATION							
		AEROSPAN HFA							
>D>		+ ACTON PHARMS	EQ 78MCG BASE/INH	N021247	001	Jan 27, 2006	Jul	CPOT

AEROSOL, METERED; INHALATION
AEROSPAN HFA

>A>	+	ACTON PHARMS	EQ 78MG BASE/INH	N021247	001	Jan 27, 2006	Jul	CPOT

FLUOCINOLONE ACETONIDE

OIL/DROPS; OTIC
FLUOCINOLONE ACETONIDE

AT		IDENTI PHARMS INC	0.01%	A091306	001	Oct 17, 2011	Jan	CPOT

FLUOCINONIDE

CREAM; TOPICAL
FLUOCINONIDE EMULSIFIED BASE

AB2		FOUGERA PHARMS	0.05%	A076586	001	Jun 23, 2004	Jan	CAHN
	@	G AND W LABS INC	0.05%	A074204	001	Jun 13, 1995	May	CAHN

OINTMENT; TOPICAL
FLUOCINONIDE

AB		FOUGERA PHARMS	0.05%	A074905	001	Aug 26, 1997	Jan	CAHN

FLUOROURACIL

CREAM; TOPICAL
CARAC

>D>	+	SANOFI AVENTIS US	0.5%	N020985	001	Oct 27, 2000	Jul	CAHN
>A>	+	VALEANT INTL	0.5%	N020985	001	Oct 27, 2000	Jul	CAHN

FLUOROPLEX

	+	AQUA PHARMS	1%	N016988	001		Jan	CAHN

INJECTABLE; INJECTION
FLUOROURACIL

>A>	AP	ONCO THERAPIES LTD	500MG/10ML (50MG/ML)	A202668	001	Jul 17, 2012	Jul	NEWA
>A>	AP		1GM/20ML (50MG/ML)	A202668	002	Jul 17, 2012	Jul	NEWA
>A>	AP		2.5GM/50ML (50MG/ML)	A202669	001	Jul 17, 2012	Jul	NEWA
>A>	AP		5GM/100ML (50MG/ML)	A202669	002	Jul 17, 2012	Jul	NEWA

FLUOXETINE HYDROCHLORIDE

CAPSULE; ORAL
PROZAC

AB1		ELI LILLY AND CO	EQ 10MG BASE	N018936	006	Dec 23, 1992	Apr	CAHN
AB1			EQ 20MG BASE	N018936	001	Dec 29, 1987	Apr	CAHN
AB	+		EQ 40MG BASE	N018936	003	Jun 15, 1999	Apr	CAHN
	@		EQ 60MG BASE	N018936	004	Jun 15, 1999	Apr	CAHN

SARAFEM

AB2		ELI LILLY AND CO	EQ 10MG BASE	N018936	007	Jul 06, 2000	Apr	CAHN
AB2	+		EQ 20MG BASE	N018936	008	Jul 06, 2000	Apr	CAHN

TABLET; ORAL
SARAFEM

		WARNER CHILCOTT LLC	EQ 10MG BASE	N021860	001	May 19, 2006	Jun	CAHN
			EQ 15MG BASE	N021860	002	May 19, 2006	Jun	CAHN
	+		EQ 20MG BASE	N021860	003	May 19, 2006	Jun	CAHN

FLUOXETINE HYDROCHLORIDE; OLANZAPINE

CAPSULE; ORAL
OLANZAPINE AND FLUOXETINE HYDROCHLORIDE

AB		TEVA PHARMS	EQ 25MG BASE;EQ 6MG BASE	A077528	001	Jun 19, 2012	Jun	NEWA
AB			EQ 25MG BASE;EQ 12MG BASE	A077528	002	Jun 19, 2012	Jun	NEWA
AB			EQ 50MG BASE;EQ 6MG BASE	A077528	003	Jun 19, 2012	Jun	NEWA
AB			EQ 50MG BASE;EQ 12MG BASE	A077528	004	Jun 19, 2012	Jun	NEWA

		CAPSULE; ORAL						
		SYMBYAX						
	AB	LILLY	EQ 25MG BASE;EQ 6MG BASE	N021520	002	Dec 24, 2003	Jun	CFTG
	AB		EQ 25MG BASE;EQ 12MG BASE	N021520	004	Dec 24, 2003	Jun	CFTG
	AB	+	EQ 50MG BASE;EQ 6MG BASE	N021520	003	Dec 24, 2003	Jun	CFTG
	AB		EQ 50MG BASE;EQ 12MG BASE	N021520	005	Dec 24, 2003	Jun	CFTG
		FLURANDRENOLIDE						
		CREAM; TOPICAL						
		CORDRAN SP						
>A>		AQUA PHARMS	0.025%	N012806	003		Jul	CAHN
>A>			0.05%	N012806	002		Jul	CAHN
>D>		WATSON PHARMS	0.025%	N012806	003		Jul	CAHN
>D>			0.05%	N012806	002		Jul	CAHN
			0.05%	N012806	002		Apr	CMFD
		LOTION; TOPICAL						
		CORDRAN						
>A>	+	AQUA PHARMS	0.05%	N013790	001		Jul	CAHN
>D>	+	WATSON LABS	0.05%	N013790	001		Jul	CAHN
		OINTMENT; TOPICAL						
		CORDRAN						
>A>		@ AQUA PHARMS	0.025%	N012806	004		Jul	CAHN
>A>		@	0.05%	N012806	001		Jul	CAHN
>D>		@ WATSON PHARMS	0.025%	N012806	004		Jul	CAHN
>D>		@	0.05%	N012806	001		Jul	CAHN
		FLUTAMIDE						
		CAPSULE; ORAL						
		FLUTAMIDE						
	AB	+ IVAX SUB TEVA PHARMS	125MG	A075780	001	Sep 19, 2001	Mar	CRLD
	AB	SANDOZ INC	125MG	A075818	001	Sep 18, 2001	Mar	CRLD
		FLUTICASONE PROPIONATE						
		CREAM; TOPICAL						
		CUTIVATE						
	AB	+ FOUGERA PHARMS	0.05%	N019958	001	Dec 18, 1990	Jan	CAHN
		FLUTICASONE PROPIONATE						
	AB	FOUGERA PHARMS	0.05%	A076451	001	May 14, 2004	Jan	CAHN
		@ NESHER PHARMS	0.05%	A076865	001	Sep 10, 2004	Jun	DISC
		OINTMENT; TOPICAL						
		FLUTICASONE PROPIONATE						
	AB	FOUGERA PHARMS	0.005%	A076300	001	May 14, 2004	Jan	CAHN
		FLUVASTATIN SODIUM						
		CAPSULE; ORAL						
		FLUVASTATIN SODIUM						
	AB	MYLAN PHARMS INC	EQ 20MG BASE	A090595	001	Apr 11, 2012	Mar	NEWA
	AB		EQ 40MG BASE	A090595	002	Apr 11, 2012	Mar	NEWA
	AB	TEVA PHARMS	EQ 20MG BASE	A078407	001	Jun 12, 2012	May	NEWA
	AB		EQ 40MG BASE	A078407	002	Jun 12, 2012	May	NEWA
		LESCOL						
	AB	NOVARTIS	EQ 20MG BASE	N020261	001	Dec 31, 1993	Mar	CFTG
	AB	+	EQ 40MG BASE	N020261	002	Dec 31, 1993	Mar	CFTG

FLUVOXAMINE MALEATE

CAPSULE, EXTENDED RELEASE; ORAL

LUVOX CR

	JAZZ PHARMS	100MG	N022033	001	Feb 28, 2008	Jun	CAHN
+		150MG	N022033	002	Feb 28, 2008	Jun	CAHN

FORMOTEROL FUMARATE; MOMETASONE FUROATE

AEROSOL, METERED; INHALATION

DULERA

+	MERCK SHARP DOHME	0.005MG/INH;0.1MG/INH	N022518	001	Jun 22, 2010	Jun	CAHN
+		0.005MG/INH;0.2MG/INH	N022518	002	Jun 22, 2010	Jun	CAHN

FOSINOPRIL SODIUM

TABLET; ORAL

FOSINOPRIL SODIUM

@	RANBAXY LABS LTD	10MG	A076580	001	Apr 23, 2004	Apr	DISC
@		20MG	A076580	002	Apr 23, 2004	Apr	DISC
@		40MG	A076580	003	Apr 23, 2004	Apr	DISC

MONOPRIL

@	BRISTOL MYERS SQUIBB	10MG	N019915	002	May 16, 1991	Mar	DISC
@		20MG	N019915	003	May 16, 1991	Mar	DISC
@		40MG	N019915	004	Mar 28, 1995	Mar	DISC

FOSPHENYTOIN SODIUM

INJECTABLE; INJECTION

FOSPHENYTOIN SODIUM

>D>	AP	BAXTER HLTHCARE	EQ 50MG PHENYTOIN NA/ML	A077989	001	Aug 06, 2007	Jul	CAHN
>A>	AP	HIKMA MAPLE	EQ 50MG PHENYTOIN NA/ML	A077989	001	Aug 06, 2007	Jul	CAHN
		@ TEVA PARENTERAL	EQ 50MG PHENYTOIN NA/ML	A076886	001	Aug 06, 2007	Mar	DISC

FOSPROPOFOL DISODIUM

SOLUTION; INTRAVENOUS

>D>	LUSEDRA							
>D>	+ EISAI INC	1050MG/30ML (35MG/ML)	N022244	001	Dec 12, 2008	Jul	DISC
>A>	@	1050MG/30ML (35MG/ML)	N022244	001	Dec 12, 2008	Jul	DISC

FUROSEMIDE

INJECTABLE; INJECTION

FUROSEMIDE

@	HOSPIRA	10MG/ML	A070578	001	Jul 08, 1987	Jun	DISC

GABAPENTIN

SOLUTION; ORAL

GABAPENTIN

AA	ACELLA PHARMS LLC	250MG/5ML	A076403	001	May 01, 2012	Jun	CAHN
AA	AMNEAL PHARMS	250MG/5ML	A202024	001	Mar 23, 2012	Mar	NEWA
AA	KIEL	250MG/5ML	A076403	001	May 01, 2012	Apr	NEWA

GANCICLOVIR

CAPSULE; ORAL

GANCICLOVIR

@	RANBAXY LABS LTD	250MG	A076457	001	Jun 27, 2003	Apr	DISC
@		500MG	A076457	002	Jun 27, 2003	Apr	DISC

GEMCITABINE HYDROCHLORIDE

INJECTABLE; INJECTION

GEMCITABINE HYDROCHLORIDE

	+	HOSPIRA INC	200MG/5.26ML (38MG/ML)	N200795	001	Aug 04, 2011	Apr	CTNA
	+		1GM/26.3ML (38MG/ML)	N200795	002	Aug 04, 2011	Apr	CTNA
	+		2GM/52.6ML (38MG/ML)	N200795	003	Aug 04, 2011	Apr	CTNA

GLIMEPIRIDE

TABLET; ORAL

GLIMEPIRIDE

AB		AUROBINDO PHARMA LTD	1MG	A202759	001	Jun 29, 2012	Jun	NEWA
AB			2MG	A202759	002	Jun 29, 2012	Jun	NEWA
AB			4MG	A202759	003	Jun 29, 2012	Jun	NEWA
AB		MICRO LABS USA	1MG	A091220	001	Jun 29, 2012	Jun	NEWA
AB			2MG	A091220	002	Jun 29, 2012	Jun	NEWA
			3MG	A091220	003	Jun 29, 2012	Jun	NEWA
AB			4MG	A091220	004	Jun 29, 2012	Jun	NEWA
			6MG	A091220	005	Jun 29, 2012	Jun	NEWA
AB			8MG	A091220	006	Jun 29, 2012	Jun	NEWA
	@	RANBAXY LABS LTD	1MG	A076875	001	Oct 06, 2005	Apr	DISC
	@		2MG	A076875	002	Oct 06, 2005	Apr	DISC
	@		4MG	A076875	003	Oct 06, 2005	Apr	DISC
	@		8MG	A076875	004	Oct 06, 2005	Apr	DISC

GLYCOPYRROLATE

TABLET; ORAL

GLYCOPYRROLATE

AA		NEXGEN PHARMA	1.5MG	A091522	001	Mar 12, 2012	Feb	NEWA

GRANISETRON HYDROCHLORIDE

INJECTABLE; INJECTION

GRANISETRON HYDROCHLORIDE

AP		CIPLA LTD	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A078262	001	Dec 31, 2007	Mar	CAHN
AP			EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A078258	001	Jun 30, 2008	Mar	CAHN
AP			EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A078258	002	Jun 30, 2008	Mar	CAHN

GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE

AP	+	APP PHARMS LLC	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A078096	001	Jun 30, 2008	Apr	CRLD
	@	TEVA PARENTERAL	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A077165	001	Dec 31, 2007	Apr	DISC

GRISEOFULVIN, MICROCRYSTALLINE

SUSPENSION; ORAL

GRIFULVIN V

AB	+	VALEANT PHARM NORTH	125MG/5ML	A062483	001	Jan 26, 1984	Feb	CAHN

TABLET; ORAL

GRIFULVIN V

>D>		@ ORTHO JANSSEN	125MG	A062279	001		Jul	CAHN
>D>		@	250MG	A062279	002		Jul	CAHN
>D>	+		500MG	A062279	003		Jul	CAHN
>A>		@ VALEANT INTL	125MG	A062279	001		Jul	CAHN
>A>		@	250MG	A062279	002		Jul	CAHN
>A>	+		500MG	A062279	003		Jul	CAHN

HALOBETASOL PROPIONATE

CREAM; TOPICAL
HALOBETASOL PROPIONATE

AB		FOUGERA PHARMS	0.05%	A077001	001	Dec 16, 2004	Jan	CAHN

OINTMENT; TOPICAL
HALOBETASOL PROPIONATE

AB		FOUGERA PHARMS	0.05%	A076903	001	Dec 16, 2004	Jan	CAHN
	@	VENUS PHARMS	0.05%	A077109	001	Jun 14, 2005	Jun	CAHN

HEPARIN SODIUM

INJECTABLE; INJECTION
HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

>D>	AP		B BRAUN	200 UNITS/100ML	N019953	001	Jul 20, 1992	Jul	CRLD
>A>	AP	+		200 UNITS/100ML	N019953	001	Jul 20, 1992	Jul	CRLD

HEPARIN SODIUM 10,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER

		@	BAXTER HLTHCARE	2,000 UNITS/100ML	N018814	002	Jul 09, 1985	Mar	DISC

HEPARIN SODIUM 20,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER

		@	BAXTER HLTHCARE	4,000 UNITS/100ML	N018814	001	Oct 31, 1983	Mar	DISC

HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER

>D>	AP		B BRAUN	4,000 UNITS/100ML	N019952	001	Jul 20, 1992	Jul	CRLD
>A>	AP	+		4,000 UNITS/100ML	N019952	001	Jul 20, 1992	Jul	CRLD

HEPARIN SODIUM 25,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER

		@	BAXTER HLTHCARE	5,000 UNITS/100ML	N018814	003	Jul 09, 1985	Mar	DISC
		@		10,000 UNITS/100ML	N018814	004	Jul 02, 1987	Mar	DISC

HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER

>D>	AP		B BRAUN	5,000 UNITS/100ML	N019952	004	Jul 20, 1992	Jul	CRLD
>A>	AP	+		5,000 UNITS/100ML	N019952	004	Jul 20, 1992	Jul	CRLD
>D>	AP			10,000 UNITS/100ML	N019952	005	Jul 20, 1992	Jul	CRLD
>A>	AP	+		10,000 UNITS/100ML	N019952	005	Jul 20, 1992	Jul	CRLD

HEXAMINOLEVULINATE HYDROCHLORIDE

FOR SOLUTION; INTRAVESICAL
CYSVIEW KIT

	+		PHOTOCURE ASA	100MG/VIAL	N022555	001	May 28, 2010	May	CAHN

HYALURONIDASE

INJECTABLE; INJECTION
HYDASE

		@	AKORN INC	150 UNITS/ML	N021716	001	Oct 25, 2005	Jun	DISC

HYDROCHLOROTHIAZIDE

CAPSULE; ORAL
HYDROCHLOROTHIAZIDE

AB			LANNETT HOLDINGS INC	12.5MG	A091662	001	Jan 27, 2012	Jan	NEWA

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET; ORAL
AVALIDE

AB	+		SANOFI AVENTIS	12.5MG;150MG	N020758	002	Sep 30, 1997	Mar	CFTG
AB	+			12.5MG;300MG	N020758	003	Aug 31, 1998	Mar	CFTG
	+			12.5MG;300MG	N020758	003	Aug 31, 1998	Feb	CRLD

IRBESARTAN AND HYDROCHLOROTHIAZIDE

AB			TEVA	12.5MG;150MG	A077369	001	Mar 30, 2012	Mar	NEWA
AB				12.5MG;300MG	A077369	002	Mar 30, 2012	Mar	NEWA
		@		25MG;300MG	A077369	003	Mar 30, 2012	Apr	DISC

TABLET; ORAL
IRBESARTAN AND HYDROCHLOROTHIAZIDE

	TEVA	25MG;300MG	A077369	003	Mar 30, 2012	Mar	NEWA

HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM

TABLET; ORAL
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE

AB	ALEMBIC LTD	12.5MG;50MG	A091617	001	Feb 17, 2012	Feb	NEWA
AB		12.5MG;100MG	A091617	002	Feb 17, 2012	Feb	NEWA
AB		25MG;100MG	A091617	003	Feb 17, 2012	Feb	NEWA
>A> AB	MACLEODS PHARMS LTD	12.5MG;50MG	A202289	001	Aug 09, 2012	Jul	NEWA
>A> AB		12.5MG;100MG	A202289	002	Aug 09, 2012	Jul	NEWA
>A> AB		25MG;100MG	A202289	003	Aug 09, 2012	Jul	NEWA

HYDROCHLOROTHIAZIDE; METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE; ORAL
DUTOPROL

	ASTRAZENECA	12.5MG;EQ 25MG TARTRATE	N021956	001	Aug 28, 2006	Jan	CMFD
		12.5MG;EQ 50MG TARTRATE	N021956	002	Aug 28, 2006	Jan	CMFD
+		12.5MG;EQ 100MG TARTRATE	N021956	003	Aug 28, 2006	Apr	CRLD
		12.5MG;EQ 100MG TARTRATE	N021956	003	Aug 28, 2006	Jan	CMFD

HYDROCHLOROTHIAZIDE; METOPROLOL TARTRATE

TABLET; ORAL
METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE

AB	MYLAN	50MG;100MG	A076792	003	Aug 20, 2004	Jan	CTEC
AB	SUN PHARM INDS	25MG;50MG	A090654	001	Jan 19, 2012	Jan	NEWA
AB		25MG;100MG	A090654	002	Jan 19, 2012	Jan	NEWA
AB		50MG;100MG	A090654	003	Jan 19, 2012	Jan	NEWA

HYDROCHLOROTHIAZIDE; MOEXIPRIL HYDROCHLORIDE

TABLET; ORAL
MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

	@ PADDOCK LLC	12.5MG;7.5MG	A090096	001	Sep 25, 2008	Jan	DISC
	@	12.5MG;15MG	A090096	002	Sep 25, 2008	Jan	DISC
	@	25MG;15MG	A090096	003	Sep 25, 2008	Jan	DISC

HYDROCORTISONE

CREAM; TOPICAL
NUTRACORT

	@ DOW PHARM	0.5%	A080442	002		Jun	CAHN
	@	1%	A080442	003		Jun	CAHN

LOTION; TOPICAL
CETACORT

	@ DOW PHARM	0.5%	A080426	002		Jun	CAHN
	@	1%	A080426	001		Jun	CAHN

HYDROCORTISONE

AT +	FOUGERA PHARMS	2.5%	A040351	001	Jul 25, 2000	Jan	CAHN

NUTRACORT

	@ DOW PHARM	0.5%	A080443	002		Jun	CAHN
AT		1%	A080443	003		Jun	CAHN
AT		2.5%	A087644	001	Aug 24, 1982	Jun	CAHN

OINTMENT; TOPICAL
HYDROCORTISONE

AT +	FOUGERA PHARMS	1%	A080692	001		Jan	CAHN

HYDROCORTISONE ACETATE; UREA

CREAM; TOPICAL
CARMOL HC

AT		FOUGERA PHARMS	1%;10%	A080505	001		Jan	CAHN

HYDROCORTISONE BUTYRATE

CREAM; TOPICAL
LOCOID

AB	+	PRECISION DERMAT	0.1%	N018514	001	Mar 31, 1982	Jun	CAHN

LOCOID LIPOCREAM

	+	PRECISION DERMAT	0.1%	N020769	001	Sep 08, 1997	Jun	CAHN

LOTION; TOPICAL
LOCOID

	+	PRECISION DERMAT	0.1%	N022076	001	May 18, 2007	May	CAHN

OINTMENT; TOPICAL
LOCOID

AB	+	PRECISION DERMAT	0.1%	N018652	001	Oct 29, 1982	May	CAHN

SOLUTION; TOPICAL
LOCOID

AT	+	PRECISION DERMAT	0.1%	N019116	001	Feb 25, 1987	Jun	CAHN

HYDROCORTISONE VALERATE

CREAM; TOPICAL
HYDROCORTISONE VALERATE

AB	+	TARO	0.2%	A075042	001	Aug 25, 1998	Mar	CRLD

WESTCORT

		@ RANBAXY	0.2%	N017950	001		Mar	DISC

OINTMENT; TOPICAL
HYDROCORTISONE VALERATE

AB		FOUGERA PHARMS	0.2%	A075085	001	Jul 31, 2001	Jan	CAHN

HYDROFLUMETHIAZIDE

TABLET; ORAL
SALURON

AB	+	SHIRE LLC	50MG	N011949	001		Jan	CAHN

HYDROMORPHONE HYDROCHLORIDE

TABLET; ORAL
HYDROMORPHONE HYDROCHLORIDE

		@ NESHER PHARMS	2MG	A077311	001	Nov 09, 2005	Jun	DISC
		@	4MG	A077311	002	Nov 09, 2005	Jun	DISC
		@	8MG	A077311	003	Nov 09, 2005	Jun	DISC

HYDROXYZINE HYDROCHLORIDE

SYRUP; ORAL
HYDROXYZINE HYDROCHLORIDE

		@ STI PHARMA LLC	10MG/5ML	A086880	001		Feb	CAHN

TABLET; ORAL
HYDROXYZINE HYDROCHLORIDE

>D>		@ ACTAVIS TOTOWA	10MG	A040600	001	Dec 28, 2004	Jul	CAHN
>D>		@	25MG	A040602	001	Dec 28, 2004	Jul	CAHN
>D>		@	50MG	A040604	001	Dec 28, 2004	Jul	CAHN
>A>		@ MIKAH PHARMA	10MG	A040600	001	Dec 28, 2004	Jul	CAHN
>A>		@	25MG	A040602	001	Dec 28, 2004	Jul	CAHN
>A>		@	50MG	A040604	001	Dec 28, 2004	Jul	CAHN

HYDROXYZINE PAMOATE

>D>		SUSPENSION; ORAL							
>D>		VISTARIL							
>D>	+	PFIZER	EQ 25MG HCL/5ML	N011795	001			Jul	DISC
>A>	@		EQ 25MG HCL/5ML	N011795	001			Jul	DISC

IBANDRONATE SODIUM

		TABLET; ORAL							
		BONIVA							
AB	+	HOFFMANN LA ROCHE	EQ 150MG BASE	N021455	002	Mar 24, 2005		Mar	CFTG
		IBANDRONATE SODIUM							
AB		APOTEX INC	EQ 150MG BASE	A078948	001	Mar 19, 2012		Mar	NEWA
AB		DR REDDYS LABS LTD	EQ 150MG BASE	A078997	001	Apr 30, 2012		Apr	NEWA
>A> AB		MUTUAL PHARM CO INC	EQ 150MG BASE	A078996	001	Aug 15, 2012		Jul	NEWA
AB		MYLAN PHARMS INC	EQ 150MG BASE	A078995	001	Mar 19, 2012		Mar	NEWA
AB		ORCHID HLTHCARE	EQ 150MG BASE	A078998	001	Mar 19, 2012		Mar	NEWA
AB		WATSON LABS INC	EQ 150MG BASE	A079003	001	Mar 20, 2012		Mar	NEWA

IBUPROFEN

		TABLET; ORAL							
		IBUPROFEN							
	@	NORTHSTAR HLTHCARE	400MG	A078132	001	Sep 10, 2007		Jun	DISC
	@		600MG	A078132	002	Sep 10, 2007		Jun	DISC
	@		800MG	A078132	003	Sep 10, 2007		Jun	DISC
	@	OHM LABS	400MG	A070818	001	Dec 26, 1985		Jun	DISC

IBUPROFEN LYSINE

		INJECTABLE; INTRAVENOUS							
		NEOPROFEN							
	+	LUNDBECK LLC	EQ 20MG BASE/2ML (EQ 10MG BASE/ML)	N021903	001	Apr 13, 2006		Mar	CAHN

>A> ICOSAPENT ETHYL

>A>		CAPSULE; ORAL							
>A>		VASCEPA							
>A>	+	AMARIN PHARMA INC	1GM	N202057	001	Jul 26, 2012		Jul	NEWA

IDARUBICIN HYDROCHLORIDE

		INJECTABLE; INJECTION							
		IDARUBICIN HYDROCHLORIDE							
	@	TEVA PARENTERAL	5MG/VIAL	A065037	003	May 01, 2002		Mar	DISC
	@		10MG/VIAL	A065037	002	May 01, 2002		Mar	DISC
	@		20MG/VIAL	A065037	001	May 01, 2002		Mar	DISC

IMIPRAMINE HYDROCHLORIDE

		TABLET; ORAL							
		IMIPRAMINE HYDROCHLORIDE							
AB		PROSAM LABS	10MG	A040753	001	Feb 28, 2008		Feb	CMFD
AB			25MG	A040752	001	Feb 28, 2008		Feb	CMFD
AB			50MG	A040751	001	Feb 28, 2008		Feb	CMFD

IMIQUIMOD

		CREAM; TOPICAL							
		IMIQUIMOD							
AB		APOTEX INC	5%	A091308	001	Apr 06, 2012		Mar	NEWA

CREAM; TOPICAL
IMIQUIMOD

AB		FOUGERA PHARMS	5%	A078548	001	Feb 25, 2010	Jan	CAHN
AB		GLENMARK GENERICS	5%	A201994	001	Mar 06, 2012	Feb	NEWA

INDOMETHACIN SODIUM

INJECTABLE; INJECTION
INDOCIN

AP	+	LUNDBECK LLC	EQ 1MG BASE/VIAL	N018878	001	Jan 30, 1985	Mar	CAHN

INGENOL MEBUTATE

GEL; TOPICAL
PICATO

		LEO PHARMA AS	0.015%	N202833	001	Jan 23, 2012	Jan	NEWA
	+		0.05%	N202833	002	Jan 23, 2012	Jan	NEWA

INSULIN LISPRO PROTAMINE RECOMBINANT; INSULIN LISPRO RECOMBINANT

INJECTABLE; INJECTION
HUMALOG MIX 50/50 PEN

		@ LILLY	50 UNITS/ML;50 UNITS/ML	N021018	003	Dec 22, 1999	Jun	DISC

HUMALOG MIX 75/25 PEN

		@ LILLY	75 UNITS/ML;25 UNITS/ML	N021017	003	Dec 22, 1999	Jun	DISC

INSULIN LISPRO RECOMBINANT

INJECTABLE; INJECTION
HUMALOG PEN

		@ LILLY	100 UNITS/ML	N020563	002	Aug 06, 1998	Jun	DISC

IRBESARTAN

TABLET; ORAL
AVAPRO

AB		SANOFI AVENTIS US	75MG	N020757	001	Sep 30, 1997	Mar	CFTG
AB			150MG	N020757	002	Sep 30, 1997	Mar	CFTG
AB	+		300MG	N020757	003	Sep 30, 1997	Mar	CFTG

IRBESARTAN

AB		TEVA PHARMS	75MG	A077159	001	Mar 30, 2012	Mar	NEWA
AB			150MG	A077159	002	Mar 30, 2012	Mar	NEWA
AB			300MG	A077159	003	Mar 30, 2012	Mar	NEWA

IRINOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION
IRINOTECAN HYDROCHLORIDE

AP		CIPLA LTD	40MG/2ML (20MG/ML)	A077219	001	Feb 20, 2008	Mar	CAHN
AP			100MG/5ML (20MG/ML)	A077219	002	Feb 20, 2008	Mar	CAHN
AP		EMCURE PHARMS LTD	40MG/2ML (20MG/ML)	A200771	001	Feb 14, 2012	Jan	NEWA
AP			100MG/5ML (20MG/ML)	A200771	002	Feb 14, 2012	Jan	NEWA
AP		HISUN PHARM HANGZHOU	40MG/2ML (20MG/ML)	A090016	001	Jan 28, 2009	Mar	CAHN
AP			100MG/5ML (20MG/ML)	A090016	002	Jan 28, 2009	Mar	CAHN
AP		TEVA PARENTERAL	40MG/2ML (20MG/ML)	A090101	002	Feb 27, 2008	Jun	NEWA
AP			100MG/5ML (20MG/ML)	A090101	003	Feb 27, 2008	Jun	NEWA
AP			500MG/25ML (20MG/ML)	A090101	001	Nov 26, 2008	Jun	CMFD
		@	500MG/25ML (20MG/ML)	A090101	001	Nov 26, 2008	Mar	DISC

ISOFLURANE

LIQUID; INHALATION

FORANE

>A>	AN	+	BAXTER HLTHCARE	99.9%	N017624	001			Jul	CAHN
>D>	AN	+	BAXTER HLTHCARE CORP	99.9%	N017624	001			Jul	CAHN

ISOSORBIDE MONONITRATE

TABLET, EXTENDED RELEASE; ORAL

ISOSORBIDE MONONITRATE

	AB		ALKERMES GAINESVILLE	60MG	A075041	001	Sep 22, 1998	Jun	CAHN
		@	SKYEPHARMA AG	60MG	A075166	001	Oct 07, 1999	Jan	DISC

ISOTRETINOIN

CAPSULE; ORAL

ABSORICA

			CIPHER	10MG	N021951	001	May 25, 2012	May	NEWA
				20MG	N021951	002	May 25, 2012	May	NEWA
				30MG	N021951	003	May 25, 2012	May	NEWA
				40MG	N021951	004	May 25, 2012	May	NEWA

MYORISAN

	AB		DOUGLAS PHARMS	10MG	A076485	001	Jan 19, 2012	Jan	NEWA
	AB			20MG	A076485	002	Jan 19, 2012	Jan	NEWA
	AB			40MG	A076485	003	Jan 19, 2012	Jan	NEWA

ITRACONAZOLE

CAPSULE; ORAL

ITRACONAZOLE

>A>	AB		MYLAN PHARMS INC	100MG	A200463	001	Jul 20, 2012	Jul	NEWA

IVACAFTOR

TABLET; ORAL

KALYDECO

		+	VERTEX PHARMS	150MG	N203188	001	Jan 31, 2012	Jan	NEWA

IVERMECTIN

LOTION; TOPICAL

SKLICE

		+	SANOFI PASTEUR	0.5%	N202736	001	Feb 07, 2012	Feb	NEWA

KETOCONAZOLE

CREAM; TOPICAL

KETOCONAZOLE

	AB		FOUGERA PHARMS	2%	A076294	001	Apr 28, 2004	Jan	CAHN

KETOPROFEN

CAPSULE; ORAL

KETOPROFEN

>A>			DORADO PHARMA	25MG	A074014	001	Jan 29, 1993	Jul	CAHN
>A>	AB			50MG	A074014	002	Jan 29, 1993	Jul	CAHN
>A>	AB			75MG	A074014	003	Jan 29, 1993	Jul	CAHN
>D>			HERITAGE PHARMS INC	25MG	A074014	001	Jan 29, 1993	Jul	CAHN
>D>	AB			50MG	A074014	002	Jan 29, 1993	Jul	CAHN
>D>	AB			75MG	A074014	003	Jan 29, 1993	Jul	CAHN

CAPSULE, EXTENDED RELEASE; ORAL
KETOPROFEN

AB	ALKERMES GAINESVILLE	200MG	A074879	001	Dec 10, 1997	Jun	CAHN

LABETALOL HYDROCHLORIDE

INJECTABLE; INJECTION
LABETALOL HYDROCHLORIDE

AP	GLAND PHARMA LTD	5MG/ML	A090699	001	Apr 03, 2012	Mar	NEWA

TABLET; ORAL
LABETALOL HYDROCHLORIDE

AB	PAR FORM	100MG	A200908	001	Jul 10, 2012	Jun	NEWA
AB		200MG	A200908	002	Jul 10, 2012	Jun	NEWA
AB		300MG	A200908	003	Jul 10, 2012	Jun	NEWA

LACTULOSE

FOR SOLUTION; ORAL
LACTULOSE

+	CUMBERLAND PHARMS	10GM/PACKET	A074712	001	Dec 10, 1997	Jun	CAHN
+		20GM/PACKET	A074712	002	Dec 10, 1997	Jun	CAHN

SOLUTION; ORAL
LACTULOSE

AA	FRESENIUS KABI	10GM/15ML	A090503	001	Jan 25, 2012	Jan	NEWA

SOLUTION; ORAL, RECTAL
LACTULOSE

AA	FRESENIUS KABI	10GM/15ML	A090502	001	Jan 25, 2012	Jan	NEWA

LAMIVUDINE; ZIDOVUDINE

TABLET; ORAL
LAMIVUDINE AND ZIDOVUDINE

AB	AUROBINDO PHARMA LTD	150MG;300MG	A202418	001	May 15, 2012	Apr	NEWA
AB	LUPIN LTD	150MG;300MG	A090246	001	May 15, 2012	Apr	NEWA

LAMOTRIGINE

TABLET; ORAL
LAMOTRIGINE

AB	GLENMARK GENERICS	25MG	A090169	001	May 12, 2012	Apr	NEWA
AB		100MG	A090169	002	May 12, 2012	Apr	NEWA
AB		150MG	A090169	003	May 12, 2012	Apr	NEWA
AB		200MG	A090169	004	May 12, 2012	Apr	NEWA

LANREOTIDE ACETATE

INJECTABLE; SUBCUTANEOUS
SOMATULINE DEPOT

+	IPSEN INC	EQ 60MG BASE	N022074	001	Aug 30, 2007	Apr	CAHN
+		EQ 90MG BASE	N022074	002	Aug 30, 2007	Apr	CAHN
+		EQ 120MG BASE	N022074	003	Aug 30, 2007	Apr	CAHN
+	IPSEN PHARMA	EQ 60MG BASE	N022074	001	Aug 30, 2007	May	CAHN
+		EQ 90MG BASE	N022074	002	Aug 30, 2007	May	CAHN
+		EQ 120MG BASE	N022074	003	Aug 30, 2007	May	CAHN

LANSOPRAZOLE

CAPSULE, DELAYED REL PELLETS; ORAL
PREVACID

AB	TAKEDA PHARMS USA	15MG	N020406	001	May 10, 1995	Mar	CAHN
AB +		30MG	N020406	002	May 10, 1995	Mar	CAHN

TABLET, DELAYED RELEASE, ORALLY DISINTEGRATING; ORAL

LANSOPRAZOLE

	@	TEVA PHARMS	15MG	A078730	001	Oct 15, 2010	Mar	DISC
	@		30MG	A078730	002	Oct 15, 2010	Mar	DISC

PREVACID

		TAKEDA PHARMS USA	15MG	N021428	001	Aug 30, 2002	Mar	CTEC
	+		30MG	N021428	002	Aug 30, 2002	Mar	CTEC

LANTHANUM CARBONATE

TABLET, CHEWABLE; ORAL

FOSRENOL

	@	SHIRE LLC	EQ 250MG BASE	N021468	001	Oct 26, 2004	Feb	CAHN
			EQ 500MG BASE	N021468	002	Oct 26, 2004	Feb	CAHN
			EQ 750MG BASE	N021468	003	Nov 23, 2005	Feb	CAHN
	+		EQ 1GM BASE	N021468	004	Nov 23, 2005	Feb	CAHN

LETROZOLE

TABLET; ORAL

LETROZOLE

	AB	APOTEX INC	2.5MG	A091303	001	Apr 19, 2012	Apr	NEWA

LEUCOVORIN CALCIUM

INJECTABLE; INJECTION

LEUCOVORIN CALCIUM

	@	TEVA PARENTERAL	EQ 50MG BASE/VIAL	A081278	001	Sep 28, 1993	Mar	DISC

LEUPROLIDE ACETATE

INJECTABLE; INJECTION

LUPRON DEPOT

	+	ABBOTT ENDOCRINE	3.75MG/VIAL	N020011	001	Oct 22, 1990	May	CAHN
	+		7.5MG/VIAL	N019732	001	Jan 26, 1989	May	CAHN
	+		11.25MG/VIAL	N020708	001	Mar 07, 1997	May	CAHN

LEVETIRACETAM

INJECTABLE; IV (INFUSION)

LEVETIRACETAM

	AP	APP PHARMS LLC	500MG/5ML (100MG/ML)	A090813	001	May 26, 2010	May	CAHN
	AP	HOSPIRA INC	500MG/ML (100MG/ML)	A202869	001	Apr 06, 2012	Mar	NEWA
>D>	AP	INNOPHARMA LLC	500MG/5ML (100MG/ML)	A091485	001	Aug 05, 2011	Jul	CAHN
	AP	PHARMAFORCE	500MG/5ML (100MG/ML)	A202143	001	Jan 31, 2012	Jan	NEWA
>A>	AP	X GEN PHARMS	500MG/5ML (100MG/ML)	A091485	001	Aug 05, 2011	Jul	CAHN

SOLUTION; ORAL

LEVETIRACETAM

	AA	HI-TECH PHARMACAL	100MG/ML	A090601	001	Feb 28, 2012	Feb	NEWA
	AA	VINTAGE PHARMS	100MG/ML	A090079	001	Apr 11, 2012	Mar	NEWA

TABLET; ORAL

LEVETIRACETAM

>D>	AB	BIOKEY	500MG	A090906	001	Nov 05, 2010	Jul	CAHN
>A>	AB	LOTUS PHARM CO LTD	500MG	A090906	001	Nov 05, 2010	Jul	CAHN
	AB	WATSON LABS INC	250MG	A078797	002	Jan 15, 2009	Apr	NEWA
	AB		500MG	A078797	003	Jan 15, 2009	Apr	NEWA
	AB		750MG	A078797	004	Jan 15, 2009	Apr	NEWA

TABLET, EXTENDED RELEASE; ORAL

LEVETIRACETAM

	AB	BOCA PHARMA	500MG	A201464	001	May 25, 2012	May	NEWA
	AB		750MG	A201464	002	May 25, 2012	May	NEWA

TABLET, EXTENDED RELEASE; ORAL
LEVETIRACETAM

AB	TORRENT PHARMS LTD	500MG	A091338	001	May 29, 2012	May	NEWA
AB		750MG	A091338	002	May 29, 2012	May	NEWA

LEVOCETIRIZINE DIHYDROCHLORIDE

TABLET; ORAL
LEVOCETIRIZINE DIHYDROCHLORIDE

AB	HETERO LABS LTD III	5MG	A091264	001	Jun 29, 2012	Jun	NEWA

LEVOFLOXACIN

TABLET; ORAL
LEVOFLOXACIN

AB	CIPLA LTD	250MG	A076890	001	Mar 30, 2012	Mar	NEWA
AB		500MG	A076890	002	Mar 30, 2012	Mar	NEWA
AB		750MG	A076890	003	Mar 30, 2012	Mar	NEWA
AB	MACLEODS PHARMS LTD	250MG	A200839	001	Mar 22, 2012	Mar	NEWA
AB		500MG	A200839	002	Mar 22, 2012	Mar	NEWA
AB		750MG	A200839	003	Mar 22, 2012	Mar	NEWA
AB	ORCHID HLTHCARE	250MG	A202200	001	Jan 30, 2012	Jan	NEWA
AB		500MG	A202200	002	Jan 30, 2012	Jan	NEWA
AB		750MG	A202200	003	Jan 30, 2012	Jan	NEWA

LEVOLEUCOVORIN CALCIUM

SOLUTION; IV (INFUSION)
FUSILEV

	@ SPECTRUM PHARMS	EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	N020140	003	Apr 29, 2011	Jun	DISC

LEVONORGESTREL

TABLET; ORAL
LEVONORGESTREL

AB	WATSON LABS INC	1.5MG	A200670	001	Jul 12, 2012	Jun	NEWA

PLAN B

	@ TEVA BRANDED PHARM	0.75MG	N021045	001	Jul 28, 1999	May	CAHN
AB	+	0.75MG	N021045	002	Aug 24, 2006	May	CAHN

PLAN B ONE-STEP

AB	+ DURAMED	1.5MG	N021998	001	Jul 10, 2009	Jun	CFTG

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION
XYLOCAINE DENTAL

	@ DENTSPLY PHARM	2%	N021380	001		May	DISC

LIDOCAINE; PRILOCAINE

CREAM; TOPICAL
LIDOCAINE AND PRILOCAINE

AB	FOUGERA PHARMS	2.5%;2.5%	A076453	001	Aug 18, 2003	Jan	CAHN

LIDOCAINE; TETRACAINE

CREAM; TOPICAL
PLIAGLIS

	+ GALDERMA LABS LP	7%;7%	N021717	001	Jun 29, 2006	Jun	CTNA

LINAGLIPTIN; METFORMIN HYDROCHLORIDE

TABLET; ORAL
JENTADUETO

		BOEHRINGER INGELHEIM	2.5MG;500MG	N201281	001	Jan 30, 2012	Jan	NEWA
			2.5MG;850MG	N201281	002	Jan 30, 2012	Jan	NEWA
	+		2.5MG;1GM	N201281	003	Jan 30, 2012	Jan	NEWA

LINEZOLID

INJECTABLE; INJECTION
LINEZOLID

AP		TEVA PHARMS	200MG/100ML	A200222	001	Jun 22, 2012	Jun	NEWA

ZYVOX

AP	+	PHARMACIA AND UPJOHN	200MG/100ML	N021131	001	Apr 18, 2000	Jun	CFTG

LITHIUM CARBONATE

TABLET, EXTENDED RELEASE; ORAL
LITHIUM CARBONATE

AB		MYLAN PHARMS INC	300MG	A202288	001	Jun 29, 2012	Jun	NEWA
>A> AB			450MG	A202219	001	Aug 08, 2012	Jul	NEWA

LOMUSTINE

CAPSULE; ORAL
CEENU

		BRISTOL MYERS SQUIBB	10MG	N017588	001		Jun	CMFD
	@		10MG	N017588	001		May	DISC
			40MG	N017588	002		Jun	CMFD
	@		40MG	N017588	002		May	DISC
	+		100MG	N017588	003		Jun	CMFD
	@		100MG	N017588	003		May	DISC

LORAZEPAM

CONCENTRATE; ORAL
LORAZEPAM

AA		HI-TECH PHARMA CO	2MG/ML	A200169	001	Jan 30, 2012	Jan	NEWA

INJECTABLE; INJECTION
LORAZEPAM

		@ BEDFORD	2MG/ML	A077076	001	Jul 13, 2005	Jun	DISC
		@	4MG/ML	A077076	002	Jul 13, 2005	Jun	DISC
		@ HOSPIRA	2MG/ML	A074300	001	Apr 12, 1994	Jun	DISC

LORCASERIN HYDROCHLORIDE

TABLET; ORAL
BELVIQ

>D>	+	ARENA PHARMS INC	10MG	N022529	001	Jun 27, 2012	Jul	CAHN
	+		10MG	N022529	001	Jun 27, 2012	Jun	NEWA
>A>	+	EISAI INC	10MG	N022529	001	Jun 27, 2012	Jul	CAHN

LOSARTAN POTASSIUM

TABLET; ORAL
LOSARTAN POTASSIUM

AB		MACLEODS PHARMS LTD	25MG	A202230	001	May 30, 2012	May	NEWA
AB			50MG	A202230	002	May 30, 2012	May	NEWA
AB			100MG	A202230	003	May 30, 2012	May	NEWA

LOXAPINE SUCCINATE

CAPSULE; ORAL
LOXAPINE SUCCINATE

>D>	@ ACTAVIS TOTOWA	EQ 5MG BASE	A076868	001	Aug 04, 2005	Jul	CAHN
>D>	@	EQ 10MG BASE	A076868	002	Aug 04, 2005	Jul	CAHN
>D>	@	EQ 25MG BASE	A076868	003	Aug 04, 2005	Jul	CAHN
>D>	@	EQ 50MG BASE	A076868	004	Aug 04, 2005	Jul	CAHN
>A>	@ MIKAH PHARMA	EQ 5MG BASE	A076868	001	Aug 04, 2005	Jul	CAHN
>A>	@	EQ 10MG BASE	A076868	002	Aug 04, 2005	Jul	CAHN
>A>	@	EQ 25MG BASE	A076868	003	Aug 04, 2005	Jul	CAHN
>A>	@	EQ 50MG BASE	A076868	004	Aug 04, 2005	Jul	CAHN

LUCINACTANT

SUSPENSION; INTRATRACHEAL
SURFAXIN

+	DISCOVERY LABS	8.5ML	N021746	001	Mar 06, 2012	Apr	NEWA

LURASIDONE HYDROCHLORIDE

TABLET; ORAL
LATUDA

	SUNOVION PHARMS INC	20MG	N200603	003	Dec 07, 2011	Apr	NEWA
+		40MG	N200603	001	Oct 28, 2010	Apr	CRLD
		80MG	N200603	002	Oct 28, 2010	Apr	CRLD
		120MG	N200603	004	Apr 26, 2012	Apr	NEWA

LUTROPIN ALFA

INJECTABLE; SUBCUTANEOUS
LUVERIS

	@ EMD SERONO	75 IU/VIAL	N021322	001	Oct 08, 2004	Jun	DISC

MAFENIDE ACETATE

CREAM; TOPICAL
SULFAMYLON

+	MYLAN LLC	EQ 85MG BASE/GM	N016763	001		Jun	CAHN

FOR SOLUTION; TOPICAL
SULFAMYLON

+	MYLAN LLC	5%	N019832	003	Jun 05, 1998	Jun	CAHN

MAGNESIUM HYDROXIDE; OMEPRAZOLE; SODIUM BICARBONATE

TABLET; ORAL
MAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATE

	@ SANTARUS	343MG;20MG;750MG	N022456	001	Dec 04, 2009	Jun	DISC
	@	343MG;40MG;750MG	N022456	002	Dec 04, 2009	Jun	DISC

MAGNESIUM SULFATE

INJECTABLE; INJECTION
MAGNESIUM SULFATE IN PLASTIC CONTAINER

	HOSPIRA	20GM/500ML (40MG/ML)	N020309	004	Jan 18, 1995	Jan	NEWA
		40GM/1000ML(40MG/ML)	N020309	005	Jan 18, 1995	Jan	NEWA

MALATHION

LOTION; TOPICAL
MALATHION

AT	MYLAN PHARMS INC	0.5%	A078743	001	Mar 06, 2009	Feb	CAHN
AT	SUVEN LIFE	0.5%	A091559	001	May 23, 2012	May	NEWA

MANNITOL

POWDER; INHALATION
ARIDOL KIT

	+	PHARMAXIS LTD	N/A,5MG,10MG,20MG,40MG	N022368	001	Oct 05, 2010	May	CAHN

MECASERMIN RECOMBINANT

INJECTABLE; SUBCUTANEOUS
INCRELEX

	+	IPSEN INC	40MG/4ML (10MG/ML)	N021839	001	Aug 30, 2005	May	CAHN

MECLIZINE HYDROCHLORIDE

TABLET; ORAL
MECLIZINE HYDROCHLORIDE

AA		EPIC PHARMA LLC	12.5MG	A200294	001	Apr 13, 2012	Mar	NEWA
AA			25MG	A200294	002	Apr 13, 2012	Mar	NEWA

MEDROXYPROGESTERONE ACETATE

INJECTABLE; INJECTION
MEDROXYPROGESTERONE ACETATE

	@	TEVA PARENTERAL	150MG/ML	A076552	001	Oct 27, 2004	Apr	DISC

MEMANTINE HYDROCHLORIDE

TABLET; ORAL
MEMANTINE HYDROCHLORIDE

	@	ORCHID HLTHCARE	5MG	A090044	001	Mar 12, 2012	Mar	DISC
AB			5MG	A090044	001	Mar 12, 2012	Feb	NEWA
	@		10MG	A090044	002	Mar 12, 2012	Mar	DISC
AB			10MG	A090044	002	Mar 12, 2012	Feb	NEWA

NAMENDA

		FOREST LABS	5MG	N021487	001	Oct 16, 2003	Mar	CTEC
AB			5MG	N021487	001	Oct 16, 2003	Feb	CTEC
	+		10MG	N021487	002	Oct 16, 2003	Mar	CTEC
AB	+		10MG	N021487	002	Oct 16, 2003	Feb	CTEC

MEPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION
POLOCAINE

	@	DENTSPLY PHARM	3%	A088653	001	Aug 21, 1984	May	DISC

MEQUINOL; TRETINOIN

SOLUTION; TOPICAL
SOLAGE

	@	AQUA PHARMS	2%;0.01%	N020922	001	Dec 10, 1999	Jun	DISC

MESALAMINE

SUPPOSITORY; RECTAL
CANASA

>A>	@	APTALIS PHARMA US	500MG	N021252	001	Jan 05, 2001	Jul	CAHN
>A>			1GM	N021252	002	Nov 05, 2004	Jul	CAHN
>D>	@	AXCAN	500MG	N021252	001	Jan 05, 2001	Jul	CAHN
>D>	+		1GM	N021252	002	Nov 05, 2004	Jul	CAHN

ROWASA

	@	MEDA PHARMS	500MG	N019919	001	Dec 18, 1990	Jan	CAHN

MESNA

INJECTABLE; INTRAVENOUS

MESNA

AP	MYLAN INSTITUTIONAL	100MG/ML	A076488	001	Mar 08, 2012	Feb	NEWA

METFORMIN HYDROCHLORIDE

TABLET; ORAL

METFORMIN HYDROCHLORIDE

AB	MARKSANS PHARMA	500MG	A090888	001	Mar 12, 2012	Feb	NEWA
AB		850MG	A090888	002	Mar 12, 2012	Feb	NEWA
AB		1GM	A090888	003	Mar 12, 2012	Feb	NEWA

TABLET, EXTENDED RELEASE; ORAL

METFORMIN HYDROCHLORIDE

>A> AB1	AUROBINDO PHARMA LTD	500MG	A079118	001	Jul 20, 2012	Jul	NEWA
>A> AB		750MG	A079118	002	Jul 20, 2012	Jul	NEWA
AB1	INVENTIA HLTHCARE	500MG	A201991	001	Jan 18, 2012	Jan	NEWA
>A> AB2	MYLAN PHARMS INC	500MG	A200690	001	Aug 01, 2012	Jul	NEWA
>A> AB		1GM	A200690	002	Aug 01, 2012	Jul	NEWA
@	RANBAXY LABS LTD	500MG	A076413	001	Jun 18, 2004	Apr	DISC
@		750MG	A077211	001	Jun 29, 2005	Apr	DISC

METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

KOMBIGLYZE XR

	BRISTOL MYERS SQUIBB	500MG;EQ 5MG BASE	N200678	001	Nov 05, 2010	Apr	CAIN
		1GM;EQ 2.5MG BASE	N200678	003	Nov 05, 2010	Apr	CAIN
+		1GM;EQ 5MG BASE	N200678	002	Nov 05, 2010	Apr	CAIN

METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE

TABLET; ORAL

JANUMET

	MERCK SHARP DOHME	500MG;EQ 50MG BASE	N022044	001	Mar 30, 2007	May	CAHN
+		1GM;EQ 50MG BASE	N022044	002	Mar 30, 2007	May	CAHN

TABLET, EXTENDED RELEASE; ORAL

JANUMET XR

	MERCK SHARP DOHME	500MG;EQ 50MG BASE	N202270	001	Feb 02, 2012	Feb	NEWA
		1GM;EQ 50MG BASE	N202270	002	Feb 02, 2012	Feb	NEWA
+		1GM;EQ 100MG BASE	N202270	003	Feb 02, 2012	Feb	NEWA

METHIMAZOLE

TABLET; ORAL

METHIMAZOLE

AB	BOCA PHARMA	5MG	A202068	001	Mar 07, 2012	Feb	NEWA
AB		10MG	A202068	002	Mar 07, 2012	Feb	NEWA

METHOCARBAMOL

TABLET; ORAL

METHOCARBAMOL

AA	SOLCO HLTHCARE	500MG	A086989	001		Mar	CMFD
AA		750MG	A086988	001		Mar	CMFD

METHOTREXATE SODIUM

INJECTABLE; INJECTION

METHOTREXATE PRESERVATIVE FREE

AP	APP PHARMS LLC	EQ 1GM BASE/VIAL	A040266	001	Feb 26, 1999	Jan	CMFD

INJECTABLE; INJECTION

METHOTREXATE PRESERVATIVE FREE

AP		PHARMACHEMIE BV	EQ 100MG BASE/4ML (EQ 25MG BASE/ML)	A200171	001	Feb 27, 2012	Feb	NEWA

METHOTREXATE SODIUM

AP	+	BEDFORD	EQ 100MG BASE/4ML (EQ 25MG BASE/ML)	A089341	001	Sep 16, 1986	Feb	CTEC

METHOTREXATE SODIUM PRESERVATIVE FREE

AP	+	MYLAN INSTITUTIONAL	EQ 50MG BASE/2ML (EQ 25MG BASE/ML)	A040767	001	Apr 30, 2007	Feb	CAHN
AP		ONCO THERAPIES LTD	EQ 50MG BASE/2ML (EQ 25MG BASE/ML)	A201529	001	Mar 29, 2012	Mar	NEWA
AP			EQ 100MG BASE/4ML (EQ 25MG BASE/ML)	A201529	002	Mar 29, 2012	Mar	NEWA
AP			EQ 200MG BASE/8ML (EQ 25MG BASE/ML)	A201529	003	Mar 29, 2012	Mar	NEWA
AP			EQ 250MG BASE/10ML (EQ 25MG BASE/ML)	A201529	004	Mar 29, 2012	Mar	NEWA
AP			EQ 1GM BASE/40ML (EQ 25MG BASE/ML)	A201530	001	Mar 29, 2012	Mar	NEWA

METHYCLOTHIAZIDE

TABLET; ORAL

ENDURON

@		ABBOTT LABS PHARM	2.5MG	N012524	001		Mar	DISC
@			5MG	N012524	004		Mar	DISC

METHYCLOTHIAZIDE

AB	+	MYLAN PHARMS INC	5MG	A087672	001	Aug 17, 1982	Mar	CRLD

METHYLDOPATE HYDROCHLORIDE

INJECTABLE; INJECTION

METHYLDOPATE HYDROCHLORIDE

@		TEVA PARENTERAL	50MG/ML	A072974	001	Nov 22, 1991	Mar	DISC

METHYLNALTREXONE BROMIDE

INJECTABLE; SUBCUTANEOUS

RELISTOR

		SALIX PHARMS	8MG/0.4ML	N021964	002	Sep 27, 2010	May	CAHN
	+		12MG/0.6ML (12MG/0.6ML)	N021964	003	Apr 24, 2008	Jun	NEWA

SOLUTION; SUBCUTANEOUS

RELISTOR

	+	SALIX PHARMS	12MG/0.6ML (12MG/0.6ML)	N021964	001	Apr 24, 2008	May	CAHN

METHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

METADATE CD

>D>	BX	UCB INC	10MG	N021259	003	May 27, 2003	Jul	CFTG
>A>	AB		10MG	N021259	003	May 27, 2003	Jul	CFTG
>D>	BX		20MG	N021259	001	Apr 03, 2001	Jul	CFTG
>A>	AB2		20MG	N021259	001	Apr 03, 2001	Jul	CFTG
>D>	BX		30MG	N021259	002	Jun 19, 2003	Jul	CFTG
>A>	AB2		30MG	N021259	002	Jun 19, 2003	Jul	CFTG
>D>	BX		40MG	N021259	004	Feb 19, 2006	Jul	CFTG
>A>	AB2		40MG	N021259	004	Feb 19, 2006	Jul	CFTG
>D>			50MG	N021259	005	Feb 19, 2006	Jul	CFTG
>A>	AB		50MG	N021259	005	Feb 19, 2006	Jul	CFTG
>D>		+	60MG	N021259	006	Feb 19, 2006	Jul	CFTG
>A>	AB	+	60MG	N021259	006	Feb 19, 2006	Jul	CFTG

CAPSULE, EXTENDED RELEASE; ORAL
METHYLPHENIDATE HYDROCHLORIDE

>D>	AB	ACTAVIS	20MG	A078458	001	Dec 01, 2011	Jul	CTEC
>A>	AB1		20MG	A078458	001	Dec 01, 2011	Jul	CTEC
>D>	AB		30MG	A078458	002	Dec 01, 2011	Jul	CTEC
>A>	AB1		30MG	A078458	002	Dec 01, 2011	Jul	CTEC
>D>	AB		40MG	A078458	003	Dec 01, 2011	Jul	CTEC
>A>	AB1		40MG	A078458	003	Dec 01, 2011	Jul	CTEC
>D>	AB	BARR LABS INC	20MG	A079031	001	Jul 13, 2012	Jul	CTEC
>A>	AB1		20MG	A079031	001	Jul 13, 2012	Jul	CTEC
	AB		20MG	A079031	001	Jul 13, 2012	Jun	NEWA
>D>	AB		30MG	A079031	002	Jul 13, 2012	Jul	CTEC
>A>	AB1		30MG	A079031	002	Jul 13, 2012	Jul	CTEC
	AB		30MG	A079031	002	Jul 13, 2012	Jun	NEWA
>D>	AB		40MG	A079031	003	Jul 13, 2012	Jul	CTEC
>A>	AB1		40MG	A079031	003	Jul 13, 2012	Jul	CTEC
	AB		40MG	A079031	003	Jul 13, 2012	Jun	NEWA
>A>	AB	TEVA PHARMS	10MG	A077707	001	Jul 19, 2012	Jul	NEWA
>A>	AB2		20MG	A077707	002	Jul 19, 2012	Jul	NEWA
>A>	AB2		30MG	A077707	003	Jul 19, 2012	Jul	NEWA
>A>	AB2		40MG	A078873	001	Jul 19, 2012	Jul	NEWA
>A>	AB		50MG	A078873	002	Jul 19, 2012	Jul	NEWA
>A>	AB		60MG	A078873	003	Jul 19, 2012	Jul	NEWA

RITALIN LA

>D>	AB	NOVARTIS	20MG	N021284	001	Jun 05, 2002	Jul	CTEC
>A>	AB1		20MG	N021284	001	Jun 05, 2002	Jul	CTEC
>D>	AB		30MG	N021284	002	Jun 05, 2002	Jul	CTEC
>A>	AB1		30MG	N021284	002	Jun 05, 2002	Jul	CTEC
>D>	AB +		40MG	N021284	003	Jun 05, 2002	Jul	CTEC
>A>	AB1 +		40MG	N021284	003	Jun 05, 2002	Jul	CTEC

TABLET; ORAL
METHYLPHENIDATE HYDROCHLORIDE

	AB	SUN PHARM INDS INC	5MG	A090710	001	Mar 15, 2012	Feb	NEWA
	AB		10MG	A090710	002	Mar 15, 2012	Feb	NEWA
	AB		20MG	A090710	003	Mar 15, 2012	Feb	NEWA

TABLET, EXTENDED RELEASE; ORAL

>D>		METADATE ER							
>D>	AB	UCB INC	10MG	A040306	001	Oct 20, 1999	Jul	DISC
>A>		@	10MG	A040306	001	Oct 20, 1999	Jul	DISC

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE; INJECTION
METHYLPREDNISOLONE SODIUM SUCCINATE

@ BEDFORD LABS	EQ 40MG BASE/VIAL	A040662	001	Feb 21, 2007	Jun	DISC
@	EQ 125MG BASE/VIAL	A040641	002	Feb 21, 2007	Jun	DISC
@	EQ 500MG BASE/VIAL	A040641	003	Feb 21, 2007	Jun	DISC
@	EQ 500MG BASE/VIAL	A040709	001	Feb 21, 2007	Jun	DISC
@	EQ 1GM BASE/VIAL	A040641	004	Feb 21, 2007	Jun	DISC
@	EQ 1GM BASE/VIAL	A040709	002	Feb 21, 2007	Jun	DISC
@ TEVA PARENTERAL	EQ 125MG BASE/VIAL	A081266	001	Nov 30, 1992	Mar	DISC

METOCLOPRAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION
METOCLOPRAMIDE HYDROCHLORIDE

@ TEVA PARENTERAL	EQ 5MG BASE/ML	A073135	001	Nov 27, 1991	Jan	DISC

METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE; ORAL
METOPROLOL SUCCINATE

>A>	AB	DR REDDYS LABS LTD	EQ 25MG TARTRATE	A090617	001	Aug 01, 2012	Jul	NEWA
>A>	AB		EQ 50MG TARTRATE	A090617	002	Aug 01, 2012	Jul	NEWA
		@ NESHER PHARMS	EQ 100MG TARTRATE	A076640	002	May 18, 2007	Jun	DISC
		@	EQ 200MG TARTRATE	A076640	001	May 18, 2007	Jun	DISC
>A>	AB	REDDYS	EQ 100MG BASE	A078889	001	Aug 15, 2012	Jul	NEWA
>A>	AB		EQ 200MG BASE	A078889	002	Aug 15, 2012	Jul	NEWA

METRONIDAZOLE

CREAM; TOPICAL
METRONIDAZOLE

	AB	FOUGERA PHARMS	0.75%	A076408	001	May 28, 2004	Jan	CAHN

NORITATE

	+	VALEANT INTL	1%	N020743	001	Sep 26, 1997	Apr	CAHN

GEL; TOPICAL
METRONIDAZOLE

	AB	FOUGERA PHARMS	0.75%	A077018	001	Jun 06, 2006	Jan	CAHN

LOTION; TOPICAL
METRONIDAZOLE

	AB	FOUGERA PHARMS	0.75%	A077197	001	May 24, 2006	Jan	CAHN

METYRAPONE

CAPSULE; ORAL
METOPIRONE

	+	HRA PHARMA	250MG	N012911	002	Aug 09, 1996	Jun	CAHN

TABLET; ORAL
METOPIRONE

		@ HRA PHARMA	250MG	N012911	001		Jun	CAHN

METYROSINE

CAPSULE; ORAL
DEMSER

	+	BIOVAIL TECHNOLOGIES	250MG	N017871	001		May	CAHN

MIDAZOLAM HYDROCHLORIDE

INJECTABLE; INJECTION
MIDAZOLAM HYDROCHLORIDE

	AP	GLAND PHARMA LTD	EQ 1MG BASE/ML	A090696	001	Feb 29, 2012	Feb	NEWA
	AP		EQ 5MG BASE/ML	A090850	001	Jan 25, 2012	Jan	NEWA

MIDODRINE HYDROCHLORIDE

TABLET; ORAL
PROAMATINE

	AB	SHIRE LLC	2.5MG	N019815	001	Sep 06, 1996	Jan	CAHN
	AB	+	5MG	N019815	002	Sep 06, 1996	Jan	CAHN
	AB		10MG	N019815	003	Mar 20, 2002	Jan	CAHN

MIFEPRISTONE

TABLET; ORAL
KORLYM

	+	CORCEPT THERAP	300MG	N202107	001	Feb 17, 2012	Feb	NEWA

MINOCYCLINE HYDROCHLORIDE

CAPSULE; ORAL
MINOCIN

AB	PRECISION DERMAT	EQ 50MG BASE	N050649	001	May 31, 1990	May		CAHN
	@	EQ 75MG BASE	N050649	003	Feb 12, 2001	May		CAHN
AB		EQ 100MG BASE	N050649	002	May 31, 1990	May		CAHN

>A> CAPSULE, EXTENDED RELEASE; ORAL
>A> XIMINO

>A>	RANBAXY LABS LTD	EQ 45MG BASE	N201922	001	Jul 11, 2012	Jul		NEWA
>A>		EQ 67.5MG BASE	N201922	002	Jul 11, 2012	Jul		NEWA
>A>		EQ 90MG BASE	N201922	003	Jul 11, 2012	Jul		NEWA
>A>		EQ 112.5MG BASE	N201922	004	Jul 11, 2012	Jul		NEWA
>A>	+	EQ 135MG BASE	N201922	005	Jul 11, 2012	Jul		NEWA

INJECTABLE; INJECTION
MINOCIN

+	PRECISION DERMAT	EQ 100MG BASE/VIAL	N050444	001		May		CAHN

SUSPENSION; ORAL
MINOCIN

@	PRECISION DERMAT	EQ 50MG BASE/5ML	N050445	001		May		CAHN

MIRABEGRON

TABLET, EXTENDED RELEASE; ORAL
MYRBETRIQ

	APGDI	25MG	N202611	001	Jun 28, 2012	Jun		NEWA
+		50MG	N202611	002	Jun 28, 2012	Jun		NEWA

MISOPROSTOL

TABLET; ORAL
MISOPROSTOL

>A> AB	NOVEL LABS INC	0.1MG	A091667	001	Jul 25, 2012	Jul		NEWA
>A> AB		0.2MG	A091667	002	Jul 25, 2012	Jul		NEWA

MITOMYCIN

FOR SOLUTION; TOPICAL
MITOSOL

+	MOBIUS THERAP	0.2MG/VIAL	N022572	001	Feb 07, 2012	Feb		NEWA

MITOXANTRONE HYDROCHLORIDE

INJECTABLE; INJECTION
MITOXANTRONE HYDROCHLORIDE

@	FRESENIUS KABI ONCOL	EQ 20MG BASE/10ML (EQ 2MG BASE/ML)	A078606	001	May 14, 2008	Jun		DISC
@		EQ 25MG BASE/12.5ML (EQ 2MG BASE/ML)	A078606	002	May 14, 2008	Jun		DISC
@		EQ 30MG BASE/15ML (EQ 2MG BASE/ML)	A078606	003	May 14, 2008	Jun		DISC

MIVACURIUM CHLORIDE

INJECTABLE; INJECTION
MIVACURIUM CHLORIDE

@	STRIDES ARCOLAB LTD	EQ 2MG BASE/ML	A078562	001	Apr 30, 2009	Jun		CAHN

MODAFINIL

TABLET; ORAL
MODAFINIL

AB	MYLAN PHARMS INC	100MG	A076594	001	Jul 16, 2012	Jun		NEWA

		TABLET; ORAL								
		MODAFINIL								
	AB	MYLAN PHARMS INC	200MG		A076594	002	Jul 16, 2012	Jun	NEWA	
		PROVIGIL								
	AB	CEPHALON	100MG		N020717	001	Dec 24, 1998	Jun	CFTG	
	AB	+	200MG		N020717	002	Dec 24, 1998	Jun	CFTG	
		MOMETASONE FUROATE								
		CREAM; TOPICAL								
		ELOCON								
	AB	+ MERCK SHARP DOHME	0.1%		N019625	001	May 06, 1987	Jun	CAHN	
		MOMETASONE FUROATE								
	AB	FOUGERA PHARMS	0.1%		A076171	001	Apr 08, 2005	Jan	CAHN	
		LOTION; TOPICAL								
		ELOCON								
>A>	AB	+ MERCK SHARP DOHME	0.1%		N019796	001	Mar 30, 1989	Jul	CAHN	
>D>	AB	+ SCHERING	0.1%		N019796	001	Mar 30, 1989	Jul	CAHN	
		MOMETASONE FUROATE								
	AB	FOUGERA PHARMS	0.1%		A075919	001	Nov 29, 2007	Jan	CAHN	
		OINTMENT; TOPICAL								
		ELOCON								
	AB	+ MERCK SHARP DOHME	0.1%		N019543	001	Apr 30, 1987	May	CAHN	
		MOMETASONE FUROATE								
	AB	FOUGERA PHARMS	0.1%		A077061	001	Mar 28, 2005	Jan	CAHN	
		MONTELUKAST SODIUM								
		GRANULE; ORAL								
>A>		MONTELUKAST SODIUM								
>A>	AB	TEVA PHARMS	EQ 4MG BASE/PACKET		A090955	001	Aug 03, 2012	Jul	NEWA	
		SINGULAIR								
>D>		+ MERCK	EQ 4MG BASE/PACKET		N021409	001	Jul 26, 2002	Jul	CFTG	
>A>	AB	+	EQ 4MG BASE/PACKET		N021409	001	Jul 26, 2002	Jul	CFTG	
		TABLET; ORAL								
>A>		MONTELUKAST SODIUM								
>A>	AB	APOTEX CORP	EQ 10MG BASE		A201294	001	Aug 03, 2012	Jul	NEWA	
>A>	AB	AUROBINDO PHARMA LTD	EQ 10MG BASE		A202468	001	Aug 03, 2012	Jul	NEWA	
>A>	AB	DR REDDYS LABS LTD	EQ 10MG BASE		A201582	001	Aug 06, 2012	Jul	NEWA	
>A>	AB	ENDO PHARMS	EQ 10MG BASE		A091576	001	Aug 03, 2012	Jul	NEWA	
>A>	AB	GLENMARK GENERICS	EQ 10MG BASE		A090926	001	Aug 03, 2012	Jul	NEWA	
>A>	AB	KUDCO IRELAND	EQ 10MG BASE		A201522	001	Aug 03, 2012	Jul	NEWA	
>A>	AB	MYLAN PHARMS INC	EQ 10MG BASE		A079103	001	Aug 03, 2012	Jul	NEWA	
>A>	AB	ROXANE	EQ 10MG BASE		A090655	001	Aug 03, 2012	Jul	NEWA	
>A>	AB	SANDOZ INC	EQ 10MG BASE		A200889	001	Aug 03, 2012	Jul	NEWA	
>A>	AB	TEVA PHARMS	EQ 10MG BASE		A078605	001	Aug 03, 2012	Jul	NEWA	
>A>	AB	TORRENT PHARMS LTD	EQ 10MG BASE		A201515	001	Aug 03, 2012	Jul	NEWA	
		SINGULAIR								
>D>		+ MERCK	EQ 10MG BASE		N020829	002	Feb 20, 1998	Jul	CFTG	
>A>	AB	+	EQ 10MG BASE		N020829	002	Feb 20, 1998	Jul	CFTG	
		TABLET, CHEWABLE; ORAL								
>A>		MONTELUKAST SODIUM								
>A>	AB	APOTEX INC	EQ 4MG BASE		A201508	001	Aug 03, 2012	Jul	NEWA	
>A>	AB		EQ 5MG BASE		A201508	002	Aug 03, 2012	Jul	NEWA	
>A>	AB	AUROBINDO PHARMA LTD	EQ 4MG BASE		A202096	001	Aug 03, 2012	Jul	NEWA	
>A>	AB		EQ 5MG BASE		A202096	002	Aug 03, 2012	Jul	NEWA	
>A>	AB	DR REDDYS LABS LTD	EQ 4MG BASE		A201581	001	Aug 06, 2012	Jul	NEWA	
>A>	AB		EQ 5MG BASE		A201581	002	Aug 06, 2012	Jul	NEWA	

TABLET, CHEWABLE; ORAL

MONTELUKAST SODIUM

>A>		ENDO PHARMS	EQ 4MG BASE	A091588	001	Aug 03, 2012	Jul	NEWA
>A>	AB		EQ 5MG BASE	A091588	002	Aug 03, 2012	Jul	NEWA
>A>	AB	KUDCO IRELAND	EQ 4MG BASE	A200405	001	Aug 03, 2012	Jul	NEWA
>A>	AB		EQ 5MG BASE	A200405	002	Aug 03, 2012	Jul	NEWA
>A>	AB	MYLAN PHARMS INC	EQ 4MG BASE	A079142	001	Aug 03, 2012	Jul	NEWA
>A>	AB		EQ 5MG BASE	A079142	002	Aug 03, 2012	Jul	NEWA
>A>	AB	ROXANE	EQ 4MG BASE	A091128	001	Aug 03, 2012	Jul	NEWA
>A>	AB		EQ 5MG BASE	A091128	002	Aug 03, 2012	Jul	NEWA
>A>	AB	SANDOZ INC	EQ 4MG BASE	A091414	001	Aug 03, 2012	Jul	NEWA
>A>	AB		EQ 5MG BASE	A091414	002	Aug 03, 2012	Jul	NEWA
>A>	AB	TEVA PHARMS	EQ 4MG BASE	A078723	001	Aug 03, 2012	Jul	NEWA
>A>	AB		EQ 5MG BASE	A078723	002	Aug 03, 2012	Jul	NEWA
>A>	AB	TORRENT PHARMS LTD	EQ 4MG BASE	A090984	001	Aug 03, 2012	Jul	NEWA
>A>	AB		EQ 5MG BASE	A090984	002	Aug 03, 2012	Jul	NEWA

SINGULAIR

>D>		MERCK	EQ 4MG BASE	N020830	002	Mar 03, 2000	Jul	CFTG
>A>	AB		EQ 4MG BASE	N020830	002	Mar 03, 2000	Jul	CFTG
>D>	+		EQ 5MG BASE	N020830	001	Feb 20, 1998	Jul	CFTG
>A>	AB +		EQ 5MG BASE	N020830	001	Feb 20, 1998	Jul	CFTG

MORPHINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

KADIAN

>A>		ACTAVIS ELIZABETH	40MG	N020616	009	Jul 09, 2012	Jul	NEWA
>A>			70MG	N020616	010	Jul 09, 2012	Jul	NEWA
>A>			130MG	N020616	011	Jul 09, 2012	Jul	NEWA
>A>			150MG	N020616	012	Jul 09, 2012	Jul	NEWA

INJECTABLE; INJECTION

DURAMORPH PF

	AP	+ HIKMA MAPLE	0.5MG/ML	N018565	001	Sep 18, 1984	Jun	CAHN
	AP	+	1MG/ML	N018565	002	Sep 18, 1984	Jun	CAHN

INFUMORPH

		+ HIKMA MAPLE	10MG/ML	N018565	003	Jul 19, 1991	Jun	CAHN
		+	25MG/ML	N018565	004	Jul 19, 1991	Jun	CAHN

INJECTABLE, LIPOSOMAL; EPIDURAL

DEPODUR

		@ PACIRA PHARMS INC	10MG/ML (10MG/ML)	N021671	001	May 18, 2004	May	CAHN
		@	15MG/1.5ML (10MG/ML)	N021671	002	May 18, 2004	May	CAHN
		@	20MG/2ML (10MG/ML)	N021671	003	May 18, 2004	May	CAHN

SOLUTION; ORAL

MORPHINE SULFATE

>A>	AA	PADDOCK LLC	100MG/5ML	A201574	001	Aug 06, 2012	Jul	NEWA

TABLET, EXTENDED RELEASE; ORAL

MORPHINE SULFATE

	AB	RANBAXY LABS LTD	15MG	A078761	001	May 11, 2012	Apr	NEWA
	AB		30MG	A078761	002	May 11, 2012	Apr	NEWA
	AB		60MG	A078761	003	May 11, 2012	Apr	NEWA
	AB		100MG	A078761	004	May 11, 2012	Apr	NEWA
	AB		200MG	A078761	005	May 11, 2012	Apr	NEWA

ORAMORPH SR

		@ XANODYNE PHARMS INC	15MG	N019977	004	Nov 23, 1994	May	DISC
		@	30MG	N019977	001	Aug 15, 1991	May	DISC
		@	60MG	N019977	002	Aug 15, 1991	May	DISC
		@	100MG	N019977	003	Aug 15, 1991	May	DISC

MUPIROCIN

OINTMENT; TOPICAL

MUPIROCIN

AB	FOUGERA PHARMS	2%	A065192	001	Nov 30, 2005	Jan	CAHN

NABUMETONE

TABLET; ORAL

NABUMETONE

AB	PROSAM LABS	500MG	A079093	001	Feb 27, 2009	Feb	CMFD
AB		750MG	A079093	002	Feb 27, 2009	Feb	CMFD

NAFTIFINE HYDROCHLORIDE

CREAM; TOPICAL

NAFTIN

+	MERZ PHARMS	2%	N019599	002	Jan 13, 2012	Jan	NEWA

NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION

NALOXONE

@	HIKMA MAPLE	0.4MG/ML	A070298	001	Sep 24, 1986	Jun	CAHN
@		0.4MG/ML	A070299	001	Sep 24, 1986	Jun	CAHN
@		0.4MG/ML	A070496	001	Sep 24, 1986	Jun	CAHN

NALOXONE HYDROCHLORIDE

@	HIKMA MAPLE	0.02MG/ML	A071272	001	May 24, 1988	Jun	CAHN
@		1MG/ML	A071273	001	May 24, 1988	Jun	CAHN
@		1MG/ML	A071274	001	May 24, 1988	Jun	CAHN
@		1MG/ML	A071287	001	May 24, 1988	Jun	CAHN

NALTREXONE HYDROCHLORIDE

TABLET; ORAL

NALTREXONE HYDROCHLORIDE

AB	SUN PHARMA GLOBAL	50MG	A090356	001	Feb 24, 2012	Feb	NEWA

NAPROXEN SODIUM

TABLET; ORAL

ANAPROX

AB	HOFFMANN LA ROCHE	EQ 250MG BASE	N018164	001		May	CAHN

ANAPROX DS

AB +	HOFFMANN LA ROCHE	EQ 500MG BASE	N018164	003	Sep 30, 1987	May	CAHN

NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE

TABLET; ORAL

TREXIMET

+	SMITHKLINE BEECHAM	500MG;EQ 85MG BASE	N021926	001	Apr 15, 2008	May	CAHN

NARATRIPTAN HYDROCHLORIDE

TABLET; ORAL

NARATRIPTAN

AB	MYLAN PHARMS INC	EQ 1MG BASE	A202431	001	May 31, 2012	May	NEWA
AB		EQ 2.5MG BASE	A202431	002	May 31, 2012	May	NEWA
AB	ORCHID HLTHCARE	EQ 1MG BASE	A091441	001	Apr 30, 2012	Apr	NEWA
AB		EQ 2.5MG BASE	A091441	002	Apr 30, 2012	Apr	NEWA

NATEGLINIDE

TABLET; ORAL
NATEGLINIDE

>D>	AB		TEVA PHARMS	60MG	A077467	001	Sep 09, 2009	Jul	DISC
>A>		@		60MG	A077467	001	Sep 09, 2009	Jul	DISC
>D>	AB			120MG	A077467	002	Sep 09, 2009	Jul	DISC
>A>		@		120MG	A077467	002	Sep 09, 2009	Jul	DISC

NEVIRAPINE

SUSPENSION; ORAL
NEVIRAPINE

	AA		AUROBINDO	50MG/5ML	A077702	001	May 22, 2012	May	NEWA

VIRAMUNE

	AA	+	BOEHRINGER INGELHEIM	50MG/5ML	N020933	001	Sep 11, 1998	May	CFTG

TABLET; ORAL
NEVIRAPINE

	AB		APOTEX INC	200MG	A203021	001	May 22, 2012	May	NEWA
	AB		AUROBINDO	200MG	A077521	001	May 22, 2012	May	NEWA
	AB		CIPLA	200MG	A077956	001	May 22, 2012	May	NEWA
	AB		HETERO LABS LTD III	200MG	A078584	001	May 22, 2012	May	NEWA
	AB		MICRO LABS LTD	200MG	A203080	001	May 22, 2012	May	NEWA
	AB		MYLAN LABS	200MG	A078864	001	May 22, 2012	May	NEWA
	AB		MYLAN PHARMS INC	200MG	A202523	001	May 22, 2012	May	NEWA
	AB		PRINSTON INC	200MG	A078644	001	May 22, 2012	May	NEWA
	AB		SCIEGEN PHARMS INC	200MG	A203176	001	May 22, 2012	May	NEWA
	AB		STRIDES	200MG	A078195	001	May 22, 2012	May	NEWA

VIRAMUNE

	AB	+	BOEHRINGER INGELHEIM	200MG	N020636	001	Jun 21, 1996	May	CFTG

NIFEDIPINE

TABLET, EXTENDED RELEASE; ORAL
NIFEDIPINE

	AB1		ACTAVIS	90MG	A077899	003	May 25, 2012	May	NEWA

NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE; ORAL
MACRODANTIN

>A>	AB		ALMATICA	25MG	N016620	003		Jul	CAHN
>A>	AB			50MG	N016620	001		Jul	CAHN
>A>	AB	+		100MG	N016620	002		Jul	CAHN
>D>	AB		ALVOGEN	25MG	N016620	003		Jul	CAHN
>D>	AB			50MG	N016620	001		Jul	CAHN
>D>	AB	+		100MG	N016620	002		Jul	CAHN

NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE; ORAL
MACROBID

>A>	AB	+	ALMATICA	75MG;25MG	N020064	001	Dec 24, 1991	Jul	CAHN
>D>	AB	+	ALVOGEN	75MG;25MG	N020064	001	Dec 24, 1991	Jul	CAHN

NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)

		@	RANBAXY LABS LTD	75MG;25MG	A076951	001	Mar 30, 2005	Apr	DISC

NITROGLYCERIN

FILM, EXTENDED RELEASE; TRANSDERMAL

MINITRAN

>D>	AB1	GRACEWAY	0.1MG/HR	A089771	001	Aug 30, 1996	Jul	CAHN
>D>	AB1		0.2MG/HR	A089772	001	Aug 30, 1996	Jul	CAHN
>D>	AB1		0.4MG/HR	A089773	001	Aug 30, 1996	Jul	CAHN
>D>	AB1		0.6MG/HR	A089774	001	Aug 30, 1996	Jul	CAHN
>A>	AB1	MEDICIS	0.1MG/HR	A089771	001	Aug 30, 1996	Jul	CAHN
>A>	AB1		0.2MG/HR	A089772	001	Aug 30, 1996	Jul	CAHN
>A>	AB1		0.4MG/HR	A089773	001	Aug 30, 1996	Jul	CAHN
>A>	AB1		0.6MG/HR	A089774	001	Aug 30, 1996	Jul	CAHN

OINTMENT; INTRA-ANAL

RECTIV

	+	APTALIS PHARMA	0.4%	N021359	001	Jun 21, 2011	Jan	CAHN

NIZATIDINE

CAPSULE; ORAL

AXID

	@	SMITHKLINE BEECHAM	150MG	N019508	001	Apr 12, 1988	Mar	DISC
	@		300MG	N019508	002	Apr 12, 1988	Mar	DISC

NIZATIDINE

	@	MYLAN PHARMS INC	150MG	A075934	001	Jul 09, 2002	Apr	DISC
AB	+		300MG	A075806	002	Jul 05, 2002	Apr	CRLD
	@		300MG	A075934	002	Jul 09, 2002	Apr	DISC

NOREPINEPHRINE BITARTRATE

INJECTABLE; INJECTION

NOREPINEPHRINE BITARTRATE

AP	CLARIS LIFESCIENCES	EQ 1MG BASE/ML	A040859	001	Mar 27, 2012	May	CAHN
AP	SINTETICA	EQ 1MG BASE/ML	A040859	001	Mar 27, 2012	Mar	NEWA

NORETHINDRONE ACETATE

TABLET; ORAL

NORETHIDRONE ACETATE

>A>	AB	AMNEAL PHARMS	5MG	A200275	001	Jul 30, 2012	Jul	NEWA

NYSTATIN

CREAM; TOPICAL

NYSTATIN

AT	FOUGERA PHARMS	100,000 UNITS/GM	A062129	001		Jan	CAHN

OINTMENT; TOPICAL

NYSTATIN

AT	+	FOUGERA PHARMS	100,000 UNITS/GM	A062124	002	Sep 23, 1982	Jan	CAHN

POWDER; TOPICAL

NYSTATIN

	@	NESHER PHARMS	100,000 UNITS/GM	A065321	001	Aug 18, 2006	Jun	DISC

NYSTATIN; TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL

MYKACET

	@	G AND W LABS INC	100,000 UNITS/GM;0.1%	A062367	001	May 28, 1985	Jun	CAHN

OINTMENT; TOPICAL

MYKACET

	@	G AND W LABS INC	100,000 UNITS/GM;0.1%	A062733	001	Mar 09, 1987	Jun	CAHN

OFLOXACIN

TABLET; ORAL

OFLOXACIN

@	RANBAXY LABS LTD	200MG	A076220	001	Sep 02, 2003	Apr	DISC
@		300MG	A076220	002	Sep 02, 2003	Apr	DISC
@		400MG	A076220	003	Sep 02, 2003	Apr	DISC

OLANZAPINE

INJECTABLE; INTRAMUSCULAR

OLANZAPINE

AP	PHARMAFORCE	10MG/VIAL	A201741	001	Mar 20, 2012	Mar	NEWA
AP	SANDOZ INC	10MG/VIAL	A201588	001	Oct 24, 2011	Mar	CAHN

TABLET; ORAL

OLANZAPINE

AB	APOTEX INC	2.5MG	A090798	001	Apr 23, 2012	Apr	NEWA
AB		5MG	A090798	002	Apr 23, 2012	Apr	NEWA
AB		7.5MG	A090798	003	Apr 23, 2012	Apr	NEWA
AB		10MG	A090798	004	Apr 23, 2012	Apr	NEWA
AB		15MG	A090798	005	Apr 23, 2012	Apr	NEWA
AB		20MG	A090798	006	Apr 23, 2012	Apr	NEWA
AB	AUROBINDO PHARMA LTD	2.5MG	A202050	001	Apr 23, 2012	Apr	NEWA
AB		5MG	A202050	002	Apr 23, 2012	Apr	NEWA
AB		7.5MG	A202050	003	Apr 23, 2012	Apr	NEWA
AB		10MG	A202050	004	Apr 23, 2012	Apr	NEWA
AB		15MG	A202050	005	Apr 23, 2012	Apr	NEWA
AB		20MG	A202050	006	Apr 23, 2012	Apr	NEWA
AB	DR REDDYS LABS LTD	2.5MG	A076255	001	Apr 23, 2012	Apr	NEWA
AB		5MG	A076255	002	Apr 23, 2012	Apr	NEWA
AB		7.5MG	A076255	003	Apr 23, 2012	Apr	NEWA
AB		10MG	A076255	004	Apr 23, 2012	Apr	NEWA
AB		15MG	A076133	001	Apr 23, 2012	Apr	NEWA
AB	MYLAN	2.5MG	A076866	001	Apr 23, 2012	Apr	NEWA
AB		5MG	A076866	002	Apr 23, 2012	Apr	NEWA
AB		7.5MG	A076866	003	Apr 23, 2012	Apr	NEWA
AB		10MG	A076866	004	Apr 23, 2012	Apr	NEWA
AB		15MG	A076866	005	Apr 23, 2012	Apr	NEWA
AB		20MG	A076866	006	Apr 23, 2012	Apr	NEWA
AB	ORCHID HLTHCARE	2.5MG	A202287	001	Apr 23, 2012	Apr	NEWA
AB		5MG	A202287	002	Apr 23, 2012	Apr	NEWA
AB		7.5MG	A202287	003	Apr 23, 2012	Apr	NEWA
AB		10MG	A202287	004	Apr 23, 2012	Apr	NEWA
AB		15MG	A202287	005	Apr 23, 2012	Apr	NEWA
AB		20MG	A202287	006	Apr 23, 2012	Apr	NEWA
AB	SUN PHARM INDS	2.5MG	A091038	001	Apr 23, 2012	Apr	NEWA
AB		5MG	A091038	002	Apr 23, 2012	Apr	NEWA
AB		7.5MG	A091038	003	Apr 23, 2012	Apr	NEWA
AB		10MG	A091038	004	Apr 23, 2012	Apr	NEWA
AB		15MG	A091038	005	Apr 23, 2012	Apr	NEWA
AB		20MG	A091038	006	Apr 23, 2012	Apr	NEWA
AB	TORRENT PHARMS LTD	2.5MG	A091434	001	Apr 23, 2012	Apr	NEWA
AB		5MG	A091434	002	Apr 23, 2012	Apr	NEWA
AB		7.5MG	A091434	003	Apr 23, 2012	Apr	NEWA
AB		10MG	A091434	004	Apr 23, 2012	Apr	NEWA
AB		15MG	A091434	005	Apr 23, 2012	Apr	NEWA
AB		20MG	A091434	006	Apr 23, 2012	Apr	NEWA

TABLET, ORALLY DISINTEGRATING; ORAL
OLANZAPINE

AB	BARR LABS INC	5MG	A077243	001	Jan 30, 2012	Jan	NEWA
AB		10MG	A077243	002	Jan 30, 2012	Jan	NEWA
AB		15MG	A077243	003	Jan 30, 2012	Jan	NEWA
AB		20MG	A077243	004	Jan 30, 2012	Jan	NEWA
AB	SUN PHARM INDS	5MG	A090881	001	Feb 28, 2012	Feb	NEWA
AB		10MG	A090881	002	Feb 28, 2012	Feb	NEWA
AB		15MG	A090881	003	Feb 28, 2012	Feb	NEWA
AB		20MG	A090881	004	Feb 28, 2012	Feb	NEWA

OMEPRAZOLE

CAPSULE, DELAYED REL PELLETS; ORAL
OMEPRAZOLE

AB	DR REDDYS LABS LTD	10MG	A078490	002	Mar 16, 2009	Apr	NEWA
AB		20MG	A078490	003	Mar 16, 2009	Apr	NEWA

ONDANSETRON

TABLET, ORALLY DISINTEGRATING; ORAL
ONDANSETRON

@	NESHER PHARMS	4MG	A077717	001	Jun 25, 2007	Jun	DISC
@		8MG	A077717	002	Jun 25, 2007	Jun	DISC

ONDANSETRON HYDROCHLORIDE

INJECTABLE; INJECTION
ONDANSETRON HYDROCHLORIDE

AP	GLAND PHARMA LTD	EQ 2MG BASE/ML	A090648	001	Jun 15, 2012	Jun	NEWA
AP	HIKMA MAPLE	EQ 2MG BASE/ML	A077365	001	Dec 26, 2006	Jun	CAHN

ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE

AP	HIKMA MAPLE	EQ 2MG BASE/ML	A077541	001	Dec 26, 2006	Jun	CAHN

ORPHENADRINE CITRATE

TABLET, EXTENDED RELEASE; ORAL
ORPHENADRINE CITRATE

>A>	AB	CNTY LINE PHARMS	100MG	A040249	001	Jan 29, 1999	Jul	CAHN
>A>	AB	INVAGEN PHARMS	100MG	A091158	001	Jul 27, 2012	Jul	NEWA
>D>	AB	KIEL	100MG	A040249	001	Jan 29, 1999	Jul	CAHN

OSELTAMIVIR PHOSPHATE

FOR SUSPENSION; ORAL
TAMIFLU

+	ROCHE	EQ 6MG BASE/ML	N021246	002	Mar 21, 2011	Jan	CRLD

OXACILLIN SODIUM

INJECTABLE; INJECTION
OXACILLIN SODIUM

AP	SAGENT PHARMS	EQ 1GM BASE/VIAL	A091246	001	Mar 30, 2012	Mar	NEWA
AP		EQ 2GM BASE/VIAL	A091246	002	Mar 30, 2012	Mar	NEWA
AP		EQ 10GM BASE/VIAL	A091245	001	Mar 30, 2012	Mar	NEWA

OXALIPLATIN

INJECTABLE; IV (INFUSION)
OXALIPLATIN

>A>	AP	ACTAVIS TOTOWA	50MG/VIAL	A078803	001	Aug 08, 2012	Jul	NEWA
>A>	AP		100MG/VIAL	A078803	002	Aug 08, 2012	Jul	NEWA
>A>	AP	ONCO THERAPIES LTD	50MG/VIAL	A200979	001	Aug 08, 2012	Jul	NEWA

INJECTABLE; IV (INFUSION)
OXALIPLATIN

>A>	AP		ONCO THERAPIES LTD	50MG/10ML (5MG/ML)	A091358	001	Aug 07, 2012	Jul	NEWA
>A>	AP			100MG/20ML (5MG/ML)	A091358	002	Aug 07, 2012	Jul	NEWA
>A>	AP			100MG/VIAL	A200979	002	Aug 08, 2012	Jul	NEWA
	AP	+	TEVA PHARMS	50MG/10ML (5MG/ML)	N022160	001	Aug 07, 2009	Mar	CRLD
	AP	+		100MG/20ML (5MG/ML)	N022160	002	Aug 07, 2009	Mar	CRLD

OXICONAZOLE NITRATE

CREAM; TOPICAL
OXISTAT

		+	FOUGERA PHARMS	EQ 1% BASE	N019828	001	Dec 30, 1988	Jan	CAHN

OXTRIPHYLLINE

TABLET, EXTENDED RELEASE; ORAL
CHOLEDYL SA

		+	WARNER CHILCOTT LLC	400MG	A087863	001	May 24, 1983	Jun	CAHN
		+		600MG	A086742	001		Jun	CAHN

OXYBUTYNIN

GEL, METERED; TRANSDERMAL
ANTUROL

		+	ARROW INTL	3%	N202513	001	Dec 07, 2011	Apr	CAHN
		+	WATSON LABS INC	3%	N202513	001	Dec 07, 2011	Feb	CAHN

OXYBUTYNIN CHLORIDE

TABLET; ORAL
DITROPAN

		@	JANSSEN PHARMS	5MG	N017577	001		Mar	DISC

OXYBUTYNIN CHLORIDE

	AB	+	VINTAGE PHARMS	5MG	A075079	001	Oct 31, 1997	Mar	CRLD

TABLET, EXTENDED RELEASE; ORAL
OXYBUTYNIN CHLORIDE

	AB		MYLAN PHARMS INC	15MG	A076644	002	May 10, 2007	Mar	NEWA

OXYCODONE HYDROCHLORIDE

CAPSULE; ORAL
>A> OXYCODONE HYDROCHLORIDE

>A>	AB		COASTAL PHARMS	5MG	A203107	001	Jul 26, 2012	Jul	NEWA
>D>		+	LEHIGH VALLEY	5MG	N200534	001	Oct 20, 2010	Jul	CFTG
>A>	AB	+		5MG	N200534	001	Oct 20, 2010	Jul	CFTG

SOLUTION; ORAL
OXYCODONE HYDROCHLORIDE

>D>		+	LEHIGH VALLEY	100MG/5ML	N200535	001	Oct 20, 2010	Jul	CFTG
>A>	AA	+		100MG/5ML	N200535	001	Oct 20, 2010	Jul	CFTG
		+	VISTAPHARM	5MG/5ML	N201194	001	Jan 12, 2012	Jan	NEWA
>A>	AA			100MG/5ML	A202537	001	Jul 30, 2012	Jul	NEWA

TABLET; ORAL
OXYCODONE HYDROCHLORIDE

	AB		MALLINCKRODT INC	5MG	A076758	003	Mar 19, 2007	Apr	NEWA

OXYMORPHONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
OPANA ER

		@	ENDO PHARMS	5MG	N021610	001	Jun 22, 2006	May	DISC
		@		10MG	N021610	002	Jun 22, 2006	May	DISC

TABLET, EXTENDED RELEASE; ORAL

OPANA ER

@ ENDO PHARMS	20MG	N021610	003	Jun 22, 2006	May	DISC
@	30MG	N021610	007	Feb 29, 2008	May	DISC
@	40MG	N021610	004	Jun 22, 2006	May	DISC

OXYMORPHONE HYDROCHLORIDE

IMPAX LABS	5MG	A079087	001	Jun 14, 2010	May	CTEC
	10MG	A079087	003	Jun 14, 2010	May	CTEC
	20MG	A079087	005	Jun 14, 2010	May	CTEC
	30MG	A079087	006	Jul 22, 2010	May	CTEC
	40MG	A079087	007	Jun 14, 2010	May	CTEC

OXYTOCIN

INJECTABLE; INJECTION

OXYTOCIN

@ TEVA PARENTERAL	10USP UNITS/ML (10USP UNITS/ML)	A077453	001	Jan 24, 2008	Jan	DISC
@	100USP UNITS/10ML (10USP UNITS/ML)	A077453	002	Jan 24, 2008	Mar	DISC

PACLITAXEL

INJECTABLE; INJECTION

TAXOL

@ CORDEN PHARMA	6MG/ML	N020262	001	Dec 29, 1992	Mar	CAHN

PAMIDRONATE DISODIUM

INJECTABLE; INJECTION

AREDIA

@ NOVARTIS	30MG/VIAL	N020036	001	Oct 31, 1991	Mar	DISC

PANCRELIPASE (AMYLASE;LIPASE;PROTEASE)

CAPSULE, DELAYED RELEASE; ORAL

CREON

ABBOTT LABS	15,000USP UNITS;3,000USP UNITS;9,500USP UNITS	N020725	004	Jul 12, 2011	Jun	NEWA
	30,000USP UNITS;6,000USP UNITS;19,000USP UNITS	N020725	001	Apr 30, 2009	Feb	CAHN
	60,000USP UNITS;12,000USP UNITS;38,000USP UNITS	N020725	002	Apr 30, 2009	Feb	CAHN
+	120,000USP UNITS;24,000USP UNITS;76,000USP UNITS	N020725	003	Apr 30, 2009	Feb	CAHN

PERTZYE

DIGESTIVE CARE INC	30,250USP/UNITS;8,000USP/UNITS;28,750USP/UNITS	N022175	001	May 17, 2012	May	NEWA
+	60,500USP/UNITS;16,000USP/UNITS;57,500USP/UNITS	N022175	002	May 17, 2012	May	NEWA

ULTRESA

APTALIS PHARMA US	27,600USP UNITS;13,800USP UNITS;27,600USP UNITS	N022222	001	Mar 01, 2012	Mar	NEWA
	41,400USP UNITS;20,700USP UNITS;41,400USP UNITS	N022222	002	Mar 01, 2012	Mar	NEWA
+	46,000USP UNITS;23,000USP UNITS;46,000USP UNITS	N022222	003	Mar 01, 2012	Mar	NEWA

ZENPEP

APTALIS PHARMA US	16,000USP UNITS;3,000USP UNITS;10,000USP UNITS	N022210	005	Jun 15, 2011	Apr	NEWA
	109,000USP UNITS;20,000USP UNITS;68,000USP UNITS	N022210	004	Aug 27, 2009	Apr	CRLD
+	136,000USP UNITS;25,000USP UNITS;85,000USP UNITS	N022210	006	Jul 13, 2011	Apr	NEWA

	TABLET; ORAL							
	VIOKACE							
	APTALIS PHARMA US	39,150USP UNITS;10,440USP UNITS;39,150USP UNITS	N022542	001	Mar 01, 2012	Mar	NEWA	
+		78,300USP UNITS;20,880USP UNITS;78,300USP UNITS	N022542	002	Mar 01, 2012	Mar	NEWA	
	PANTOPRAZOLE SODIUM							
	TABLET, DELAYED RELEASE; ORAL							
	PANTOPRAZOLE SODIUM							
AB	APOTEX INC	EQ 20MG BASE	A090807	001	May 02, 2012	Apr	NEWA	
AB		EQ 40MG BASE	A090807	002	May 02, 2012	Apr	NEWA	
AB	MACLEODS PHARMS LTD	EQ 20MG BASE	A200821	001	Feb 16, 2012	Jan	NEWA	
AB		EQ 40MG BASE	A200821	002	Feb 16, 2012	Jan	NEWA	
AB	RANBAXY LABS LTD	EQ 20MG BASE	A200794	001	May 02, 2012	Apr	NEWA	
AB		EQ 40MG BASE	A200794	002	May 02, 2012	Apr	NEWA	
	PAROXETINE HYDROCHLORIDE							
	TABLET; ORAL							
	PAROXETINE HYDROCHLORIDE							
AB	ACTAVIS ELIZABETH	EQ 10MG BASE	A076968	001	Jun 21, 2010	Feb	CMFD	
AB		EQ 20MG BASE	A076968	002	Jun 21, 2010	Feb	CMFD	
AB		EQ 30MG BASE	A076968	003	Jun 21, 2010	Feb	CMFD	
AB		EQ 40MG BASE	A076968	004	Jun 21, 2010	Feb	CMFD	
	PEGAPTANIB SODIUM							
	INJECTABLE; INTRAVITREAL							
	MACUGEN							
+	VALEANT PHARMS LLC	EQ 0.3MG ACID/0.09ML	N021756	001	Dec 17, 2004	May	CAHN	
	PEGINESATIDE ACETATE							
	SOLUTION; INTRAVENOUS, SUBCUTANEOUS							
	OMONTYS							
+	AFFYMAX	EQ 10MG BASE/ML (EQ 10MG BASE/ML)	N202799	007	Mar 27, 2012	Mar	NEWA	
+		EQ 20MG BASE/2ML (EQ 10MG BASE/ML)	N202799	008	Mar 27, 2012	Mar	NEWA	
	OMONTYS PRESERVATIVE FREE							
+	AFFYMAX	EQ 1MG BASE/0.5ML (EQ 1MG BASE/0.5ML)	N202799	001	Mar 27, 2012	Mar	NEWA	
+		EQ 2MG BASE/0.5ML (EQ 2MG BASE/0.5ML)	N202799	002	Mar 27, 2012	Mar	NEWA	
+		EQ 3MG BASE/0.5ML (EQ 3MG BASE/0.5ML)	N202799	003	Mar 27, 2012	Mar	NEWA	
+		EQ 4MG BASE/0.5ML (EQ 4MG BASE/0.5ML)	N202799	004	Mar 27, 2012	Mar	NEWA	
+		EQ 5MG BASE/0.5ML (EQ 5MG BASE/0.5ML)	N202799	005	Mar 27, 2012	Mar	NEWA	
+		EQ 6MG BASE/0.5ML (EQ 6MG BASE/0.5ML)	N202799	006	Mar 27, 2012	Mar	NEWA	
	PENTOBARBITAL SODIUM							
	INJECTABLE; INJECTION							
	NEMBUTAL SODIUM							
+	OAK PHARMS	50MG/ML	A083246	001		Feb	CAHN	
	PERINDOPRIL ERBUMINE							
	TABLET; ORAL							
	ACEON							
AB	XOMA	2MG	N020184	001	Dec 30, 1993	Jan	CAHN	

TABLET; ORAL
ACEON

AB		XOMA	4MG	N020184	002	Dec 30, 1993	Jan	CAHN
AB	+		8MG	N020184	003	Dec 30, 1993	Jan	CAHN

PERMETHRIN

CREAM; TOPICAL
ELIMITE

AB	+	RENAISSANCE PHARMA	5%	N019855	001	Aug 25, 1989	May	CAHN

PHENOXYBENZAMINE HYDROCHLORIDE

CAPSULE; ORAL
DIBENZYLINE

AB	+	WELLSPRING PHARM	10MG	N008708	001		Jun	CFTG

PHENOXYBENZAMINE HYDROCHLORIDE

AB		ROXANE	10MG	A201050	001	Jul 16, 2012	Jun	NEWA

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL
PHENTERMINE HYDROCHLORIDE

>D>		@ ACTAVIS TOTOWA	15MG	A040460	001	Jan 14, 2003	Jul	CAHN
>D>		@	30MG	A040227	001	Jun 18, 1997	Jul	CAHN
>D>		@	30MG	A040448	001	Jan 22, 2003	Jul	CAHN
>D>		@	37.5MG	A040228	001	Jun 19, 1997	Jul	CAHN
AA		LANNETT	15MG	A087022	002	Jan 20, 2012	Feb	NEWA
>A>		@ MIKAH PHARMA	15MG	A040460	001	Jan 14, 2003	Jul	CAHN
>A>		@	30MG	A040448	001	Jan 22, 2003	Jul	CAHN
>A>		@	30MG	A040227	001	Jun 18, 1997	Jul	CAHN
>A>		@	37.5MG	A040228	001	Jun 19, 1997	Jul	CAHN

TABLET; ORAL
PHENTERMINE HYDROCHLORIDE

>D>		@ ACTAVIS TOTOWA	37.5MG	A040190	001	May 30, 1997	Jul	CAHN
>A>		@ MIKAH PHARMA	37.5MG	A040190	001	May 30, 1997	Jul	CAHN
		@ SANDOZ INC	30MG	A088605	001	Sep 28, 1987	Feb	DISC

TABLET, ORALLY DISINTEGRATING; ORAL
SUPRENZA

		CITIUS PHARMS	30MG	N202088	002	Jun 13, 2011	Apr	CRLD
	+		37.5MG	N202088	003	Mar 27, 2012	Apr	CRLD
			37.5MG	N202088	003	Mar 27, 2012	Mar	NEWA

>A> PHENTERMINE HYDROCHLORIDE; TOPIRAMATE

>A> CAPSULE, EXTENDED RELEASE; ORAL
>A> QSYMIA

>A>		VIVUS	EQ 3.75MG BASE;23MG	N022580	001	Jul 17, 2012	Jul	NEWA
>A>			EQ 7.5MG BASE;46MG	N022580	002	Jul 17, 2012	Jul	NEWA
>A>			EQ 11.25MG BASE;69MG	N022580	003	Jul 17, 2012	Jul	NEWA
>A>	+		EQ 15MG BASE;92MG	N022580	004	Jul 17, 2012	Jul	NEWA

PHENTERMINE RESIN COMPLEX

CAPSULE, EXTENDED RELEASE; ORAL
PHENTERMINE RESIN COMPLEX

	+	LANNETT HOLDINGS INC	EQ 15MG BASE	A040872	001	Jul 28, 2011	Jan	CRLD
	+		EQ 30MG BASE	A040872	002	Jul 28, 2011	Jan	CRLD

PHENYTOIN SODIUM

INJECTABLE; INJECTION

PHENYTOIN SODIUM

AP	+	HIKMA MAPLE	50MG/ML	A084307	001		Jun	CAHN

PHYTONADIONE

INJECTABLE; INJECTION

PHYTONADIONE

BP	+	INTL MEDICATION	1MG/0.5ML	A083722	001		Feb	CRLD

TABLET; ORAL

MEPHYTON

	+	VALEANT PHARMS	5MG	N010104	003		Jun	CAHN

PINDOLOL

TABLET; ORAL

PINDOLOL

	@	MYLAN PHARMS INC	5MG	A074013	001	Sep 24, 1992	May	CAHN
	@		10MG	A074018	001	Sep 24, 1992	May	CAHN

PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL

ACTOS

		TAKEDA PHARMS USA	EQ 15MG BASE	N021073	001	Jul 15, 1999	Mar	CAHN
			EQ 30MG BASE	N021073	002	Jul 15, 1999	Mar	CAHN
	+		EQ 45MG BASE	N021073	003	Jul 15, 1999	Mar	CAHN

POTASSIUM CHLORIDE

TABLET, EXTENDED RELEASE; ORAL

K+10

	@	FUTURE PAK	10MEQ	A070999	001	Oct 22, 1987	Mar	DISC

KAON CL-10

	@	SAVAGE LABS	10MEQ	N017046	002		Mar	DISC

KLOR-CON M20

AB	+	UPSHER SMITH LABS	20MEQ	A074726	001	Nov 20, 1998	Mar	CRLD

KLOTRIX

	@	APOTHECON	10MEQ	N017850	001		Mar	DISC

POTASSIUM CHLORIDE

	@	NESHER PHARMS	20MEQ	A076044	001	Apr 05, 2002	Mar	DISC
	@	SCHERING	10MEQ	N019439	002	Jun 13, 1986	Mar	DISC
	@		20MEQ	N019439	001	Jun 13, 1986	Mar	DISC

POTASSIUM CITRATE

FOR SOLUTION; ORAL

POTASSIUM CITRATE

	@	NOVA K	10MEQ/PACKET	N019647	002	Oct 13, 1988	Feb	CAHN
	@		20MEQ/PACKET	N019647	001	Oct 13, 1988	Feb	CAHN

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET; ORAL

PRAMIPEXOLE DIHYDROCHLORIDE

AB		APOTEX INC	0.125MG	A090151	001	Apr 30, 2012	Apr	NEWA
AB			0.25MG	A090151	002	Apr 30, 2012	Apr	NEWA
AB			0.5MG	A090151	003	Apr 30, 2012	Apr	NEWA
AB			0.75MG	A090151	006	Apr 30, 2012	Apr	NEWA
AB			1MG	A090151	004	Apr 30, 2012	Apr	NEWA

TABLET; ORAL
PRAMIPEXOLE DIHYDROCHLORIDE

AB		APOTEX INC	1.5MG	A090151	005	Apr 30, 2012	Apr	NEWA

PRAVASTATIN SODIUM

TABLET; ORAL
PRAVASTATIN SODIUM

		@ PLIVA HRVATSKA DOO	10MG	A077730	001	Nov 21, 2006	Jun	DISC
		@	20MG	A077730	002	Nov 21, 2006	Jun	DISC
		@	30MG	A077730	003	Nov 21, 2006	Jun	DISC
		@	40MG	A077730	005	Nov 21, 2006	Jun	DISC
		@ RANBAXY LABS LTD	10MG	A076445	001	Apr 23, 2007	Apr	DISC
		@	20MG	A076445	002	Apr 23, 2007	Apr	DISC
		@	40MG	A076445	003	Apr 23, 2007	Apr	DISC
		@	80MG	A076445	004	Apr 23, 2007	Apr	DISC

PREDNICARBATE

CREAM; TOPICAL
PREDNICARBATE

AB		FOUGERA PHARMS	0.1%	A077287	001	Sep 19, 2006	Jan	CAHN

OINTMENT; TOPICAL
PREDNICARBATE

AB		FOUGERA PHARMS	0.1%	A077236	001	Mar 09, 2007	Jan	CAHN

PREDNISOLONE

SYRUP; ORAL
PREDNISOLONE

>D>	AA	HI TECH PHARMA	15MG/5ML	A040401	001	Feb 27, 2003	Jul	CRLD
>A>	AA +	HI TECH PHARMA CO	15MG/5ML	A040401	001	Feb 27, 2003	Jul	CRLD
		@ NESHER PHARMS	5MG/5ML	A040423	001	Oct 22, 2001	Jun	DISC
		@	15MG/5ML	A040364	001	Apr 10, 2002	Jun	DISC

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION; ORAL
PREDNISOLONE SODIUM PHOSPHATE

>A>	+	MISSION PHARMA	EQ 25MG BASE/5ML	A091396	001	Sep 13, 2010	Jul	CAHN
		@ NESHER PHARMS	EQ 5MG BASE/5ML	A076982	001	May 24, 2005	Jun	DISC
>D>	+	PHARM ASSOC	EQ 25MG BASE/5ML	A091396	001	Sep 13, 2010	Jul	CAHN

PREDNISONE

>A> TABLET, DELAYED RELEASE; ORAL
>A> RAYOS

>A>		HORIZON PHARMA	1MG	N202020	001	Jul 26, 2012	Jul	NEWA
>A>			2MG	N202020	002	Jul 26, 2012	Jul	NEWA
>A>	+		5MG	N202020	003	Jul 26, 2012	Jul	NEWA

PREGABALIN

CAPSULE; ORAL
LYRICA

AB		PF PRISM	25MG	N021446	001	Dec 30, 2004	Jun	CFTG
			25MG	N021446	001	Dec 30, 2004	Jan	CAHN
AB			50MG	N021446	002	Dec 30, 2004	Jun	CFTG
			50MG	N021446	002	Dec 30, 2004	Jan	CAHN
AB			75MG	N021446	003	Dec 30, 2004	Jun	CFTG
			75MG	N021446	003	Dec 30, 2004	Jan	CAHN
			100MG	N021446	004	Dec 30, 2004	Jan	CAHN

	CAPSULE; ORAL							
	LYRICA							
AB	PF PRISM	150MG	N021446	005	Dec 30, 2004	Jun		CFTG
		150MG	N021446	005	Dec 30, 2004	Jan		CAHN
AB		200MG	N021446	006	Dec 30, 2004	Jun		CFTG
		200MG	N021446	006	Dec 30, 2004	Jan		CAHN
AB		225MG	N021446	007	Dec 30, 2004	Jun		CFTG
		225MG	N021446	007	Dec 30, 2004	Jan		CAHN
AB +		300MG	N021446	008	Dec 30, 2004	Jun		CFTG
+		300MG	N021446	008	Dec 30, 2004	Jan		CAHN
	PREGABALIN							
AB	LUPIN LTD	25MG	A091040	001	Jul 03, 2012	Jun		NEWA
AB		50MG	A091040	002	Jul 03, 2012	Jun		NEWA
AB		75MG	A091040	003	Jul 03, 2012	Jun		NEWA
AB		100MG	A091040	004	Jul 03, 2012	Jun		NEWA
AB		150MG	A091040	005	Jul 03, 2012	Jun		NEWA
AB		200MG	A091040	006	Jul 03, 2012	Jun		NEWA
AB		225MG	A091040	007	Jul 03, 2012	Jun		NEWA
AB		300MG	A091040	008	Jul 03, 2012	Jun		NEWA
AB	TEVA PHARMS	25MG	A091219	001	Jul 03, 2012	Jun		NEWA
AB		50MG	A091219	002	Jul 03, 2012	Jun		NEWA
AB		75MG	A091224	001	Jul 03, 2012	Jun		NEWA
AB		100MG	A091224	002	Jul 03, 2012	Jun		NEWA
AB		150MG	A091224	003	Jul 03, 2012	Jun		NEWA
AB		200MG	A091224	004	Jul 03, 2012	Jun		NEWA
AB		225MG	A091224	005	Jul 03, 2012	Jun		NEWA
AB		300MG	A091224	006	Jul 03, 2012	Jun		NEWA
AB	WATSON LABS INC	25MG	A091221	001	Jul 03, 2012	Jun		NEWA
AB		50MG	A091221	002	Jul 03, 2012	Jun		NEWA
AB		75MG	A091221	003	Jul 03, 2012	Jun		NEWA
AB		100MG	A091221	004	Jul 03, 2012	Jun		NEWA
AB		150MG	A091221	005	Jul 03, 2012	Jun		NEWA
AB		200MG	A091221	006	Jul 03, 2012	Jun		NEWA
AB		225MG	A091221	007	Jul 03, 2012	Jun		NEWA
AB		300MG	A091221	008	Jul 03, 2012	Jun		NEWA
	SOLUTION; ORAL							
	LYRICA							
+	PF PRISM	20MG/ML	N022488	001	Jan 04, 2010	Jan		CAHN

PRILOCAINE HYDROCHLORIDE

	INJECTABLE; INJECTION							
	CITANEST PLAIN DENTAL							
	@ DENTSPLY PHARM	4%	N021382	001		May		DISC
	PRILOCAINE HYDROCHLORIDE							
+	SEPTODONT INC	4%	A079235	001	Sep 29, 2010	May		CRLD

PROCAINAMIDE HYDROCHLORIDE

	INJECTABLE; INJECTION							
	PROCAINAMIDE HYDROCHLORIDE							
	@ HIKMA MAPLE	100MG/ML	A089029	001	Apr 17, 1986	Jun		CAHN
	@	500MG/ML	A089030	001	Apr 17, 1986	Jun		CAHN

PROCHLORPERAZINE EDISYLATE

	INJECTABLE; INJECTION							
	PROCHLORPERAZINE EDISYLATE							
	@ HIKMA MAPLE	EQ 5MG BASE/ML	A089523	001	May 03, 1988	Jun		CAHN

		INJECTABLE; INJECTION						
		PROCHLORPERAZINE EDISYLATE						
AP	+	HIKMA MAPLE	EQ 5MG BASE/ML	A089903	001	Aug 29, 1989	Jun	CAHN
		PROGESTERONE						
		CAPSULE; ORAL						
		PROGESTERONE						
AB		TEVA PHARMS	100MG	A202121	001	Feb 29, 2012	Feb	NEWA
AB			200MG	A202121	002	Feb 29, 2012	Feb	NEWA
		PROMETRIUM						
AB		ABBOTT LABS	100MG	N019781	001	May 14, 1998	Feb	CFTG
AB	+		200MG	N019781	002	Oct 15, 1999	Feb	CFTG
		PROMETHAZINE HYDROCHLORIDE						
		SYRUP; ORAL						
		PROMETHAZINE HYDROCHLORIDE						
AA		TRIS PHARMA INC	6.25MG/5ML	A091675	001	Jun 28, 2012	Jun	NEWA
		PROPAFENONE HYDROCHLORIDE						
		TABLET; ORAL						
		PROPAFENONE HYDROCHLORIDE						
		@ NESHER PHARMS	150MG	A076193	001	Feb 07, 2002	Jun	DISC
		@	225MG	A076193	002	Feb 07, 2002	Jun	DISC
		@	300MG	A076193	003	Feb 07, 2002	Jun	DISC
		PROTRIPTYLINE HYDROCHLORIDE						
		TABLET; ORAL						
		VIVACTIL						
>D>		@ ODYSSEY PHARMS	5MG	N016012	001		Jul	CAHN
>D>		@	10MG	N016012	002		Jul	CAHN
>A>		@ TEVA WOMENS R AND D	5MG	N016012	001		Jul	CAHN
>A>		@	10MG	N016012	002		Jul	CAHN
		PYRIDOSTIGMINE BROMIDE						
		TABLET; ORAL						
		MESTINON						
AB	+	VALEANT PHARMS LLC	60MG	N009829	002		Jun	CAHN
		TABLET, EXTENDED RELEASE; ORAL						
		MESTINON						
	+	VALEANT PHARMS LLC	180MG	N011665	001		Jun	CAHN
		QUETIAPINE FUMARATE						
		TABLET; ORAL						
		QUETIAPINE FUMARATE						
AB		ACCORD HLTHCARE INC	EQ 25MG BASE	A202152	001	Mar 27, 2012	Mar	NEWA
AB			EQ 50MG BASE	A202152	002	Mar 27, 2012	Mar	NEWA
AB			EQ 100MG BASE	A202152	003	Mar 27, 2012	Mar	NEWA
AB			EQ 200MG BASE	A202152	004	Mar 27, 2012	Mar	NEWA
AB			EQ 300MG BASE	A202152	005	Mar 27, 2012	Mar	NEWA
AB			EQ 400MG BASE	A202152	006	Mar 27, 2012	Mar	NEWA
AB		APOTEX INC	EQ 25MG BASE	A090960	001	Mar 27, 2012	Mar	NEWA
AB			EQ 50MG BASE	A090960	002	Mar 27, 2012	Mar	NEWA
AB			EQ 100MG BASE	A090960	003	Mar 27, 2012	Mar	NEWA
AB			EQ 200MG BASE	A090960	004	Mar 27, 2012	Mar	NEWA
AB			EQ 300MG BASE	A090960	005	Mar 27, 2012	Mar	NEWA
AB			EQ 400MG BASE	A090960	006	Mar 27, 2012	Mar	NEWA

TABLET; ORAL

QUETIAPINE FUMARATE

AB		AUROBINDO PHARMA LTD	EQ 25MG BASE	A091388	001	Mar 27, 2012	Mar	NEWA
AB			EQ 50MG BASE	A091388	002	Mar 27, 2012	Mar	NEWA
AB			EQ 100MG BASE	A091388	003	Mar 27, 2012	Mar	NEWA
AB			EQ 150MG BASE	A091388	004	Mar 27, 2012	Mar	NEWA
AB			EQ 200MG BASE	A091388	005	Mar 27, 2012	Mar	NEWA
AB			EQ 300MG BASE	A091388	006	Mar 27, 2012	Mar	NEWA
AB			EQ 400MG BASE	A091388	007	Mar 27, 2012	Mar	NEWA
AB		DR REDDYS LABS LTD	EQ 25MG BASE	A077380	001	Mar 27, 2012	Mar	NEWA
AB			EQ 50MG BASE	A077380	002	Mar 27, 2012	Mar	NEWA
AB			EQ 100MG BASE	A077380	003	Mar 27, 2012	Mar	NEWA
AB			EQ 150MG BASE	A077380	004	Mar 27, 2012	Mar	NEWA
AB			EQ 200MG BASE	A077380	005	Mar 27, 2012	Mar	NEWA
AB			EQ 300MG BASE	A077380	006	Mar 27, 2012	Mar	NEWA
AB			EQ 400MG BASE	A077380	007	Mar 27, 2012	Mar	NEWA
AB		LUPIN LTD	EQ 25MG BASE	A201109	001	Mar 27, 2012	Mar	NEWA
AB			EQ 50MG BASE	A201109	002	Mar 27, 2012	Mar	NEWA
AB			EQ 100MG BASE	A201109	003	Mar 27, 2012	Mar	NEWA
AB			EQ 200MG BASE	A201109	004	Mar 27, 2012	Mar	NEWA
AB			EQ 300MG BASE	A201109	005	Mar 27, 2012	Mar	NEWA
AB			EQ 400MG BASE	A201109	006	Mar 27, 2012	Mar	NEWA
AB		MYLAN PHARMS INC	EQ 25MG BASE	A090323	001	Mar 27, 2012	Mar	NEWA
AB		ROXANE	EQ 25MG BASE	A090120	001	Mar 27, 2012	Mar	NEWA
AB			EQ 50MG BASE	A090749	001	Mar 27, 2012	Mar	NEWA
AB			EQ 100MG BASE	A090749	002	Mar 27, 2012	Mar	NEWA
AB			EQ 200MG BASE	A090749	003	Mar 27, 2012	Mar	NEWA
AB			EQ 300MG BASE	A090749	004	Mar 27, 2012	Mar	NEWA
AB			EQ 400MG BASE	A090749	005	Mar 27, 2012	Mar	NEWA
AB		SUN PHARMA GLOBAL	EQ 25MG BASE	A201190	001	Mar 27, 2012	Mar	NEWA
AB			EQ 50MG BASE	A201190	002	Mar 27, 2012	Mar	NEWA
AB			EQ 100MG BASE	A201190	003	Mar 27, 2012	Mar	NEWA
AB			EQ 200MG BASE	A201190	004	Mar 27, 2012	Mar	NEWA
AB			EQ 300MG BASE	A201190	005	Mar 27, 2012	Mar	NEWA
AB			EQ 400MG BASE	A201190	006	Mar 27, 2012	Mar	NEWA
AB		TEVA PHARMS	EQ 25MG BASE	A077745	001	Mar 27, 2012	Mar	NEWA
AB			EQ 50MG BASE	A077745	002	Mar 27, 2012	Mar	NEWA
AB			EQ 100MG BASE	A077745	003	Mar 27, 2012	Mar	NEWA
AB			EQ 150MG BASE	A077745	004	Mar 27, 2012	Mar	NEWA
AB			EQ 200MG BASE	A077745	005	Mar 27, 2012	Mar	NEWA
AB			EQ 300MG BASE	A077745	006	Mar 27, 2012	Mar	NEWA
AB			EQ 400MG BASE	A077745	007	Mar 27, 2012	Mar	NEWA
AB		TORRENT PHARMS LTD	EQ 25MG BASE	A200363	001	Mar 27, 2012	Mar	NEWA
AB			EQ 50MG BASE	A200363	002	Mar 27, 2012	Mar	NEWA
AB			EQ 100MG BASE	A200363	003	Mar 27, 2012	Mar	NEWA
AB			EQ 200MG BASE	A200363	004	Mar 27, 2012	Mar	NEWA
AB			EQ 300MG BASE	A200363	005	Mar 27, 2012	Mar	NEWA
AB			EQ 400MG BASE	A200363	006	Mar 27, 2012	Mar	NEWA

SEROQUEL

AB	+	ASTRAZENECA	EQ 25MG BASE	N020639	001	Sep 26, 1997	Mar	CFTG
AB			EQ 50MG BASE	N020639	007	Oct 04, 2005	Mar	CFTG
AB			EQ 100MG BASE	N020639	002	Sep 26, 1997	Mar	CFTG
AB			EQ 200MG BASE	N020639	003	Sep 26, 1997	Mar	CFTG
AB	+		EQ 300MG BASE	N020639	005	Jul 26, 2000	Mar	CFTG
AB			EQ 400MG BASE	N020639	006	Oct 04, 2005	Mar	CFTG

RAMELTEON

TABLET; ORAL
ROZEREM

>D>	+	TAKEDA GLOBAL	8MG	N021782	001	Jul 22, 2005	Jul	CAHN
>A>	+	TAKEDA PHARMS USA	8MG	N021782	001	Jul 22, 2005	Jul	CAHN

RAMIPRIL

CAPSULE; ORAL
RAMIPRIL

	@	RANBAXY LABS LTD	5MG	A078849	001	Mar 06, 2009	Apr	DISC
	@		10MG	A078849	002	Mar 06, 2009	Apr	DISC

TABLET; ORAL
ALTACE

	@	KING PFIZER	1.25MG	N022021	001	Feb 27, 2007	Jan	DISC
	@		2.5MG	N022021	002	Feb 27, 2007	Jan	DISC
	@		5MG	N022021	003	Feb 27, 2007	Jan	DISC
	@		10MG	N022021	004	Feb 27, 2007	Jan	DISC

RANITIDINE HYDROCHLORIDE

INJECTABLE; INJECTION
ZANTAC

AP	+	COVIS PHARMA	EQ 25MG BASE/ML	N019090	001	Oct 19, 1984	Mar	CAHN

ZANTAC IN PLASTIC CONTAINER

	+	COVIS PHARMA	EQ 1MG BASE/ML	N019593	002	Sep 27, 1991	Mar	CAHN
	@		EQ 50MG BASE/100ML	N019593	001	Dec 17, 1986	Mar	CAHN

RIFAMPIN

CAPSULE; ORAL
RIMACTANE

AB		PROSAM LABS	300MG	N050429	001		Feb	CMFD

RILPIVIRINE HYDROCHLORIDE

TABLET; ORAL
EDURANT

	+	JANSSEN PRODS	EQ 25MG BASE	N202022	001	May 20, 2011	Feb	CAHN

RISEDRONATE SODIUM

TABLET; ORAL
ACTONEL

AB		WARNER CHILCOTT LLC	5MG	N020835	002	Apr 14, 2000	Jun	CAHN
AB			30MG	N020835	001	Mar 27, 1998	Jun	CAHN
AB	+		35MG	N020835	003	May 25, 2002	Jun	CAHN
	@		75MG	N020835	004	Apr 16, 2007	Jun	CAHN
	+		150MG	N020835	005	Apr 22, 2008	Jun	CAHN

TABLET, DELAYED RELEASE; ORAL
ATELVIA

	+	WARNER CHILCOTT LLC	35MG	N022560	001	Oct 08, 2010	Jun	CAHN

RISPERIDONE

TABLET; ORAL
RISPERIDONE

AB		PROSAM LABS	0.25MG	A078071	001	Jun 17, 2009	Feb	CMFD
AB			0.5MG	A078071	002	Jun 17, 2009	Feb	CMFD
AB			1MG	A078071	003	Jun 17, 2009	Feb	CMFD
AB			2MG	A078071	004	Jun 17, 2009	Feb	CMFD

TABLET; ORAL
RISPERIDONE

AB	PROSAM LABS	3MG	A078071	005	Jun 17, 2009	Feb	CMFD
AB		4MG	A078071	006	Jun 17, 2009	Feb	CMFD

TABLET, ORALLY DISINTEGRATING; ORAL
RISPERIDONE

AB	TEVA	0.5MG	A076908	001	Mar 12, 2012	Feb	NEWA
AB		1MG	A076908	002	Mar 12, 2012	Feb	NEWA
AB		2MG	A076908	003	Mar 12, 2012	Feb	NEWA

RIVASTIGMINE TARTRATE

CAPSULE; ORAL
RIVASTIGMINE TARTRATE

AB	ALEMBIC PHARMS LTD	EQ 1.5MG BASE	A091689	001	Jun 12, 2012	May	NEWA
AB		EQ 3MG BASE	A091689	002	Jun 12, 2012	May	NEWA
AB		EQ 4.5MG BASE	A091689	003	Jun 12, 2012	May	NEWA
AB		EQ 6MG BASE	A091689	004	Jun 12, 2012	May	NEWA

ROPINIROLE HYDROCHLORIDE

TABLET; ORAL
ROPINIROLE HYDROCHLORIDE

AB	APOTEX	EQ 0.25MG BASE	A079165	001	Feb 07, 2012	Jan	NEWA
AB		EQ 0.5MG BASE	A079165	002	Feb 07, 2012	Jan	NEWA
AB		EQ 1MG BASE	A079165	003	Feb 07, 2012	Jan	NEWA
AB		EQ 2MG BASE	A079165	004	Feb 07, 2012	Jan	NEWA
AB		EQ 3MG BASE	A079165	005	Feb 07, 2012	Jan	NEWA
AB		EQ 4MG BASE	A079165	006	Feb 07, 2012	Jan	NEWA
AB		EQ 5MG BASE	A079165	007	Feb 07, 2012	Jan	NEWA

TABLET, EXTENDED RELEASE; ORAL
REQUIP XL

AB	+ SMITHKLINE BEECHAM	EQ 2MG BASE	N022008	001	Jun 13, 2008	Apr	CFTG
AB		EQ 4MG BASE	N022008	003	Jun 13, 2008	Apr	CFTG
AB		EQ 6MG BASE	N022008	006	Apr 10, 2009	Apr	CFTG
AB		EQ 8MG BASE	N022008	004	Jun 13, 2008	Apr	CFTG
AB		EQ 12MG BASE	N022008	005	Oct 31, 2008	Apr	CFTG

ROPINIROLE HYDROCHLORIDE

AB	ACTAVIS	EQ 2MG BASE	A090869	001	May 17, 2012	Apr	NEWA
AB		EQ 4MG BASE	A090869	002	May 17, 2012	Apr	NEWA
AB		EQ 6MG BASE	A090869	003	May 17, 2012	Apr	NEWA
AB		EQ 8MG BASE	A090869	004	May 17, 2012	Apr	NEWA
AB		EQ 12MG BASE	A090869	005	May 17, 2012	Apr	NEWA
AB	DR REDDYS LABS LTD	EQ 2MG BASE	A201576	001	Jun 06, 2012	May	NEWA
AB		EQ 4MG BASE	A201576	002	Jun 06, 2012	May	NEWA
AB		EQ 6MG BASE	A201576	003	Jun 06, 2012	May	NEWA
AB		EQ 8MG BASE	A201576	004	Jun 06, 2012	May	NEWA
AB		EQ 12MG BASE	A201576	005	Jun 06, 2012	May	NEWA
AB	SANDOZ INC	EQ 2MG BASE	A201047	001	Jun 06, 2012	May	NEWA
AB		EQ 4MG BASE	A201047	003	Jun 06, 2012	May	NEWA
AB		EQ 6MG BASE	A201047	004	Jun 06, 2012	May	NEWA
AB		EQ 8MG BASE	A201047	005	Jun 06, 2012	May	NEWA
AB		EQ 12MG BASE	A201047	006	Jun 06, 2012	May	NEWA
AB	WATSON LABS INC	EQ 2MG BASE	A200431	001	Jun 06, 2012	May	NEWA
AB		EQ 4MG BASE	A200431	002	Jun 06, 2012	May	NEWA
AB		EQ 6MG BASE	A200431	003	Jun 06, 2012	May	NEWA
AB		EQ 8MG BASE	A200431	004	Jun 06, 2012	May	NEWA
AB		EQ 12MG BASE	A200431	005	Jun 06, 2012	May	NEWA

ROTIGOTINE

FILM, EXTENDED RELEASE; TRANSDERMAL

NEUPRO

	UCB INC	1MG/24HR	N021829	004	Apr 02, 2012	Apr	NEWA
		2MG/24HR	N021829	001	May 09, 2007	Apr	CMFD
		3MG/24HR	N021829	005	Apr 02, 2012	Apr	NEWA
		4MG/24HR	N021829	002	May 09, 2007	Apr	CMFD
		6MG/24HR	N021829	003	May 09, 2007	Apr	CMFD
+		8MG/24HR	N021829	006	Apr 02, 2012	Apr	NEWA

SAMARIUM SM-153 LEXIDRONAM PENTASODIUM

INJECTABLE; INJECTION

QUADRAMET

>D> +	EUSA PHARMA USA	50mCi/ML	N020570	001	Mar 28, 1997	Jul	CAHN
>A> +	JAZZ EUSA PHARMA	50mCi/ML	N020570	001	Mar 28, 1997	Jul	CAHN

SERTACONAZOLE NITRATE

CREAM; TOPICAL

ERTACZO

+	VALEANT INTL	2%	N021385	001	Dec 10, 2003	Jan	CAHN

SERTRALINE HYDROCHLORIDE

TABLET; ORAL

SERTRALINE HYDROCHLORIDE

AB	PROSAM LABS	EQ 25MG BASE	A078175	001	Jul 21, 2010	Feb	CMFD
AB		EQ 50MG BASE	A078175	002	Jul 21, 2010	Feb	CMFD
AB		EQ 100MG BASE	A078175	003	Jul 21, 2010	Feb	CMFD

SILVER SULFADIAZINE

CREAM; TOPICAL

THERMAZENE

AB	THEPHARMANETWORK LLC	1%	N018810	001	Dec 23, 1985	Jun	CAHN

SIMVASTATIN

TABLET; ORAL

SIMVASTATIN

AB	PROSAM LABS	5MG	A078735	001	Aug 30, 2010	Feb	CMFD
AB		10MG	A078735	002	Aug 30, 2010	Feb	CMFD
AB		20MG	A078735	003	Aug 30, 2010	Feb	CMFD
AB		40MG	A078735	004	Aug 30, 2010	Feb	CMFD
AB		80MG	A078735	005	Aug 30, 2010	Feb	CMFD

SITAGLIPTIN PHOSPHATE

TABLET; ORAL

JANUVIA

	MERCK SHARP DOHME	EQ 25MG BASE	N021995	001	Oct 16, 2006	May	CAHN
		EQ 50MG BASE	N021995	002	Oct 16, 2006	May	CAHN
+		EQ 100MG BASE	N021995	003	Oct 16, 2006	May	CAHN

SODIUM BICARBONATE; TARTARIC ACID

GRANULE, EFFERVESCENT; ORAL

BAROS

@	MALLINCKRODT INC	460MG/GM;420MG/GM	N018509	001	Aug 07, 1985	Jan	CAHN

SODIUM CHLORIDE

INJECTABLE; INJECTION
SODIUM CHLORIDE 0.9%

AP	HIKMA (MAPLE)	9MG/ML	A201850	001	Jan 20, 2012	Jan	NEWA

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

	MEDEFIL	9MG/ML	N202832	001	Jan 06, 2012	Jan	NEWA

SODIUM CHROMATE CR-51

INJECTABLE; INJECTION
CHROMITOPE SODIUM

	@ BRACCO	200uCi/ML	N013993	001		Jun	DISC

SODIUM FERRIC GLUCONATE COMPLEX

INJECTABLE; INJECTION
SODIUM FERRIC GLUCONATE COMPLEX IN SUCROSE

AB	HIKMA PHARMS	62.5MG/5ML	A078215	001	Mar 31, 2011	May	CAHN

SODIUM IODIDE I-123

CAPSULE; ORAL
SODIUM IODIDE I 123

	@ GE HEALTHCARE	100uCi	N017630	001		May	DISC

SOLUTION; ORAL
SODIUM IODIDE I 123

>D>	+ GE HEALTHCARE	2mCi/ML	N017630	002		Jul	DISC
>A>	@	2mCi/ML	N017630	002		Jul	DISC

SODIUM IODIDE I-131

CAPSULE; ORAL
SODIUM IODIDE I-131

	JUBILANT DRAXIMAGE	9-100mCi	N021305	006	May 19, 2005	Feb	CAHN
	@	2-200mCi	N021305	004	Nov 18, 2004	Jan	DISC

SOLUTION; ORAL
HICON

	@ JUBILANT DRAXIMAGE	1-500mCi/0.5ML	N021305	003	Jan 24, 2003	Feb	DISC
	@	1-250mCi/0.25ML	N021305	002	Jan 24, 2003	Feb	DISC
	@	1-1000mCi/ML	N021305	005	Apr 04, 2006	Feb	DISC
	+	250-1000mCi	N021305	007	Dec 05, 2011	Jan	NEWA

SODIUM NITRITE

SOLUTION; INTRAVENOUS
SODIUM NITRITE

	+ HOPE PHARMS	300MG/10ML (30MG/ML)	N203922	001	Feb 14, 2012	Feb	NEWA

SODIUM OXYBATE

SOLUTION; ORAL
XYREM

	+ JAZZ PHARMS	500MG/ML	N021196	001	Jul 17, 2002	Jun	CAHN

SODIUM POLYSTYRENE SULFONATE

POWDER; ORAL, RECTAL
SODIUM POLYSTYRENE SULFONATE

	@ CITRUSPHRMA	454GM/BOT	A040909	001	Dec 03, 2008	Jun	DISC

SODIUM THIOSULFATE

SOLUTION; INTRAVENOUS
SODIUM THIOSULFATE

+		HOPE PHARMS	12.5GM/50ML (250MG/ML)	N203923	001	Feb 14, 2012	Feb	NEWA

SOMATROPIN RECOMBINANT

INJECTABLE; INJECTION
NORDITROPIN

>D>								
>D>	BX	NOVO NORDISK INC	5MG/1.5ML	N021148	001	Jun 20, 2000	Jul	DISC
>A>		@	5MG/1.5ML	N021148	001	Jun 20, 2000	Jul	DISC
>D>	BX		10MG/1.5ML	N021148	002	Jun 20, 2000	Jul	DISC
>A>		@	10MG/1.5ML	N021148	002	Jun 20, 2000	Jul	DISC
>D>		+	15MG/1.5ML	N021148	003	Jun 20, 2000	Jul	DISC
>A>		@	15MG/1.5ML	N021148	003	Jun 20, 2000	Jul	DISC

SOTALOL HYDROCHLORIDE

TABLET; ORAL
SOTALOL HYDROCHLORIDE

	AB2	EPIC PHARMA INC	80MG	A077070	001	Nov 04, 2005	Jun	CAHN
	AB2		120MG	A077070	002	Nov 04, 2005	Jun	CAHN
	AB2		160MG	A077070	003	Nov 04, 2005	Jun	CAHN

SPINOSAD

SUSPENSION; TOPICAL
NATROBA

+		PARAPRO LLC	0.9%	N022408	001	Jan 18, 2011	May	CAHN

SUCCIMER

CAPSULE; ORAL
CHEMET

+		LUNDBECK LLC	100MG	N019998	002	Jan 30, 1991	Mar	CAHN

SULFACETAMIDE SODIUM

LOTION; TOPICAL
SULFACETAMIDE SODIUM

	AB	FOUGERA PHARMS	10%	A077015	001	Nov 17, 2006	Jan	CAHN

SULFANILAMIDE

CREAM; VAGINAL
AVC

+		JAZZ PHARMS COMMERCL	15%	N006530	003	Jan 27, 1987	Mar	CAHN
>A>	+	JAZZ PHARMS II	15%	N006530	003	Jan 27, 1987	Jul	CAHN
>D>	+	JAZZ PHARMS III	15%	N006530	003	Jan 27, 1987	Jul	CAHN
+			15%	N006530	003	Jan 27, 1987	Jun	CAHN

SUPPOSITORY; VAGINAL
AVC

@		JAZZ PHARMS COMMERCL	1.05GM	N006530	004	Jan 27, 1987	Mar	CAHN
>A>	@	JAZZ PHARMS II	1.05GM	N006530	004	Jan 27, 1987	Jul	CAHN
>D>	@	JAZZ PHARMS III	1.05GM	N006530	004	Jan 27, 1987	Jul	CAHN
@			1.05GM	N006530	004	Jan 27, 1987	Jun	CAHN

SUMATRIPTAN SUCCINATE

INJECTABLE; SUBCUTANEOUS

ALSUMA

BX	MERIDIAN MEDCL	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	N022377	001	Jun 29, 2010	Jun	CRLD

SUMATRIPTAN SUCCINATE

AP	INJECTALIA	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A090310	001	Aug 11, 2010	Mar	CAHN

SUMAVEL DOSEPRO

BX	+ ZOGENIX INC	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	N022239	001	Jul 15, 2009	Jun	CTEC

TABLET; ORAL

SUMATRIPTAN SUCCINATE

AB	APOTEX INC	EQ 25MG BASE	A200263	001	Jun 19, 2012	Jun	NEWA
AB		EQ 50MG BASE	A200263	002	Jun 19, 2012	Jun	NEWA
AB		EQ 100MG BASE	A200263	003	Jun 19, 2012	Jun	NEWA

TAFLUPROST

SOLUTION/DROPS; OPHTHALMIC

ZIOPTAN

+	MERCK SHARP DOHME	0.0015%	N202514	001	Feb 10, 2012	Feb	NEWA

TALIGLUCERASE ALFA

POWDER; IV (INFUSION)

ELELYSO

+	PFIZER	200 UNITS/VIAL	N022458	001	May 01, 2012	May	NEWA

TAMOXIFEN CITRATE

TABLET; ORAL

TAMOXIFEN CITRATE

@	AEGIS PHARMS	EQ 10MG BASE	A076398	001	Mar 31, 2003	Jun	DISC
@		EQ 20MG BASE	A076398	002	Mar 31, 2003	Jun	DISC

TAZAROTENE

AEROSOL, FOAM; TOPICAL

FABIOR

+	STIEFEL LABS INC	0.1%	N202428	001	May 11, 2012	May	NEWA

TECHNETIUM TC-99M MEDRONATE

INJECTABLE; INJECTION

DRAXIMAGE MDP-10

@	JUBILANT DRAXIMAGE	N/A	N018035	001		May	CAHN

DRAXIMAGE MDP-25

+	JUBILANT DRAXIMAGE	N/A	N018035	002	Feb 27, 2004	May	CAHN

TEMAZEPAM

CAPSULE; ORAL

TEMAZEPAM

AB	NOVEL LABS INC	7.5MG	A071457	002	Jun 22, 2012	Jun	NEWA
AB		22.5MG	A071457	003	Jun 22, 2012	Jun	NEWA

TEMOZOLOMIDE

CAPSULE; ORAL

TEMODAR

AB	MERCK SHARP DOHME	5MG	N021029	001	Aug 11, 1999	Jun	CAHN
AB		20MG	N021029	002	Aug 11, 1999	Jun	CAHN

CAPSULE; ORAL
TEMODAR

AB		MERCK SHARP DOHME	100MG	N021029	003	Aug 11, 1999	Jun	CAHN
AB			140MG	N021029	005	Oct 19, 2006	Jun	CAHN
AB			180MG	N021029	006	Oct 19, 2006	Jun	CAHN
AB	+		250MG	N021029	004	Aug 11, 1999	Jun	CAHN

POWDER; INTRAVENOUS
TEMODAR

	+	MERCK SHARP DOHME	100MG/VIAL	N022277	001	Feb 27, 2009	Jun	CAHN

TENOFOVIR DISOPROXIL FUMARATE

POWDER; ORAL
VIREAD

	+	GILEAD SCIENCES INC	40MG/SCOOPFUL	N022577	001	Jan 18, 2012	Jan	NEWA

TABLET; ORAL
VIREAD

		GILEAD SCIENCES INC	150MG	N021356	002	Jan 18, 2012	Apr	NEWA
			200MG	N021356	003	Jan 18, 2012	Apr	NEWA
			250MG	N021356	004	Jan 18, 2012	Apr	NEWA

TERAZOSIN HYDROCHLORIDE

CAPSULE; ORAL
TERAZOSIN HYDROCHLORIDE

	@	RANBAXY LABS LTD	EQ 1MG BASE	A076021	001	Aug 22, 2002	Apr	DISC
	@		EQ 2MG BASE	A076021	002	Aug 22, 2002	Apr	DISC
	@		EQ 5MG BASE	A076021	003	Aug 22, 2002	Apr	DISC
	@		EQ 10MG BASE	A076021	004	Aug 22, 2002	Apr	DISC

TERBUTALINE SULFATE

INJECTABLE; INJECTION
TERBUTALINE SULFATE

	@	TEVA PARENTERAL	1MG/ML	A076853	001	Jul 20, 2004	Jan	DISC

TERCONAZOLE

CREAM; VAGINAL
TERCONAZOLE

AB		FOUGERA PHARMS	0.4%	A076712	001	Feb 18, 2005	Jan	CAHN

SUPPOSITORY; VAGINAL
TERCONAZOLE

AB		FOUGERA PHARMS	80MG	A076850	001	Jul 12, 2006	Jan	CAHN

TESAMORELIN ACETATE

POWDER; SUBCUTANEOUS
EGRIFTA

	@	EMD SERONO	EQ 1MG BASE/VIAL	N022505	001	Nov 10, 2010	Jun	DISC
	+		EQ 1MG BASE/VIAL	N022505	001	Nov 10, 2010	May	CAHN
	+		EQ 2MG BASE/VIAL	N022505	002	Nov 29, 2011	Jun	NEWA

TESTOSTERONE

GEL; TRANSDERMAL
ANDROGEL

BX	+	ABBOTT LABS	1% (50MG/5GM PACKET)	N021015	002	Feb 28, 2000	Feb	CPOT
			1% (25MG/2.5GM PACKET)	N021015	001	Feb 28, 2000	Feb	CPOT

TESTIM

BX	+	AUXILIUM PHARMS	1% (50MG/5GM PACKET)	N021454	001	Oct 31, 2002	Feb	CPOT

	GEL; TRANSDERMAL							
	TESTOSTERONE							
	TEVA PHARMS	25MG/2.5GM PACKET	N202763	001	Feb 14, 2012	Feb	NEWA
		50MG/5GM PACKET	N202763	002	Feb 14, 2012	Feb	NEWA
	GEL, METERED; TRANSDERMAL							
	ANDROGEL							
+	ABBOTT LABS	1% (1.25GM/ACTUATION)	N021015	003	Sep 26, 2003	Jun	CPOT
	PELLET; IMPLANTATION							
	TESTOPEL							
+	ACTIENT PHARMS	75MG	A080911	001		May	CAHN
	TESTOSTERONE CYPIONATE							
	INJECTABLE; INJECTION							
	TESTOSTERONE CYPIONATE							
AO	HIKMA FARMACEUTICA	200MG/ML	A091244	001	May 01, 2012	Apr	NEWA
AO	MYLAN INSTITUTIONAL	200MG/ML	A040652	001	Dec 11, 2006	Feb	CAHN
	TESTOSTERONE ENANTHATE							
	INJECTABLE; INJECTION							
	TESTOSTERONE ENANTHATE							
AO	MYLAN INSTITUTIONAL	200MG/ML	A040647	001	Oct 05, 2009	Feb	CAHN
	TETRABENAZINE							
	TABLET; ORAL							
	XENAZINE							
	VALEANT PHARMS	12.5MG	N021894	001	Aug 15, 2008	Apr	CAHN
+		25MG	N021894	002	Aug 15, 2008	Apr	CAHN
	TETRAHYDROZOLINE HYDROCHLORIDE							
	SOLUTION; NASAL							
	TYZINE							
+	FOUGERA PHARMS	0.05%	A086576	002		Jan	CAHN
		0.1%	A086576	001		Jan	CAHN
	SPRAY; NASAL							
	TYZINE							
+	FOUGERA PHARMS	0.1%	A086576	003		Jan	CAHN
	THEOPHYLLINE							
	CAPSULE, EXTENDED RELEASE; ORAL							
	THEO-24							
	UCB INC	100MG	A087942	001	Aug 22, 1983	May	CTEC
		200MG	A087943	001	Aug 22, 1983	May	CTEC
		300MG	A087944	001	Aug 22, 1983	May	CTEC
+		400MG	A081034	001	Feb 28, 1992	May	CRLD
	THEOPHYLLINE							
	@ INWOOD LABS	100MG	A040052	001	Feb 14, 1994	May	DISC
	@	125MG	A040052	002	Feb 14, 1994	May	DISC
	@	200MG	A040052	003	Feb 14, 1994	May	DISC
	@	300MG	A040052	004	Feb 14, 1994	May	DISC
	INJECTABLE; INJECTION							
	THEOPHYLLINE AND DEXTROSE 5% IN PLASTIC CONTAINER							
	@ BAXTER HLTHCARE	4MG/ML	N018649	007	Jul 26, 1982	Mar	DISC
	@	40MG/100ML	N018649	001	Jul 26, 1982	Mar	DISC
	@	80MG/100ML	N018649	002	Jul 26, 1982	Mar	DISC
	@	160MG/100ML	N018649	003	Jul 26, 1982	Mar	DISC
	@	200MG/100ML	N018649	004	Jul 26, 1982	Mar	DISC

		INJECTABLE; INJECTION							
		THEOPHYLLINE AND DEXTROSE 5% IN PLASTIC CONTAINER							
		@ BAXTER HLTHCARE	320MG/100ML	N018649	006	Nov 13, 1985	Mar	DISC	
		@	400MG/100ML	N018649	005	Jul 26, 1982	Mar	DISC	
		SOLUTION; ORAL							
		THEOPHYLLINE							
AA	+	SILARX	80MG/15ML	A091156	001	Apr 13, 2011	Jun	CTEC	
AA		TRIS PHARMA INC	80MG/15ML	A091586	001	Jun 15, 2012	Jun	NEWA	
		TABLET; ORAL							
		THEOLAIR							
>D>	+	GRACEWAY	125MG	A086399	001		Jul	CAHN	
>D>	+		250MG	A086399	002		Jul	CAHN	
>A>	+	MEDICIS	125MG	A086399	001		Jul	CAHN	
>A>	+		250MG	A086399	002		Jul	CAHN	
		THIAMINE HYDROCHLORIDE							
		INJECTABLE; INJECTION							
		THIAMINE HYDROCHLORIDE							
AP		MYLAN INSTITUTIONAL	100MG/ML	A091623	001	Jun 25, 2012	Jun	NEWA	
		TIAGABINE HYDROCHLORIDE							
		TABLET; ORAL							
		GABITRIL							
		@ CEPHALON	6MG	N020646	006	Nov 29, 2005	Jan	DISC	
		@	8MG	N020646	007	Nov 29, 2005	Jan	DISC	
		@	10MG	N020646	008	Nov 29, 2005	Jan	DISC	
		TINIDAZOLE							
		TABLET; ORAL							
		TINDAMAX							
AB		MISSION PHARMA	250MG	N021618	001	May 17, 2004	Apr	CFTG	
AB	+		500MG	N021618	002	May 17, 2004	Apr	CFTG	
		TINIDAZOLE							
AB		NOVEL LABS INC	250MG	A202044	001	Apr 30, 2012	Apr	NEWA	
AB			500MG	A202044	002	Apr 30, 2012	Apr	NEWA	
AB		ROXANE	250MG	A201172	001	Apr 30, 2012	Apr	NEWA	
AB			500MG	A201172	002	Apr 30, 2012	Apr	NEWA	
		TINZAPARIN SODIUM							
		INJECTABLE; INJECTION							
		INNOHEP							
		@ LEO PHARMA AS	20,000 IU/ML	N020484	001	Jul 14, 2000	Jun	DISC	
		TIZANIDINE HYDROCHLORIDE							
		CAPSULE; ORAL							
		TIZANIDINE HYDROCHLORIDE							
AB		APOTEX INC	EQ 2MG BASE	A078868	001	Feb 03, 2012	Jan	NEWA	
AB			EQ 4MG BASE	A078868	002	Feb 03, 2012	Jan	NEWA	
AB			EQ 6MG BASE	A078868	003	Feb 03, 2012	Jan	NEWA	
		ZANAFLEX							
AB		ACORDA	EQ 2MG BASE	N021447	001	Aug 29, 2002	Jan	CFTG	
AB			EQ 4MG BASE	N021447	002	Aug 29, 2002	Jan	CFTG	
AB	+		EQ 6MG BASE	N021447	003	Aug 29, 2002	Jan	CFTG	
		TABLET; ORAL							
		TIZANIDINE HYDROCHLORIDE							
AB		PROSAM LABS	EQ 2MG BASE	A076281	001	Oct 20, 2003	Feb	CMFD	

TABLET; ORAL
TIZANIDINE HYDROCHLORIDE

AB		PROSAM LABS	EQ 4MG BASE	A076281	002	Oct 20, 2003	Feb	CMFD
AB		SANDOZ INC	EQ 2MG BASE	A076280	001	Nov 26, 2002	Feb	NEWA

TOLBUTAMIDE

TABLET; ORAL
TOLBUTAMIDE

	+	MYLAN PHARMS INC	500MG	A086445	001		Mar	CRLD
	@	WATSON LABS	500MG	A086109	001		Mar	DISC
	@		500MG	A087318	001		Mar	DISC

TOLCAPONE

TABLET; ORAL
TASMAR

	+	VALEANT PHARMS LLC	100MG	N020697	001	Jan 29, 1998	May	CAHN
	@		200MG	N020697	002	Jan 29, 1998	May	CAHN

TOPOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION
TOPOTECAN HYDROCHLORIDE

>A>	AP		INNOPHARMA INC	EQ 4MG BASE/VIAL	A201166	001	Aug 08, 2012	Jul	NEWA

TRAMADOL HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
TRAMADOL HYDROCHLORIDE

	AB2		ACTAVIS	100MG	A091609	001	Jun 27, 2012	Jun	NEWA
	AB2			200MG	A091609	002	Jun 27, 2012	Jun	NEWA
	AB2			300MG	A091609	003	Jun 27, 2012	Jun	NEWA
	AB2		ANCHEN PHARMS	100MG	A200491	001	Jun 27, 2012	Jun	NEWA
	AB2			200MG	A200491	002	Jun 27, 2012	Jun	NEWA
	AB2			300MG	A200491	003	Jun 27, 2012	Jun	NEWA

TABLET, ORALLY DISINTEGRATING; ORAL
RYBIX ODT

	+	SHIONOGI INC	50MG	N021693	001	May 05, 2005	Mar	CTNA

TRANEXAMIC ACID

INJECTABLE; INJECTION
TRANEXAMIC ACID

AP		APP PHARMS LLC	100MG/ML	A091596	001	Mar 02, 2012	May	CAHN
AP		NEXUS PHARMS	100MG/ML	A091596	001	Mar 02, 2012	Feb	NEWA

TRANYLCYPROMINE SULFATE

TABLET; ORAL
PARNATE

AB	+	COVIS PHARMA	EQ 10MG BASE	N012342	003	Aug 16, 1985	Jan	CAHN

TRETINOIN

CREAM; TOPICAL
AVITA

AB		MYLAN PHARMS INC	0.025%	N020404	003	Jan 14, 1997	Jun	CAHN

RENOVA

	+	VALEANT INTL	0.02%	N021108	001	Aug 31, 2000	Jan	CAHN
AB2	+		0.05%	N019963	001	Dec 29, 1995	Jan	CAHN

RETIN-A

AB	+	VALEANT INTL	0.025%	N019049	001	Sep 16, 1988	Jan	CAHN

CREAM; TOPICAL
RETIN-A

AB1	+	VALEANT INTL	0.05%	N017522	001		Jan	CAHN
AB	+		0.1%	N017340	001		Jan	CAHN

TRETINOIN

AB		PRECISION DERMAT	0.025%	A075264	001	Dec 24, 1998	May	CAHN
	+		0.0375%	A090098	001	Mar 22, 2010	May	CAHN
AB1			0.05%	A075265	001	Dec 24, 1998	May	CAHN
AB			0.1%	A075213	001	Dec 24, 1998	May	CAHN
AB2		SUNEVA MEDCL	0.05%	A076498	001	Sep 15, 2005	May	CAHN

GEL; TOPICAL
RETIN-A

AB	+	VALEANT INTL	0.01%	N017955	001		Jan	CAHN
AB	+		0.025%	N017579	002		Jan	CAHN

TRETINOIN

AB		PRECISION DERMAT	0.01%	A075589	001	Jun 11, 2002	May	CAHN
AB			0.025%	A075529	001	Feb 22, 2000	May	CAHN

SOLUTION; TOPICAL
RETIN-A

AT	+	VALEANT INTL	0.05%	N016921	001		Jan	CAHN

SWAB; TOPICAL
RETIN-A

		@ VALEANT INTL	0.05%	N016921	002		Jan	CAHN

TRIAMCINOLONE ACETONIDE

AEROSOL, METERED; INHALATION
AZMACORT

		@ ABBOTT	0.1MG/INH	N018117	001	Apr 23, 1982	May	DISC

CREAM; TOPICAL
TRIAMCINOLONE ACETONIDE

AT		FOUGERA PHARMS	0.025%	A085692	001		Jan	CAHN
AT			0.1%	A085692	003		Jan	CAHN
AT	+		0.5%	A085692	002		Jan	CAHN

LOTION; TOPICAL
TRIAMCINOLONE ACETONIDE

AT		FOUGERA PHARMS	0.025%	A040467	001	Apr 21, 2003	Jan	CAHN
AT			0.1%	A040467	002	Apr 21, 2003	Jan	CAHN

OINTMENT; TOPICAL
TRIAMCINOLONE ACETONIDE

AT		FOUGERA PHARMS	0.025%	A085691	001		Jan	CAHN
AT			0.1%	A085691	003		Jan	CAHN
AT			0.5%	A085691	002		Jan	CAHN

SPRAY, METERED; NASAL
TRIAMCINOLONE ACETONIDE

AB		TEVA PHARMS	0.055MG/SPRAY	A078104	001	Jul 30, 2009	Mar	CAHN

TRIMETHOBENZAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION
TRIMETHOBENZAMIDE HYDROCHLORIDE

		@ HOSPIRA	100MG/ML	A088804	001	Apr 03, 1987	Jun	DISC

VALACYCLOVIR HYDROCHLORIDE

TABLET; ORAL
VALACYCLOVIR HYDROCHLORIDE

AB		JUBILANT ORGANOSYS	EQ 500MG BASE	A201506	001	Apr 03, 2012	Mar	NEWA
AB			EQ 1GM BASE	A201506	002	Apr 03, 2012	Mar	NEWA

VALGANCICLOVIR HYDROCHLORIDE

FOR SOLUTION; ORAL
VALCYTE

	+	HOFFMANN LA ROCHE	50MG/ML	N022257	001	Aug 28, 2009	May	CAHN

TABLET; ORAL
VALCYTE

	+	HOFFMANN LA ROCHE	EQ 450MG BASE	N021304	001	Mar 29, 2001	May	CAHN

VANCOMYCIN HYDROCHLORIDE

CAPSULE; ORAL
VANCOCIN HYDROCHLORIDE

AB		VIROPHARMA	EQ 125MG BASE	N050606	001	Apr 15, 1986	Mar	CFTG
AB	+		EQ 250MG BASE	N050606	002	Apr 15, 1986	Mar	CFTG

VANCOMYCIN HYDROCHLORIDE

AB		AKORN	EQ 125MG BASE	A065478	001	Apr 09, 2012	Mar	NEWA
AB			EQ 250MG BASE	A065478	002	Apr 09, 2012	Mar	NEWA
AB		APP PHARMS LLC	EQ 125MG BASE	A065453	001	Jun 18, 2012	Jun	NEWA
AB			EQ 250MG BASE	A065453	002	Jun 18, 2012	Jun	NEWA
AB		STRIDES ARCOLAB LTD	EQ 125MG BASE	A065490	001	Apr 09, 2012	Mar	NEWA
AB			EQ 250MG BASE	A065490	002	Apr 09, 2012	Mar	NEWA
AB		WATSON LABS	EQ 125MG BASE	A065510	001	Apr 09, 2012	Mar	NEWA
AB			EQ 250MG BASE	A065510	002	Apr 09, 2012	Mar	NEWA

INJECTABLE; INJECTION
VANCOMYCIN HYDROCHLORIDE

>A>	AP	SAGENT PHARMS	EQ 5GM BASE/VIAL	A200837	001	Aug 10, 2012	Jul	NEWA
>A>	AP	SANDOZ INC	EQ 5GM BASE/VIAL	A201048	001	Aug 10, 2012	Jul	NEWA
>A>	AP		EQ 10GM BASE/VIAL	A201048	002	Aug 10, 2012	Jul	NEWA

VANDETANIB

TABLET; ORAL
CAPRELSA

		IPR PHARMS INC	100MG	N022405	001	Apr 06, 2011	Feb	CTNA
	+		300MG	N022405	002	Apr 06, 2011	Feb	CTNA

VARDENAFIL HYDROCHLORIDE

TABLET; ORAL
LEVITRA

AB		BAYER HLTHCARE	2.5MG	N021400	003	Aug 19, 2003	Apr	CFTG
AB			5MG	N021400	001	Aug 19, 2003	Apr	CFTG
AB			10MG	N021400	002	Aug 19, 2003	Apr	CFTG
AB	+		20MG	N021400	004	Aug 19, 2003	Apr	CFTG

VARDENAFIL HYDROCHLORIDE

AB		TEVA PHARMS	2.5MG	A091347	001	May 03, 2012	Apr	NEWA
AB			5MG	A091347	002	May 03, 2012	Apr	NEWA
AB			10MG	A091347	003	May 03, 2012	Apr	NEWA
AB			20MG	A091347	004	May 03, 2012	Apr	NEWA

VECURONIUM BROMIDE

INJECTABLE; INJECTION
VECURONIUM BROMIDE

AP		BEDFORD	10MG/VIAL	A075549	001	Jun 13, 2000	Jun	CRLD
			20MG/VIAL	A075549	002	Jun 13, 2000	Jun	CRLD
AP	+	SUN PHARMA GLOBAL	10MG/VIAL	A079001	001	Jun 17, 2009	Jun	CRLD
AP	+		20MG/VIAL	A079001	002	Jun 17, 2009	Jun	CRLD

VENLAFAXINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

VENLAFAXINE HYDROCHLORIDE

AB		ANCHEN PHARMS	EQ 37.5MG BASE	A078087	001	Mar 16, 2012	Mar	NEWA
AB			EQ 75MG BASE	A078087	002	Mar 16, 2012	Mar	NEWA
AB			EQ 150MG BASE	A078087	003	Mar 16, 2012	Mar	NEWA

VERAPAMIL HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

CALAN SR

AB	+	PFIZER	120MG	N019152	003	Mar 06, 1991	Feb	CTNA
AB	+		180MG	N019152	002	Dec 15, 1989	Feb	CTNA
AB	+		240MG	N019152	001	Dec 16, 1986	Feb	CTNA

VERAPAMIL HYDROCHLORIDE

AB		APOTEX CORP	120MG	A200878	001	Apr 20, 2012	Apr	NEWA
AB			180MG	A200878	002	Apr 20, 2012	Apr	NEWA
AB			240MG	A200878	003	Apr 20, 2012	Apr	NEWA

VIGABATRIN

FOR SOLUTION; ORAL

SABRIL

	+	LUNDBECK LLC	500MG/PACKET	N022006	001	Aug 21, 2009	Apr	CAHN

TABLET; ORAL

SABRIL

	+	LUNDBECK LLC	500MG	N020427	001	Aug 21, 2009	Apr	CAHN

VILAZODONE HYDROCHLORIDE

TABLET; ORAL

VIIBRYD

	+	FOREST LABS INC	10MG	N022567	001	Jan 21, 2011	Apr	CRLD
			40MG	N022567	003	Jan 21, 2011	Apr	CRLD

VISMODEGIB

CAPSULE; ORAL

ERIVEDGE

	+	GENENTECH	150MG	N203388	001	Jan 30, 2012	Jan	NEWA

VORICONAZOLE

INJECTABLE; IV (INFUSION)

VFEND

AP	+	PFIZER	200MG/VIAL	N021267	001	May 24, 2002	May	CFTG

VORICONAZOLE

AP		SANDOZ INC	200MG/VIAL	A090862	001	May 30, 2012	May	NEWA

TABLET; ORAL

VORICONAZOLE

AB		TEVA PHARMS	50MG	A091658	001	Apr 06, 2012	Mar	NEWA
AB			200MG	A091658	002	Apr 06, 2012	Mar	NEWA

ZICONOTIDE

INJECTABLE; INTRATHECAL

PRIALT

		@ JAZZ PHARMS COMMERCL	200MCG/2ML (100MCG/ML)	N021060	003	Dec 28, 2004	Mar	CAHN
		@ JAZZ PHARMS INTL	200MCG/2ML (100MCG/ML)	N021060	003	Dec 28, 2004	Jun	CAHN

ZICONOTIDE ACETATE

INJECTABLE; INTRATHECAL

PRIALT

+	JAZZ PHARMS COMMERCL	100MCG/1ML (100MCG/ML)	N021060	002	Dec 28, 2004	Mar	CAHN
+		500MCG/20ML (25MCG/ML)	N021060	001	Dec 28, 2004	Mar	CAHN
+		500MCG/5ML (100MCG/ML)	N021060	004	Dec 28, 2004	Mar	CAHN
+	JAZZ PHARMS INTL	100MCG/1ML (100MCG/ML)	N021060	002	Dec 28, 2004	Jun	CAHN
+		500MCG/20ML (25MCG/ML)	N021060	001	Dec 28, 2004	Jun	CAHN
+		500MCG/5ML (100MCG/ML)	N021060	004	Dec 28, 2004	Jun	CAHN

ZIDOVUDINE

TABLET; ORAL

ZIDOVUDINE

@	RANBAXY LABS LTD	300MG	A077327	001	Sep 19, 2005	Apr	DISC

ZIPRASIDONE HYDROCHLORIDE

CAPSULE; ORAL

GEODON

AB	+	PFIZER	EQ 20MG BASE	N020825	001	Feb 05, 2001	Feb	CFTG
AB			EQ 40MG BASE	N020825	002	Feb 05, 2001	Feb	CFTG
AB			EQ 60MG BASE	N020825	003	Feb 05, 2001	Feb	CFTG
AB			EQ 80MG BASE	N020825	004	Feb 05, 2001	Feb	CFTG

ZIPRASIDONE HYDROCHLORIDE

AB		APOTEX CORP	EQ 20MG BASE	A077561	001	Mar 02, 2012	Feb	NEWA
AB			EQ 40MG BASE	A077561	002	Mar 02, 2012	Feb	NEWA
AB			EQ 60MG BASE	A077561	003	Mar 02, 2012	Feb	NEWA
AB			EQ 80MG BASE	A077561	004	Mar 02, 2012	Feb	NEWA
AB		DR REDDYS LABS INC	EQ 20MG BASE	A077565	001	Mar 02, 2012	Feb	NEWA
AB			EQ 40MG BASE	A077565	002	Mar 02, 2012	Feb	NEWA
AB			EQ 60MG BASE	A077565	003	Mar 02, 2012	Feb	NEWA
AB			EQ 80MG BASE	A077565	004	Mar 02, 2012	Feb	NEWA
AB		LUPIN PHARMS	EQ 20MG BASE	A077560	001	Mar 02, 2012	Feb	NEWA
AB			EQ 40MG BASE	A077560	002	Mar 02, 2012	Feb	NEWA
AB			EQ 60MG BASE	A077560	003	Mar 02, 2012	Feb	NEWA
AB			EQ 80MG BASE	A077560	004	Mar 02, 2012	Feb	NEWA
AB		SANDOZ INC	EQ 20MG BASE	A077562	001	Jun 01, 2012	May	NEWA
AB			EQ 40MG BASE	A077562	002	Jun 01, 2012	May	NEWA
AB			EQ 60MG BASE	A077562	003	Jun 01, 2012	May	NEWA
AB			EQ 80MG BASE	A077562	004	Jun 01, 2012	May	NEWA

ZOLPIDEM TARTRATE

TABLET; ORAL

ZOLPIDEM TARTRATE

>A>	AB	CIPLA LTD	5MG	A077388	001	Jul 30, 2012	Jul	NEWA
>A>	AB		10MG	A077388	002	Jul 30, 2012	Jul	NEWA

CALCIUM CARBONATE; FAMOTIDINE; MAGNESIUM HYDROXIDE

TABLET, CHEWABLE; ORAL

PEPCID COMPLETE

+	MCNEIL CONS	800MG;10MG;165MG	N020958	001	Oct 16, 2000	Mar	CAHN

CETIRIZINE HYDROCHLORIDE

SYRUP; ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

>D>	RANBAXY	5MG/5ML	A090183	002	Apr 24, 2008	Jul	DISC
>A>	@ RANBAXY LABS LTD	5MG/5ML	A090183	002	Apr 24, 2008	Jul	DISC

CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF

>D>	RANBAXY	5MG/5ML	A090183	001	Apr 24, 2008	Jul	DISC
>A>	@ RANBAXY LABS LTD	5MG/5ML	A090183	001	Apr 24, 2008	Jul	DISC

CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL

SWAB; TOPICAL

CHLORASCRUB MAXI SWABSTICK

+	PROF DSPLS	3.15%;70% (5.1ML)	N021524	003	Jun 03, 2005	Mar	CAHN

CHLORASCRUB SWAB

+	PROF DSPLS	3.15%;70% (1ML)	N021524	001	Jun 03, 2005	Mar	CAHN

CHLORASCRUB SWABSTICK

+	PROF DSPLS	3.15%;70% (1.6ML)	N021524	002	Jun 03, 2005	Mar	CAHN

DEXTROMETHORPHAN POLISTIREX

SUSPENSION, EXTENDED RELEASE; ORAL

DEXTROMETHORPHAN POLISTIREX

	TRIS PHARMA INC	EQ 30MG HBR/5ML	A091135	001	May 25, 2012	May	NEWA

DIPHENHYDRAMINE HYDROCHLORIDE; IBUPROFEN

CAPSULE; ORAL

IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE

	STRIDES ARCOLAB LTD	25MG;EQ 200MG FREE ACID AND POTASSIUM SALT	A200888	001	Mar 05, 2012	Feb	NEWA

FAMOTIDINE

TABLET, CHEWABLE; ORAL

PEPCID AC

	@ MCNEIL CONS	10MG	N020801	001	Sep 24, 1998	Mar	CAHN
+		20MG	N020801	002	Dec 17, 2007	Mar	CAHN

TABLET; ORAL

PEPCID AC

	MCNEIL CONS	10MG	N020325	001	Apr 28, 1995	Mar	CAHN
+		20MG	N020325	002	Sep 23, 2003	Mar	CAHN

PEPCID AC (GELTAB)

	MCNEIL CONS	10MG	N020902	001	Aug 05, 1999	Mar	CAHN

FEXOFENADINE HYDROCHLORIDE

TABLET; ORAL

CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY

	SUN PHARM INDS	30MG	A091567	002	Feb 06, 2012	Jan	NEWA
	WOCKHARDT LTD	30MG	A079112	002	Feb 08, 2012	Jan	NEWA

CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES

	SUN PHARM INDS	30MG	A091567	001	Feb 06, 2012	Jan	NEWA

TABLET; ORAL
CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES

	WOCKHARDT LTD	30MG	A079112	001	Feb 08, 2012	Jan	NEWA

FEXOFENADINE HYDROCHLORIDE ALLERGY

	SUN PHARM INDS	60MG	A091567	004	Feb 06, 2012	Jan	NEWA
		180MG	A091567	006	Feb 06, 2012	Jan	NEWA
	WOCKHARDT LTD	60MG	A079112	004	Feb 08, 2012	Jan	NEWA
		180MG	A079112	006	Feb 08, 2012	Jan	NEWA

FEXOFENADINE HYDROCHLORIDE HIVES

	SUN PHARM INDS	60MG	A091567	003	Feb 06, 2012	Jan	NEWA
		180MG	A091567	005	Feb 06, 2012	Jan	NEWA
	WOCKHARDT LTD	60MG	A079112	003	Feb 08, 2012	Jan	NEWA
		180MG	A079112	005	Feb 08, 2012	Jan	NEWA

IBUPROFEN

CAPSULE; ORAL
IBUPROFEN

	ACCUCAPS INDS	EQ 200MG FREE ACID AND POTASSIUM SALT	A077338	001	Jul 10, 2009	Jan	CAHN

IBUPROFEN SODIUM

TABLET; ORAL
ADVIL

+	PFIZER CONS HLTHCARE	EQ 200MG BASE	N201803	001	Jun 12, 2012	Jun	NEWA

LANSOPRAZOLE

CAPSULE, DELAYED REL PELLETS; ORAL
LANSOPRAZOLE

	DR REDDYS LABS LTD	15MG	A202194	001	May 18, 2012	Apr	NEWA
	PERRIGO R AND D	15MG	A202319	001	May 18, 2012	Apr	NEWA
	WOCKHARDT LTD	15MG	A202727	001	May 18, 2012	Apr	NEWA

PREVACID 24 HR

+	NOVARTIS	15MG	N022327	001	May 18, 2009	Apr	CFTG

LEVONORGESTREL

TABLET; ORAL
LEVONORGESTREL

	WATSON LABS INC	1.5MG	A200670	001	Jul 12, 2012	Jun	NEWA

PLAN B

+	TEVA BRANDED PHARM	0.75MG	N021045	002	Aug 24, 2006	May	CAHN

PLAN B ONE-STEP

+	DURAMED	1.5MG	N021998	001	Jul 10, 2009	Jun	CFTG

LORATADINE

SYRUP; ORAL
LORATADINE

>D>	RANBAXY	1MG/ML	A076529	001	Aug 20, 2004	Jul	DISC
>A>	@ RANBAXY LABS LTD	1MG/ML	A076529	001	Aug 20, 2004	Jul	DISC

NICOTINE

FILM, EXTENDED RELEASE; TRANSDERMAL
NICOTINE

	AVEVA	7MG/24HR	A074612	002	Jul 28, 2003	Apr	NEWA
		14MG/24HR	A074612	003	Oct 20, 1997	Apr	NEWA

RANITIDINE HYDROCHLORIDE

TABLET; ORAL

RANITIDINE HYDROCHLORIDE

APOTEX INC	EQ 150MG BASE	A200172	001	May 31, 2012	May	NEWA
SHASUN CHEMS	EQ 75MG BASE	A201745	001	Feb 29, 2012	Feb	NEWA

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST

CUMULATIVE SUPPLEMENT NUMBER 07 JULY 2012

NO JULY 2012 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of List of Orphan Designations and Approvals is available at:

http://www.fda.gov/orphan/designat/list.htm

DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION

NO JULY 2012 ADDITIONS

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ACETYLCYSTEINE - ACETADOTE						
N021539 001	8148356	May 21, 2026	DP			
ACLIDINIUM BROMIDE - TUDORZA PRESSAIR						
N202450 001					**>A>** NCE	Jul 23, 2017
ADAPALENE; BENZOYL PEROXIDE - EPIDUO						
N022320 001	8105618	Dec 23, 2022	U-1078			
	8129362	Jul 18, 2027	U-1078			
ALBUTEROL SULFATE - PROAIR HFA						
N021457 001	6446627	Dec 18, 2017	DP			
	8132712	Sep 07, 2028	DP			
ALENDRONATE SODIUM - BINOSTO						
N202344 001	7488496	Aug 11, 2023	DS DP			
	7964212	Mar 06, 2023	DS DP			
ALISKIREN HEMIFUMARATE; VALSARTAN - VALTURNA						
N022217 001	8168616	Jul 05, 2025	DP			
ALISKIREN HEMIFUMARATE; VALSARTAN - VALTURNA						
N022217 002	8168616	Jul 05, 2025	DP			
ALVIMOPAN - ENTEREG						
N021775 001	8112290	Jul 31, 2030	U-1225			
AMBRISENTAN - LETAIRIS						
N022081 001	RE42462	Jul 29, 2018	DS			
AMBRISENTAN - LETAIRIS						
N022081 002	RE42462	Jul 29, 2018	DS			
AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT						
N022314 001	8101599	May 16, 2023	DP			
AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT						
N022314 002	8101599	May 16, 2023	DP			
AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT						
N022314 003	8101599	May 16, 2023	DP			
AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT						
N022314 004	8101599	May 16, 2023	DP			
AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT						
N022314 005	8101599	May 16, 2023	DP			
ARFORMOTEROL TARTRATE - BROVANA						
N021912 001	6589508	Apr 03, 2013	U-793			
	6667344	Jun 22, 2021	DP			
	6814953	Jun 22, 2021	U-793			
	8110706	Nov 09, 2021	DP			
ATOVAQUONE; PROGUANIL HYDROCHLORIDE - ATOVAQUONE AND PROGUANIL HYDROCHLORIDE						
A091211 001					PC	Mar 13, 2012
AVANAFIL - STENDRA						
N202276 001	6656935	Sep 13, 2020	DS DP U-155		NCE	Apr 27, 2017

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
AVANAFIL - STENDRA						
N202276 002	6656935	Sep 13, 2020	DS DP U-155		NCE	Apr 27, 2017
AVANAFIL - STENDRA						
N202276 003	6656935	Sep 13, 2020	DS DP U-155		NCE	Apr 27, 2017
AXITINIB - INLYTA						
N202324 001	6534524	Jun 30, 2020	DS DP		NCE	Jan 27, 2017
	7141581	Jun 30, 2020	U-1220			
AXITINIB - INLYTA						
N202324 002	6534524	Jun 30, 2020	DS DP		NCE	Jan 27, 2017
	7141581	Jun 30, 2020	U-1220			
AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE - DYMISTA						
N202236 001	8163723	Aug 29, 2023	U-81		NC	May 01, 2015
	8163723	Aug 29, 2023	U-77			
	8163723	Aug 29, 2023	U-707			
	8163723	Aug 29, 2023	U-644			
	8168620	Feb 24, 2026	DP			
AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE - EDARBYCLOR						
N202331 001	5583141	Dec 10, 2013	DS DP U-3			
	5736555	Jun 25, 2012	DS DP U-3			
	7157584	May 22, 2025	DS			
	7572920	Jan 07, 2025	DP U-3			
AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE - EDARBYCLOR						
N202331 002	5583141	Dec 10, 2013	DS DP U-3			
	5736555	Jun 25, 2012	DS DP U-3			
	7157584	May 22, 2025	DS			
	7572920	Jan 07, 2025	DP U-3			
BALSALAZIDE DISODIUM - GIAZO						
N022205 001	6197341	Mar 13, 2018	DP U-1229		NDF	Feb 03, 2015
	7452872	Aug 24, 2026	U-1229			
	7625884	Aug 24, 2026	U-1229			
BECLOMETHASONE DIPROPIONATE - QNASL						
N202813 001	5605674	Feb 25, 2014	DP		NP	Mar 23, 2015
	5683677	Nov 04, 2014	DP			
	5776432	Jul 07, 2015	DP			
	7780038	Jan 24, 2027	DP			
BENDAMUSTINE HYDROCHLORIDE - TREANDA						
N022249 001					NCE	Mar 20, 2013
					ODE	Mar 20, 2015
					PED	Sep 20, 2015
					PED	Sep 20, 2013
BENDAMUSTINE HYDROCHLORIDE - TREANDA						
N022249 002					NCE	Mar 20, 2013
					ODE	Mar 20, 2015
					PED	Sep 20, 2015
					PED	Sep 20, 2013

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BIMATOPROST - LATISSE						
N022369 001	8101161	May 25, 2024	U-1218			
	8101161	May 25, 2024	U-1217			
BIVALIRUDIN - ANGIOMAX						
N020873 001	5196404	Dec 15, 2014	DS DP U-1232			
	5196404	Dec 15, 2014	DS DP U-1040			
	5196404*PED	Jun 15, 2015				
BOCEPREVIR - VICTRELIS						
N202258 001	8119602	Mar 17, 2027	U-1233			
	RE43298	Feb 22, 2022	DS DP U-1128			
BORTEZOMIB - VELCADE						
N021602 001					NR	Jan 23, 2015
BRIMONIDINE TARTRATE; TIMOLOL MALEATE - COMBIGAN						
N021398 001	8133890	Apr 19, 2022	U-1235			
BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT						
N021929 001	8143239	Jan 29, 2023	DP U-1073			
BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT						
N021929 002	8143239	Jan 29, 2023	DP U-1073			
BUPIVACAINE - EXPAREL						
N022496 001	6132766	Nov 16, 2013	DP			
	8182835	Sep 18, 2018	DP U-1246			
BUPIVACAINE - EXPAREL						
N022496 002	6132766	Nov 16, 2013	DP			
	8182835	Sep 18, 2018	DP U-1246			
CARFILZOMIB - KYPROLIS						
N202714 001	**>A>** 7232818	Apr 14, 2025	DS DP		**>A>** NCE	Jul 20, 2017
	>A> 7417042	Jun 07, 2026	DS DP			
	>A> 7491704	Apr 14, 2025	U-1260			
	>A> 7737112	Dec 07, 2027	DP			
	>A> 8129346	Dec 25, 2026	U-1260			
	>A> 8207125	Apr 14, 2025	DS DP			
	>A> 8207126	Apr 14, 2025	DP			
	>A> 8207127	Apr 14, 2025	U-1260			
	>A> 8207297	Apr 14, 2025	DS DP			
CARVEDILOL PHOSPHATE - COREG CR						
N022012 001	6022562	Oct 17, 2015	DP	Y		
	8101209	Sep 11, 2025	DP			
	8101209*PED	Mar 11, 2026				
CARVEDILOL PHOSPHATE - COREG CR						
N022012 002	6022562	Oct 17, 2015	DP	Y		
	8101209	Sep 11, 2025	DP			
	8101209*PED	Mar 11, 2026				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2012

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CARVEDILOL PHOSPHATE - COREG CR							
N022012 003		6022562	Oct 17, 2015	DP	Y		
		8101209	Sep 11, 2025	DP			
		8101209*PED	Mar 11, 2026				
CARVEDILOL PHOSPHATE - COREG CR							
N022012 004		6022562	Oct 17, 2015	DP	Y		
		8101209	Sep 11, 2025	DP			
		8101209*PED	Mar 11, 2026				
CHLORHEXIDINE GLUCONATE - CHLORHEXIDINE GLUCONATE							
N021669 001		7717889	Feb 27, 2025	DP U-1022			
CICLESONIDE - ZETONNA							
N202129 001		5482934	Oct 24, 2017	DS DP U-1002		NP	Jan 20, 2015
		5605674	Feb 25, 2014	DP			
		5683677	Nov 04, 2014	DP			
		5775321	Jul 07, 2015	DP			
		6006745	Dec 28, 2016	DP			
		6036942	Apr 30, 2013	DP			
		6120752	May 13, 2018	DP			
		6264923	May 13, 2018	DP			
CICLOPIROX - LOPROX							
N021159 001	**>A>**	8227490	Sep 16, 2017	U-1256			
CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE - PREPOPIK							
N202535 001						**>A>** NP	Jul 16, 2015
CLEVIDIPINE BUTYRATE - CLEVIPREX							
N022156 001		5856346	Jan 05, 2021	DS DP U-893			
CLEVIDIPINE BUTYRATE - CLEVIPREX							
N022156 002		5856346	Jan 05, 2021	DS DP U-893			
CLOBETASOL PROPIONATE - CLOBETASOL PROPIONATE							
A078223 001						PC	Jun 30, 2012
CLOBETASOL PROPIONATE - CLOBETASOL PROPIONATE							
A078854 001						PC	Jun 30, 2012
CLOPIDOGREL BISULFATE - CLOPIDOGREL BISULFATE							
A077665 002						PC	Nov 13, 2012
CLOPIDOGREL BISULFATE - CLOPIDOGREL BISULFATE							
A091023 001						PC	Nov 13, 2012
COLCHICINE - COLCRYS							
N022352 001		7964648	Oct 06, 2028	U-1161			
		8097655	Oct 06, 2028	U-1020			
CRIZOTINIB - XALKORI							
N202570 001	**>A>**	8217057	Nov 06, 2029	DS DP			
CRIZOTINIB - XALKORI							
N202570 002	**>A>**	8217057	Nov 06, 2029	DS DP			
DAPTOMYCIN - CUBICIN							
N021572 002		8129342	Nov 28, 2020	DS DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DARUNAVIR ETHANOLATE - PREZISTA						
N021976 001	5843946*PED	Jun 01, 2016				
	6037157	Jun 26, 2016	U-935			
	6037157	Jun 26, 2016	U-1209			
	6037157*PED	Dec 26, 2016				
	6335460	Aug 25, 2012	DS DP U-935			
	6335460	Aug 25, 2012	DS DP U-903			
	6335460	Aug 25, 2012	DS DP U-744			
	6335460	Aug 25, 2012	DS DP U-1209			
	6335460*PED	Feb 25, 2013				
	6703403	Jun 26, 2016	U-935			
	6703403	Jun 26, 2016	U-1209			
	6703403*PED	Dec 26, 2016				
	7470506	Jun 23, 2019	U-935			
	7470506	Jun 23, 2019	U-1209			
	7470506*PED	Dec 23, 2019				
DARUNAVIR ETHANOLATE - PREZISTA						
N021976 002	5843946*PED	Jun 01, 2016				
	6037157	Jun 26, 2016	U-935			
	6037157	Jun 26, 2016	U-1209			
	6037157*PED	Dec 26, 2016				
	6335460	Aug 25, 2012	DS DP U-935			
	6335460	Aug 25, 2012	DS DP U-903			
	6335460	Aug 25, 2012	DS DP U-744			
	6335460	Aug 25, 2012	DS DP U-1209			
	6335460*PED	Feb 25, 2013				
	6703403	Jun 26, 2016	U-935			
	6703403	Jun 26, 2016	U-1209			
	6703403*PED	Dec 26, 2016				
	7470506	Jun 23, 2019	U-935			
	7470506	Jun 23, 2019	U-1209			
	7470506*PED	Dec 23, 2019				
DARUNAVIR ETHANOLATE - PREZISTA						
N021976 003	5843946*PED	Jun 01, 2016				
	6037157	Jun 26, 2016	U-1209			
	6037157	Jun 26, 2016	U-935			
	6037157*PED	Dec 26, 2016				
	6335460	Aug 25, 2012	DS DP U-935			
	6335460	Aug 25, 2012	DS DP U-903			
	6335460	Aug 25, 2012	DS DP U-744			
	6335460	Aug 25, 2012	DS DP U-1209			
	6335460*PED	Feb 25, 2013				
	6703403	Jun 26, 2016	U-935			
	6703403	Jun 26, 2016	U-1209			
	6703403*PED	Dec 26, 2016				
	7470506	Jun 23, 2019	U-935			
	7470506	Jun 23, 2019	U-1209			
	7470506*PED	Dec 23, 2019				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DARUNAVIR ETHANOLATE - PREZISTA						
N021976 004	5843946*PED	Jun 01, 2016				
	6037157	Jun 26, 2016	U-935			
	6037157	Jun 26, 2016	U-1209			
	6037157*PED	Dec 26, 2016				
	6335460	Aug 25, 2012	DS DP U-935			
	6335460	Aug 25, 2012	DS DP U-903			
	6335460	Aug 25, 2012	DS DP U-744			
	6335460	Aug 25, 2012	DS DP U-1209			
	6335460*PED	Feb 25, 2013				
	6703403	Jun 26, 2016	U-935			
	6703403	Jun 26, 2016	U-1209			
	6703403*PED	Dec 26, 2016				
	7470506	Jun 23, 2019	U-935			
	7470506	Jun 23, 2019	U-1209			
	7470506*PED	Dec 23, 2019				
DARUNAVIR ETHANOLATE - PREZISTA						
N021976 005	5843946*PED	Jun 01, 2016				
	6037157	Jun 26, 2016	U-935			
	6037157	Jun 26, 2016	U-1209			
	6037157*PED	Dec 26, 2016				
	6335460	Aug 25, 2012	DS DP U-935			
	6335460	Aug 25, 2012	DS DP U-903			
	6335460	Aug 25, 2012	DS DP U-744			
	6335460	Aug 25, 2012	DS DP U-1209			
	6335460*PED	Feb 25, 2013				
	6703403	Jun 26, 2016	U-935			
	6703403	Jun 26, 2016	U-1209			
	6703403*PED	Dec 26, 2016				
	7470506	Jun 23, 2019	U-935			
	7470506	Jun 23, 2019	U-1209			
	7470506*PED	Dec 23, 2019				
DARUNAVIR ETHANOLATE - PREZISTA						
N202895 001	5843946	Dec 01, 2015	DP U-1209			
	5843946*PED	Jun 01, 2016				
	6037157	Jun 26, 2016	U-1209			
	6037157*PED	Dec 26, 2016				
	6248775	Aug 13, 2014	DS			
	6248775*PED	Feb 13, 2015				
	6335460	Aug 25, 2012	DS DP U-1209			
	6335460*PED	Feb 25, 2013				
	6703403	Jun 26, 2016	U-1209			
	6703403*PED	Dec 26, 2016				
	7470506	Jun 23, 2019	U-1209			
	7470506*PED	Dec 23, 2019				
	7700645	Dec 26, 2026	DS DP			
	7700645*PED	Jun 26, 2027				
	RE42889	Oct 19, 2016	DP			
	RE42889*PED	Apr 19, 2017				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2012

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DEGARELIX ACETATE - FIRMAGON							
N022201 001		5925730	May 18, 2021	DS DP U-943			
DEGARELIX ACETATE - FIRMAGON							
N022201 002		5925730	May 18, 2021	DS DP U-943			
DESLORATADINE; PSEUDOEPHEDRINE SULFATE - CLARINEX-D 12 HOUR							
N021313 001		8187630	Dec 19, 2020	DP U-1017			
DEXAMETHASONE - OZURDEX							
N022315 001		8088407	Oct 20, 2020	DP U-1205			
DEXLANSOPRAZOLE - DEXILANT							
N022287 001		8105626	Sep 27, 2026	DP			
		8105626*PED	Mar 27, 2027				
		8173158	Mar 17, 2030	U-951			
		8173158	Mar 17, 2030	U-950			
		8173158	Mar 17, 2030	U-949			
		8173158*PED	Sep 17, 2030				
DEXLANSOPRAZOLE - DEXILANT							
N022287 002		8105626	Sep 27, 2026	DP			
		8105626*PED	Mar 27, 2027				
		8173158	Mar 17, 2030	U-951			
		8173158	Mar 17, 2030	U-950			
		8173158	Mar 17, 2030	U-949			
		8173158*PED	Sep 17, 2030				
DEXTROMETHORPHAN HYDROBROMIDE; QUINIDINE SULFATE - NUEDEXTA							
N021879 001	**>A>**	8227484	Jul 17, 2023	U-1093			
DICLOFENAC POTASSIUM - CAMBIA							
N022165 001		8097651	Jun 16, 2026	DS DP U-436			
DICLOFENAC POTASSIUM - ZIPSOR							
N022202 001		8110606	Feb 24, 2029	U-980			
DICLOFENAC SODIUM - PENNSAID							
N020947 001		8217078	Jul 10, 2029	U-1248			
DIENOGEST; ESTRADIOL VALERATE - NATAZIA							
N022252 001		8153616	Jan 30, 2028	U-1240		I-648	Mar 14, 2015
DIFLUPREDNATE - DUREZOL							
N022212 001						I-653	Jun 13, 2015
						ODE	Jun 13, 2019
DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE - COSOPT PF							
N202667 001						NP	Feb 01, 2015
DOXYCYCLINE - ORACEA							
N050805 001		8206740	Dec 24, 2025	DP U-925			
DRONEDARONE HYDROCHLORIDE - MULTAQ							
N022425 001	**>A>**	5223510	Jul 26, 2012	DS DP U-992			
	>A>	5223510	Jul 26, 2012	DS DP U-1261			
DROSPIRENONE; ESTRADIOL - ANGELIQ							
N021355 001						NS	Mar 01, 2015

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DULOXETINE HYDROCHLORIDE - CYMBALTA						
N021427 001	5023269	Jun 11, 2013	DS DP U-882		I-632	Nov 04, 2013
	5023269	Jun 11, 2013	DS DP U-839		I-617	Nov 19, 2012
	5023269	Jun 11, 2013	DS DP U-799		PED	May 04, 2014
	5023269	Jun 11, 2013	DS DP U-797		PED	May 19, 2013
	5023269	Jun 11, 2013	DS DP U-796			
	5023269	Jun 11, 2013	DS DP U-795			
	5023269	Jun 11, 2013	DS DP U-605			
	5023269	Jun 11, 2013	DS DP U-398			
	5023269	Jun 11, 2013	DS DP U-1094			
	5023269*PED	Dec 11, 2013				
	5508276	Jul 18, 2014	DP			
	5508276*PED	Jan 18, 2015				
	6596756	Sep 10, 2019	U-882			
	6596756*PED	Mar 10, 2020				
DULOXETINE HYDROCHLORIDE - CYMBALTA						
N021427 002	5023269	Jun 11, 2013	DS DP U-882		I-632	Nov 04, 2013
	5023269	Jun 11, 2013	DS DP U-839		I-617	Nov 19, 2012
	5023269	Jun 11, 2013	DS DP U-799		PED	May 04, 2014
	5023269	Jun 11, 2013	DS DP U-797		PED	May 19, 2013
	5023269	Jun 11, 2013	DS DP U-796			
	5023269	Jun 11, 2013	DS DP U-795			
	5023269	Jun 11, 2013	DS DP U-605			
	5023269	Jun 11, 2013	DS DP U-398			
	5023269	Jun 11, 2013	DS DP U-1094			
	5023269*PED	Dec 11, 2013				
	5508276	Jul 18, 2014	DP			
	5508276*PED	Jan 18, 2015				
	6596756	Sep 10, 2019	U-882			
	6596756*PED	Mar 10, 2020				
DULOXETINE HYDROCHLORIDE - CYMBALTA						
N021427 004	5023269	Jun 11, 2013	DS DP U-882		I-632	Nov 04, 2013
	5023269	Jun 11, 2013	DS DP U-839		I-617	Nov 19, 2012
	5023269	Jun 11, 2013	DS DP U-799		PED	May 04, 2014
	5023269	Jun 11, 2013	DS DP U-797		PED	May 19, 2013
	5023269	Jun 11, 2013	DS DP U-796			
	5023269	Jun 11, 2013	DS DP U-795			
	5023269	Jun 11, 2013	DS DP U-605			
	5023269	Jun 11, 2013	DS DP U-398			
	5023269	Jun 11, 2013	DS DP U-1094			
	5023269*PED	Dec 11, 2013				
	5508276	Jul 18, 2014	DP			
	5508276*PED	Jan 18, 2015				
	6596756	Sep 10, 2019	U-882			
	6596756*PED	Mar 10, 2020				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - ATRIPLA						
N021937 001	5663169	Sep 02, 2014	U-750			
	5663169	Sep 02, 2014	U-1170			
	5811423	Aug 07, 2012	U-750			
	5811423	Aug 07, 2012	U-1170			
	5922695	Jul 25, 2017	DS U-750			
	5922695	Jul 25, 2017	DS U-1170			
	5935946	Jul 25, 2017	DS DP U-750			
	5935946	Jul 25, 2017	DS DP U-1170			
	5977089	Jul 25, 2017	DS DP U-750			
	5977089	Jul 25, 2017	DS DP U-1170			
	6043230	Jul 25, 2017	U-750			
	6043230	Jul 25, 2017	U-1170			
	6642245	Nov 04, 2020	U-750			
	6642245	Nov 04, 2020	U-1170			
EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE - COMPLERA						
N202123 001	8080551	Apr 11, 2023	DS DP		NCE	May 20, 2016
	8101629	Aug 09, 2022	DP			
EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA						
N021752 001	**>A>** 5922695	Jul 25, 2017	DS U-1259			
	>A> 5922695	Jul 25, 2017	DS U-248			
	>A> 5922695	Jul 25, 2017	DS U-541			
	>A> 5922695	Jul 25, 2017	DS U-1170			
	>A> 5935946	Jul 25, 2017	DS DP U-541			
	>A> 5935946	Jul 25, 2017	DS DP U-1170			
	>A> 5935946	Jul 25, 2017	DS DP U-1259			
	>A> 5935946	Jul 25, 2017	DS DP U-248			
	>A> 5977089	Jul 25, 2017	DS DP U-1259			
	>A> 5977089	Jul 25, 2017	DS DP U-248			
	>A> 5977089	Jul 25, 2017	DS DP U-541			
	>A> 5977089	Jul 25, 2017	DS DP U-1170			
	>A> 6043230	Jul 25, 2017	DP U-541			
	>A> 6043230	Jul 25, 2017	DP U-1170			
	>A> 6043230	Jul 25, 2017	DP U-1259			
	>A> 6043230	Jul 25, 2017	DP U-248			
EPROSARTAN MESYLATE - EPROSARTAN MESYLATE						
A202012 001					PC	Jun 17, 2012
EPROSARTAN MESYLATE - EPROSARTAN MESYLATE						
A202012 002					PC	Jun 17, 2012
ERIBULIN MESYLATE - HALAVEN						
N201532 001	8097648	Jan 22, 2021	U-1096			
ESCITALOPRAM OXALATE - ESCITALOPRAM OXALATE						
A076765 001					PC	Sep 10, 2012
ESCITALOPRAM OXALATE - ESCITALOPRAM OXALATE						
A076765 002					PC	Sep 10, 2012
ESCITALOPRAM OXALATE - ESCITALOPRAM OXALATE						
A076765 003					PC	Sep 10, 2012

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ESOMEPRAZOLE MAGNESIUM - NEXIUM						
N021957 001	5877192	May 27, 2014	U-773			
	5877192	May 27, 2014	U-729			
	5877192	May 27, 2014	U-1207			
	5877192*PED	Nov 27, 2014				
ESOMEPRAZOLE MAGNESIUM - NEXIUM						
N021957 002	5877192	May 27, 2014	U-773			
	5877192	May 27, 2014	U-729			
	5877192	May 27, 2014	U-1207			
	5877192*PED	Nov 27, 2014				
ESOMEPRAZOLE MAGNESIUM - NEXIUM						
N021957 003	**>A>** 5690960	Nov 25, 2014	DP U-1207			
	>A> 5690960*PED	May 25, 2015				
	>A> 5714504	Feb 03, 2015	DP U-1207			
	>A> 5714504*PED	Aug 03, 2015				
	>A> 5877192	May 27, 2014	U-1207			
	>A> 5877192*PED	Nov 27, 2014				
	>A> 5900424	May 04, 2016	DS U-1207			
	>A> 5900424*PED	Nov 04, 2016				
	>A> 6369085	May 25, 2018	DS DP U-1207			
	>A> 6369085*PED	Nov 25, 2018				
	>A> 6428810	Nov 03, 2019	DP U-1207			
	>A> 6428810*PED	May 03, 2020				
	>A> 6875872	May 27, 2014	DS			
	>A> 6875872*PED	Nov 27, 2014				
	>A> 7411070	May 25, 2018	DS			
	>A> 7411070*PED	Nov 25, 2018				
ESOMEPRAZOLE MAGNESIUM - NEXIUM						
N021957 004	**>A>** 5690960	Nov 25, 2014	DP U-1207			
	>A> 5690960*PED	May 25, 2015				
	>A> 5714504	Feb 03, 2015	DP U-1207			
	>A> 5714504*PED	Aug 03, 2015				
	>A> 5877192	May 27, 2014	U-1207			
	>A> 5877192*PED	Nov 27, 2014				
	>A> 5900424	May 04, 2016	DS U-1207			
	>A> 5900424*PED	Nov 04, 2016				
	>A> 6369085	May 25, 2018	DS DP U-1207			
	>A> 6369085*PED	Nov 25, 2018				
	>A> 6428810	Nov 03, 2019	DP U-1207			
	>A> 6428810*PED	May 03, 2020				
	>A> 6875872	May 27, 2014	DS			
	>A> 6875872*PED	Nov 27, 2014				
	>A> 7411070	May 25, 2018	DS			
	>A> 7411070*PED	Nov 25, 2018				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ESZOPICLONE - LUNESTA						
N021476 001	6319926	Jan 16, 2012	U-620			
	6319926*PED	Jul 16, 2012				
	6444673	Feb 14, 2014	DS DP			
	6444673*PED	Aug 14, 2014				
	6864257	Aug 30, 2012	U-629			
	6864257*PED	Mar 02, 2013				
	7381724	Jan 16, 2012	DS DP U-629			
	7381724*PED	Jul 16, 2012				
ESZOPICLONE - LUNESTA						
N021476 002	6319926	Jan 16, 2012	U-620			
	6319926*PED	Jul 16, 2012				
	6444673	Feb 14, 2014	DS DP			
	6444673*PED	Aug 14, 2014				
	6864257	Aug 30, 2012	U-629			
	6864257*PED	Mar 02, 2013				
	7381724	Jan 16, 2012	DS DP U-629			
	7381724*PED	Jul 16, 2012				
ESZOPICLONE - LUNESTA						
N021476 003	6319926	Jan 16, 2012	U-620			
	6319926*PED	Jul 16, 2012				
	6444673	Feb 14, 2014	DS DP			
	6444673*PED	Aug 14, 2014				
	6864257	Aug 30, 2012	U-629			
	6864257*PED	Mar 02, 2013				
	7381724	Jan 16, 2012	DS DP U-629			
	7381724*PED	Jul 16, 2012				
ETONOGESTREL - NEXPLANON						
N021529 002					NP	May 31, 2014
ETRAVIRINE - INTELENCE						
N022187 001	6878717	Nov 05, 2019	U-256		NPP	Mar 26, 2015
	6878717	Nov 05, 2019	U-1237			
	6878717	Nov 05, 2019	U-1016			
	7037917	Dec 13, 2020	DS DP U-256			
	7037917	Dec 13, 2020	DS DP U-1237			
	7037917	Dec 13, 2020	DS DP U-1016			
ETRAVIRINE - INTELENCE						
N022187 002	6878717	Nov 05, 2019	U-256		NPP	Mar 26, 2015
	6878717	Nov 05, 2019	U-1237			
	6878717	Nov 05, 2019	U-1016			
	7037917	Dec 13, 2020	DS DP U-256			
	7037917	Dec 13, 2020	DS DP U-1237			
	7037917	Dec 13, 2020	DS DP U-1016			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ETRAVIRINE - INTELENCE						
N022187 003	6878717	Nov 05, 2019	U-256		NPP	Mar 26, 2015
	6878717	Nov 05, 2019	U-1237		NCE	Jan 18, 2013
	6878717	Nov 05, 2019	U-1016			
	7037917	Dec 13, 2020	DS DP U-1237			
	7887845	Mar 25, 2019	DP			
	8003789	Nov 01, 2019	DS DP			
EVEROLIMUS - AFINITOR						
N022334 001	5665772	Sep 09, 2019	DS DP		>A> I-655	Jul 20, 2015
	5665772*PED	Mar 09, 2020			I-650	Apr 26, 2015
	6004973	Jul 12, 2016	DP		I-638	May 05, 2014
	6004973*PED	Jan 12, 2017			I-630	Oct 29, 2013
	7297703	Dec 06, 2019	DP		NCE	Mar 30, 2014
	7297703*PED	Jun 06, 2020			ODE	Apr 26, 2019
					ODE	May 05, 2018
					ODE	Oct 29, 2017
					PED	Oct 26, 2019
					PED	Nov 05, 2018
					PED	Apr 29, 2018
					PED	Oct 26, 2015
					PED	Nov 05, 2014
					PED	Sep 30, 2014
					PED	Apr 29, 2014
EVEROLIMUS - AFINITOR						
N022334 002	5665772	Sep 09, 2019	DS DP		>A> I-655	Jul 20, 2015
	5665772*PED	Mar 09, 2020			I-650	Apr 26, 2015
	6004973	Jul 12, 2016	DP		I-638	May 05, 2014
	6004973*PED	Jan 12, 2017			I-630	Oct 29, 2013
	7297703	Dec 06, 2019	DP		NCE	Mar 30, 2014
	7297703*PED	Jun 06, 2020			ODE	Apr 26, 2019
					ODE	May 05, 2018
					ODE	Oct 29, 2017
					PED	Oct 26, 2019
					PED	Nov 05, 2018
					PED	Apr 29, 2018
					PED	Oct 26, 2015
					PED	Nov 05, 2014
					PED	Sep 30, 2014
					PED	Apr 29, 2014
EVEROLIMUS - AFINITOR						
N022334 003	5665772	Sep 09, 2019	DS DP		>A> I-655	Jul 20, 2015
	5665772*PED	Mar 09, 2020			I-650	Apr 26, 2015
	6004973	Jul 12, 2016	DP		I-638	May 05, 2014
	6004973*PED	Jan 12, 2017			I-630	Oct 29, 2013
	7297703	Dec 06, 2019	DP		NCE	Mar 30, 2014
	7297703*PED	Jun 06, 2020			ODE	Apr 26, 2019
					ODE	May 05, 2018
					ODE	Oct 29, 2017
					PED	Oct 26, 2019
					PED	Nov 05, 2018
					PED	Apr 29, 2018
					PED	Oct 26, 2015
					PED	Nov 05, 2014
					PED	Sep 30, 2014
					PED	Apr 29, 2014

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
EVEROLIMUS - AFINITOR						
N022334 004	5665772	Sep 09, 2019	DS DP		>A> I-655	Jul 20, 2015
	5665772*PED	Mar 09, 2020			I-650	Apr 26, 2015
	6004973	Jul 12, 2016	DP		I-638	May 05, 2014
	6004973*PED	Jan 12, 2017			I-630	Oct 29, 2013
	7297703	Dec 06, 2019	DP		NCE	Mar 30, 2014
	7297703*PED	Jun 06, 2020			ODE	Apr 26, 2019
					ODE	May 05, 2018
					ODE	Oct 29, 2017
					PED	Oct 26, 2019
					PED	Nov 05, 2018
					PED	Apr 29, 2018
					PED	Oct 26, 2015
					PED	Nov 05, 2014
					PED	Sep 30, 2014
					PED	Apr 29, 2014
EVEROLIMUS - ZORTRESS						
N021560 001	5665772	Sep 09, 2019	DS DP U-1049		NP	Apr 20, 2013
	5665772*PED	Mar 09, 2020			NCE	Mar 30, 2014
	6004973	Jul 12, 2016	DP U-1049		PED	Sep 30, 2014
	6004973*PED	Jan 12, 2017			PED	Oct 20, 2013
	6239124	Aug 11, 2017	U-1049			
	6239124*PED	Feb 11, 2018				
	6440990	Sep 24, 2013	DP U-1049			
	6440990*PED	Mar 24, 2014				
	6455518	Jul 29, 2017	U-1049			
	6455518*PED	Jan 29, 2018				
EVEROLIMUS - ZORTRESS						
N021560 002	5665772	Sep 09, 2019	DS DP U-1049		NP	Apr 20, 2013
	5665772*PED	Mar 09, 2020			NCE	Mar 30, 2014
	6004973	Jul 12, 2016	DP U-1049		PED	Sep 30, 2014
	6004973*PED	Jan 12, 2017			PED	Oct 20, 2013
	6239124	Aug 11, 2017	U-1049			
	6239124*PED	Feb 11, 2018				
	6440990	Sep 24, 2013	DP U-1049			
	6440990*PED	Mar 24, 2014				
	6455518	Jul 29, 2017	U-1049			
	6455518*PED	Jan 29, 2018				
EVEROLIMUS - ZORTRESS						
N021560 003	5665772	Sep 09, 2019	DS DP U-1049		NP	Apr 20, 2013
	5665772*PED	Mar 09, 2020			NCE	Mar 30, 2014
	6004973	Jul 12, 2016	DP U-1049		PED	Sep 30, 2014
	6004973*PED	Jan 12, 2017			PED	Oct 20, 2013
	6239124	Aug 11, 2017	U-1049			
	6239124*PED	Feb 11, 2018				
	6440990	Sep 24, 2013	DP U-1049			
	6440990*PED	Mar 24, 2014				
	6455518	Jul 29, 2017	U-1049			
	6455518*PED	Jan 29, 2018				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
EXENATIDE SYNTHETIC - BYDUREON						
N022200 001	5424286	Dec 01, 2016	U-1108		NP	Jan 27, 2015
	6479065	Aug 10, 2020	DP			
	6495164	May 25, 2020	DP			
	6667061	May 25, 2020	DP			
	6824822	Oct 09, 2022	DP			
	6858576	Jan 06, 2017	U-656			
	6872700	Jan 14, 2020	U-654			
	6956026	Jan 07, 2018	U-687			
	7223440	Aug 31, 2021	DP			
	7456254	Jun 30, 2025	DP U-1223			
	7563871	Apr 15, 2024	DP			
	7612176	Apr 13, 2025	DP U-1223			
	7741269	Jan 07, 2018	U-1224			
EXENATIDE SYNTHETIC - BYETTA						
N021773 001					M-113	Oct 19, 2014
					M-111	Oct 19, 2014
EXENATIDE SYNTHETIC - BYETTA						
N021773 002					M-113	Oct 19, 2014
					M-111	Oct 19, 2014
EZETIMIBE - ZETIA						
N021445 001					M-109	Jan 24, 2015
EZETIMIBE; SIMVASTATIN - VYTORIN						
N021687 001					M-109	Jan 24, 2015
EZETIMIBE; SIMVASTATIN - VYTORIN						
N021687 002					M-109	Jan 24, 2015
EZETIMIBE; SIMVASTATIN - VYTORIN						
N021687 003					M-109	Jan 24, 2015
EZETIMIBE; SIMVASTATIN - VYTORIN						
N021687 004					M-109	Jan 24, 2015
FAMCICLOVIR - FAMVIR						
N020363 001					M-112	Feb 09, 2015
FAMCICLOVIR - FAMVIR						
N020363 002					M-112	Feb 09, 2015
FAMCICLOVIR - FAMVIR						
N020363 003					M-112	Feb 09, 2015
FENOFIBRATE - FENOGLIDE						
N022118 001	8124125	Oct 01, 2024	DP U-1234			
FENOFIBRATE - FENOGLIDE						
N022118 002	8124125	Oct 01, 2024	DP U-1234			
FENTANYL - SUBSYS						
N202788 001					NP	Jan 04, 2015
FENTANYL - SUBSYS						
N202788 002					NP	Jan 04, 2015
FENTANYL - SUBSYS						
N202788 003					NP	Jan 04, 2015

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FENTANYL - SUBSYS						
N202788 004					NP	Jan 04, 2015
FENTANYL - SUBSYS						
N202788 005					NP	Jan 04, 2015
FENTANYL CITRATE - FENTORA						
N021947 001	8092832	Dec 30, 2024	DP			
FENTANYL CITRATE - FENTORA						
N021947 002	8092832	Dec 30, 2024	DP			
	8119158	Dec 30, 2024	DP			
FENTANYL CITRATE - FENTORA						
N021947 003	8092832	Dec 30, 2024	DP			
	8119158	Dec 30, 2024	DP			
FENTANYL CITRATE - FENTORA						
N021947 004	8092832	Dec 30, 2024	DP			
	8119158	Dec 30, 2024	DP			
FENTANYL CITRATE - FENTORA						
N021947 005	8092832	Dec 30, 2024	DP			
	8119158	Dec 30, 2024	DP			
FENTANYL CITRATE - LAZANDA						
N022569 001 **>A>**	8216604	Oct 03, 2024	U-767			
FENTANYL CITRATE - LAZANDA						
N022569 002 **>A>**	8216604	Oct 03, 2024	U-767			
FENTANYL CITRATE - ONSOLIS						
N022266 001	7579019	Jan 22, 2020	U-767			
FENTANYL CITRATE - ONSOLIS						
N022266 002	7579019	Jan 22, 2020	U-767			
FENTANYL CITRATE - ONSOLIS						
N022266 003	7579019	Jan 22, 2020	U-767			
FENTANYL CITRATE - ONSOLIS						
N022266 004	7579019	Jan 22, 2020	U-767			
FENTANYL CITRATE - ONSOLIS						
N022266 005	7579019	Jan 22, 2020	U-767			
FESOTERODINE FUMARATE - TOVIAZ						
N022030 001	8088398	Jun 07, 2027	DP U-913			
FESOTERODINE FUMARATE - TOVIAZ						
N022030 002	8088398	Jun 07, 2027	DP U-913			
FINGOLIMOD - GILENYA						
N022527 001	6004565	Sep 23, 2017	U-1086			
FLORBETAPIR F-18 - AMYVID						
N202008 001	7687052	Apr 30, 2027	DS DP		NCE	Apr 06, 2017
FLORBETAPIR F-18 - AMYVID						
N202008 002	7687052	Apr 30, 2027	DS DP		NCE	Apr 06, 2017

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FLORBETAPIR F-18 - AMYVID						
N202008 003	7687052	Apr 30, 2027	DS DP		NCE	Apr 06, 2017
FLUNISOLIDE - AEROSPAN HFA						
N021247 001	5776433	Jul 07, 2015	DP			
	5980867	Jul 06, 2018	DP			
FLUOCINONIDE - VANOS						
N021758 001	**>A>** 8232264	Mar 09, 2023	DP			
FOSAMPRENAVIR CALCIUM - LEXIVA						
N021548 001					NPP	Apr 27, 2015
					PED	Oct 27, 2015
FOSAMPRENAVIR CALCIUM - LEXIVA						
N022116 001					NPP	Apr 27, 2015
					PED	Oct 27, 2015
FOSAPREPITANT DIMEGLUMINE - EMEND						
N022023 002	5512570	Mar 04, 2014	U-850			
	5538982	Jul 23, 2013	U-850			
	5716942	Feb 10, 2015	U-850			
	7214692	Sep 18, 2012	U-850			
FOSPROPOFOL DISODIUM - LUSEDRA						
N022244 001	6204257	Jul 01, 2022	DS DP U-945			
GABAPENTIN - GRALISE						
N022544 001	8192756	Oct 25, 2022	DP U-1114			
GABAPENTIN - GRALISE						
N022544 002	8192756	Oct 25, 2022	DP U-1114			
GABAPENTIN ENACARBIL - HORIZANT						
N022399 001	8048917	Nov 06, 2022	DS DP U-1247		I-652	Jun 06, 2015
	8114909	Apr 11, 2026	U-1231			
GABAPENTIN ENACARBIL - HORIZANT						
N022399 002	8048917	Nov 06, 2022	DS DP U-1247		I-652	Jun 06, 2015
	8114909	Apr 11, 2026	U-1231			
GADOBENATE DIMEGLUMINE - MULTIHANCE						
N021357 001					I-654	Jul 06, 2015
GADOBENATE DIMEGLUMINE - MULTIHANCE						
N021357 002					I-654	Jul 06, 2015
GADOBENATE DIMEGLUMINE - MULTIHANCE						
N021357 003					I-654	Jul 06, 2015
GADOBENATE DIMEGLUMINE - MULTIHANCE						
N021357 004					I-654	Jul 06, 2015
GADOBENATE DIMEGLUMINE - MULTIHANCE MULTIPACK						
N021358 001					I-654	Jul 06, 2015
GADOBENATE DIMEGLUMINE - MULTIHANCE MULTIPACK						
N021358 002					I-654	Jul 06, 2015
GADOFOSVESET TRISODIUM - ABLAVAR						
N021711 001	6676929	May 04, 2020	DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2012

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
GADOFOSVESET TRISODIUM - ABLAVAR							
N021711 002		6676929	May 04, 2020	DP			
GADOXETATE DISODIUM - EOVIST							
N022090 001		5798092	Aug 25, 2015	DS DP			
		6039931	Nov 13, 2021	U-1239			
GLYCOPYRROLATE - CUVPOSA							
N022571 001						ODE	Jul 28, 2017
HYDROCHLOROTHIAZIDE; IRBESARTAN - IRBESARTAN AND HYDROCHLOROTHIAZIDE							
A077369 001						PC	Sep 26, 2012
HYDROCHLOROTHIAZIDE; IRBESARTAN - IRBESARTAN AND HYDROCHLOROTHIAZIDE							
A077369 002						PC	Sep 26, 2012
ICOSAPENT ETHYL - VASCEPA							
N202057 001	**>A>**	8188146	Jan 27, 2020	DS DP			
IMATINIB MESYLATE - GLEEVEC							
N021588 001						ODE	Dec 19, 2015
IMATINIB MESYLATE - GLEEVEC							
N021588 002						ODE	Dec 19, 2015
IMIQUIMOD - ZYCLARA							
N022483 001	**>A>**	8236816	Dec 11, 2029	U-68			
IMIQUIMOD - ZYCLARA							
N022483 002	**>A>**	8222270	Dec 11, 2029	U-68			
INGENOL MEBUTATE - PICATO							
N202833 001		6432452	Aug 19, 2018	DS U-68		NCE	Jan 23, 2017
		6844013	Aug 19, 2018	DS DP U-1221			
		7410656	Aug 19, 2018	DS U-1222			
INGENOL MEBUTATE - PICATO							
N202833 002		6432452	Aug 19, 2018	DS U-68		NCE	Jan 23, 2017
		6844013	Aug 19, 2018	DS DP U-1221			
		7410656	Aug 19, 2018	DS U-1222			
INSULIN DETEMIR RECOMBINANT - LEVEMIR							
N021536 001	**>A>**	5750497	Jun 16, 2019	DS DP U-668		M-117	May 18, 2015
						M-115	Apr 06, 2015
IOFLUPANE I-123 - DATSCAN							
N022454 001		5310912	Feb 25, 2013	DS			
IRBESARTAN - IRBESARTAN							
A077159 001						PC	Sep 26, 2012
IRBESARTAN - IRBESARTAN							
A077159 002						PC	Sep 26, 2012
IRBESARTAN - IRBESARTAN							
A077159 003						PC	Sep 26, 2012
ISOTRETINOIN - ABSORICA							
N021951 001		7435427	Sep 21, 2021	DP		NP	May 25, 2015
ISOTRETINOIN - ABSORICA							
N021951 002		7435427	Sep 21, 2021	DP		NP	May 25, 2015

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ISOTRETINOIN - ABSORICA						
N021951 003	7435427	Sep 21, 2021	DP		NP	May 25, 2015
ISOTRETINOIN - ABSORICA						
N021951 004	7435427	Sep 21, 2021	DP		NP	May 25, 2015
IVACAFTOR - KALYDECO						
N203188 001	7495103	May 20, 2027	DS DP		NCE	Jan 31, 2017
					ODE	Jan 31, 2019
IVERMECTIN - SKLICE						
N202736 001	6103248	May 22, 2018	DP		NP	Feb 07, 2015
IXABEPILONE - IXEMPRA KIT						
N022065 001	RE41911	Sep 28, 2020	DS DP U-961			
	RE41911*PED	Mar 28, 2021				
IXABEPILONE - IXEMPRA KIT						
N022065 002	RE41911	Sep 28, 2020	DS DP U-961			
	RE41911*PED	Mar 28, 2021				
KETOCONAZOLE - EXTINA						
N021738 001	8026238	Oct 19, 2018	DP U-1213			
KETOROLAC TROMETHAMINE - ACULAR LS						
N021528 001	>A> 8008338*PED	Nov 24, 2027				
	>A> 8207215	May 28, 2024	U-1251			
	>A> 8207215*PED	Nov 28, 2024				
LAMIVUDINE; ZIDOVUDINE - LAMIVUDINE AND ZIDOVUDINE						
A079081 001					PC	May 15, 2012
LENALIDOMIDE - REVLIMID						
N021880 001	5635517	Oct 04, 2019	DS U-1211			
	6045501	Aug 28, 2018	U-1210			
	6281230	Jul 24, 2016	U-1212			
	6315720	Oct 23, 2020	U-1210			
	6555554	Jul 24, 2016	DP U-1211			
	6561976	Aug 28, 2018	U-1210			
	6561977	Oct 23, 2020	U-1210			
	6755784	Oct 23, 2020	U-1210			
	6908432	Aug 28, 2018	U-1210			
	7189740	Apr 11, 2023	U-1215			
	7465800	Apr 27, 2027	DS DP			
	7968569	Oct 07, 2023	U-1216			
	8204763	Aug 28, 2018	U-1249			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LENALIDOMIDE - REVLIMID						
N021880 002	5635517	Oct 04, 2019	DS U-1211			
	6045501	Aug 28, 2018	U-1210			
	6281230	Jul 24, 2016	U-1212			
	6315720	Oct 23, 2020	U-1210			
	6555554	Jul 24, 2016	DP U-1211			
	6561976	Aug 28, 2018	U-1210			
	6561977	Oct 23, 2020	U-1210			
	6755784	Oct 23, 2020	U-1210			
	6908432	Aug 28, 2018	U-1210			
	7189740	Apr 11, 2023	U-1215			
	7465800	Apr 27, 2027	DS DP			
	7968569	Oct 07, 2023	U-1216			
	8204763	Aug 28, 2018	U-1249			
LENALIDOMIDE - REVLIMID						
N021880 003	5635517	Oct 04, 2019	DS U-1211			
	6045501	Aug 28, 2018	U-1210			
	6281230	Jul 24, 2016	U-1212			
	6315720	Oct 23, 2020	U-1210			
	6555554	Jul 24, 2016	DP U-1211			
	6561976	Aug 28, 2018	U-1210			
	6561977	Oct 23, 2020	U-1210			
	6755784	Oct 23, 2020	U-1210			
	6908432	Aug 28, 2018	U-1210			
	7189740	Apr 11, 2023	U-1215			
	7465800	Apr 27, 2027	DS DP			
	7855217	Nov 24, 2024	DS DP			
	7968569	Oct 07, 2023	U-1216			
	8204763	Aug 28, 2018	U-1249			
LENALIDOMIDE - REVLIMID						
N021880 004	5635517	Oct 04, 2019	DS U-1211			
	6045501	Aug 28, 2018	U-1210			
	6281230	Jul 24, 2016	U-1212			
	6315720	Oct 23, 2020	U-1210			
	6555554	Jul 24, 2016	DP U-1211			
	6561976	Aug 28, 2018	U-1210			
	6561977	Oct 23, 2020	U-1210			
	6755784	Oct 23, 2020	U-1210			
	6908432	Aug 28, 2018	U-1210			
	7189740	Apr 11, 2023	U-1215			
	7465800	Apr 27, 2027	DS DP			
	7968569	Oct 07, 2023	U-1216			
	8204763	Aug 28, 2018	U-1249			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2012

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LENALIDOMIDE - REVLIMID							
N021880 005		5635517	Oct 04, 2019	DS U-1211			
		6045501	Aug 28, 2018	U-1210			
		6281230	Jul 24, 2016	U-1212			
		6315720	Oct 23, 2020	U-1210			
		6555554	Jul 24, 2016	DP U-1211			
		6561976	Aug 28, 2018	U-1210			
		6561977	Oct 23, 2020	U-1210			
		6755784	Oct 23, 2020	U-1210			
		6908432	Aug 28, 2018	U-1210			
		7119106	Jul 24, 2016	DP			
		7189740	Apr 11, 2023	U-1215			
		7465800	Apr 27, 2027	DS DP			
		7855217	Nov 24, 2024	DS DP			
		7968569	Oct 07, 2023	U-1216			
		8204763	Aug 28, 2018	U-1249			
LEVETIRACETAM - KEPPRA							
N021035 001						**>A>** NPP	Dec 16, 2014
LEVETIRACETAM - KEPPRA							
N021035 002						**>A>** NPP	Dec 16, 2014
LEVETIRACETAM - KEPPRA							
N021035 003						**>A>** NPP	Dec 16, 2014
LEVETIRACETAM - KEPPRA							
N021035 004						**>A>** NPP	Dec 16, 2014
LEVETIRACETAM - KEPPRA							
N021505 001						**>A>** NPP	Dec 16, 2014
LIDOCAINE; TETRACAINE - SYNERA							
N021623 001	**>A>**	6465709	Jul 07, 2020	DP			
LINAGLIPTIN - TRADJENTA							
N201280 001		8119648	Aug 12, 2023	U-774			
		8178541	Aug 12, 2023	U-775			
		8178541	Aug 12, 2023	U-1245			
		8178541	Aug 12, 2023	U-1244			
LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO							
N201281 001		6303661	Apr 24, 2017	U-802		NCE	May 02, 2016
		6890898	Feb 02, 2019	U-1039		NC	Jan 30, 2015
		7078381	Feb 02, 2019	U-1039			
		7407955	Aug 12, 2023	DS DP			
		7459428	Feb 02, 2019	U-1039			
		8119648	Aug 12, 2023	U-802			
		8178541	Aug 12, 2023	DP U-775			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO						
N201281 002	6303661	Apr 24, 2017	U-802		NCE	May 02, 2016
	6890898	Feb 02, 2019	U-1039		NC	Jan 30, 2015
	7078381	Feb 02, 2019	U-1039			
	7407955	Aug 12, 2023	DS DP			
	7459428	Feb 02, 2019	U-1039			
	8119648	Aug 12, 2023	U-802			
	8178541	Aug 12, 2023	DP U-775			
LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO						
N201281 003	6303661	Apr 24, 2017	U-802		NCE	May 02, 2016
	6890898	Feb 02, 2019	U-1039		NC	Jan 30, 2015
	7078381	Feb 02, 2019	U-1039			
	7407955	Aug 12, 2023	DS DP			
	7459428	Feb 02, 2019	U-1039			
	8119648	Aug 12, 2023	U-802			
	8178541	Aug 12, 2023	DP U-775			
LIRAGLUTIDE RECOMBINANT - VICTOZA						
N022341 001	8114833	Aug 13, 2025	DP		M-115	Apr 06, 2015
LISDEXAMFETAMINE DIMESYLATE - VYVANSE						
N021977 001	7662788	Feb 24, 2023	U-727		I-645	Jan 31, 2015
	7713936	Feb 24, 2023	U-727			
LISDEXAMFETAMINE DIMESYLATE - VYVANSE						
N021977 002	7662788	Feb 24, 2023	U-727		I-645	Jan 31, 2015
	7713936	Feb 24, 2023	U-727			
LISDEXAMFETAMINE DIMESYLATE - VYVANSE						
N021977 003	7662788	Feb 24, 2023	U-727		I-645	Jan 31, 2015
	7713936	Feb 24, 2023	U-727			
LISDEXAMFETAMINE DIMESYLATE - VYVANSE						
N021977 004	7662788	Feb 24, 2023	U-727		I-645	Jan 31, 2015
	7671030	Feb 24, 2023	DP U-727			
	7674774	Mar 18, 2023	DP U-842			
	7678771	Mar 25, 2023	DP U-842			
	7687467	Apr 08, 2023	DP U-842			
	7713936	Feb 24, 2023	U-727			
	7718619	Feb 24, 2023	DP U-842			
	7723305	Feb 24, 2023	DP U-842			
LISDEXAMFETAMINE DIMESYLATE - VYVANSE						
N021977 005	7662788	Feb 24, 2023	U-727		I-645	Jan 31, 2015
	7713936	Feb 24, 2023	U-727			
LISDEXAMFETAMINE DIMESYLATE - VYVANSE						
N021977 006	7662788	Feb 24, 2023	U-727		I-645	Jan 31, 2015
	7713936	Feb 24, 2023	U-727			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LORCASERIN HYDROCHLORIDE - BELVIQ						
N022529 001	**>A>** 6953787	Apr 10, 2023	DS DP U-1253		NCE	Jun 27, 2017
	>A> 6953787	Apr 10, 2023	DS DP U-1254			
	>A> 6953787	Apr 10, 2023	DS DP U-1255			
	>A> 6953787	Apr 10, 2023	DS DP U-1252			
	>A> 7514422	Apr 10, 2023	U-1255			
	>A> 7514422	Apr 10, 2023	U-1252			
	>A> 7514422	Apr 10, 2023	U-1253			
	>A> 7514422	Apr 10, 2023	U-1254			
	>A> 7977329	Apr 10, 2023	DS DP U-1253			
	>A> 7977329	Apr 10, 2023	DS DP U-1254			
	>A> 7977329	Apr 10, 2023	DS DP U-1255			
	>A> 7977329	Apr 10, 2023	DS DP U-1252			
	>A> 8168624	Apr 18, 2029	DS DP			
	>A> 8207158	Apr 10, 2023	U-1255			
	>A> 8207158	Apr 10, 2023	U-1252			
	>A> 8207158	Apr 10, 2023	U-1253			
	>A> 8207158	Apr 10, 2023	U-1254			
LUBIPROSTONE - AMITIZA						
N021908 001	8097649	Oct 16, 2020	DP			
	8097653	Nov 14, 2022	U-1214			
	8114890	Sep 05, 2020	DP			
LUBIPROSTONE - AMITIZA						
N021908 002	8097649	Oct 16, 2020	DP			
	8114890	Sep 05, 2020	DP			
LUCINACTANT - SURFAXIN						
N021746 001	5407914	Nov 17, 2012	DS DP U-1242			
LURASIDONE HYDROCHLORIDE - LATUDA						
N200603 001					D-134	Apr 26, 2015
LURASIDONE HYDROCHLORIDE - LATUDA						
N200603 002					D-134	Apr 26, 2015
LURASIDONE HYDROCHLORIDE - LATUDA						
N200603 003					D-134	Apr 26, 2015
					NCE	Oct 28, 2015
LURASIDONE HYDROCHLORIDE - LATUDA						
N200603 004					D-134	Apr 26, 2015
					NCE	Oct 28, 2015
METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET						
N021842 001					M-116	May 17, 2015
METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET						
N021842 002					M-116	May 17, 2015

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR						
N202270 001	6303661	Apr 24, 2017	U-1227			
	6340475	Sep 19, 2016	DP			
	6635280	Sep 19, 2016	DP			
	6699871	Jul 26, 2022	DS DP U-1227			
	6890898	Feb 02, 2019	U-1228			
	7078381	Feb 02, 2019	U-1227			
	7125873	Jul 26, 2022	DP U-1227			
	7326708	Apr 11, 2026	DS DP U-1227			
	7459428	Feb 02, 2019	U-1227			
METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR						
N202270 002	6303661	Apr 24, 2017	U-1227			
	6340475	Sep 19, 2016	DP			
	6635280	Sep 19, 2016	DP			
	6699871	Jul 26, 2022	DS DP U-1227			
	6890898	Feb 02, 2019	U-1228			
	7078381	Feb 02, 2019	U-1227			
	7125873	Jul 26, 2022	DP U-1227			
	7326708	Apr 11, 2026	DS DP U-1227			
	7459428	Feb 02, 2019	U-1227			
METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR						
N202270 003	6303661	Apr 24, 2017	U-1227			
	6340475	Sep 19, 2016	DP			
	6635280	Sep 19, 2016	DP			
	6699871	Jul 26, 2022	DS DP U-1227			
	6890898	Feb 02, 2019	U-1228			
	7078381	Feb 02, 2019	U-1227			
	7125873	Jul 26, 2022	DP U-1227			
	7326708	Apr 11, 2026	DS DP U-1227			
	7459428	Feb 02, 2019	U-1227			
METHYLPHENIDATE HYDROCHLORIDE - CONCERTA						
N021121 001	8163798	Jul 31, 2017	DP			
	8163798*PED	Jan 31, 2018				
METHYLPHENIDATE HYDROCHLORIDE - CONCERTA						
N021121 002	8163798	Jul 31, 2017	DP			
	8163798*PED	Jan 31, 2018				
METHYLPHENIDATE HYDROCHLORIDE - CONCERTA						
N021121 003	8163798	Jul 31, 2017	DP			
	8163798*PED	Jan 31, 2018				
METHYLPHENIDATE HYDROCHLORIDE - CONCERTA						
N021121 004	8163798	Jul 31, 2017	DP			
	8163798*PED	Jan 31, 2018				
METHYLPHENIDATE HYDROCHLORIDE - METHYLPHENIDATE HYDROCHLORIDE						
A078458 001					PC	Jul 01, 2012
METHYLPHENIDATE HYDROCHLORIDE - METHYLPHENIDATE HYDROCHLORIDE						
A078458 002					PC	Jul 01, 2012

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2012

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
METHYLPHENIDATE HYDROCHLORIDE - METHYLPHENIDATE HYDROCHLORIDE							
A078458 003						PC	Jul 01, 2012
MICONAZOLE - ORAVIG							
N022404 001		7651698	Sep 11, 2022	U-1051			
MIFEPRISTONE - KORLYM							
N202107 001						NP	Feb 17, 2015
MINOCYCLINE HYDROCHLORIDE - ARESTIN							
N050781 001		6682348	Mar 29, 2022	DP			
MIRABEGRON - MYRBETRIQ							
N202611 001	>A>	6346532	Oct 15, 2018	DS DP		NCE	Jun 28, 2017
	>A>	6562375	Aug 01, 2020	DP			
	>A>	6699503	Sep 10, 2013	DP			
	>A>	7342117	Nov 04, 2023	DS			
	>A>	7750029	Dec 18, 2023	U-913			
	>A>	7982049	Nov 04, 2023	DP			
MIRABEGRON - MYRBETRIQ							
N202611 002	>A>	6346532	Oct 15, 2018	DS DP		NCE	Jun 28, 2017
	>A>	6562375	Aug 01, 2020	DP			
	>A>	6699503	Sep 10, 2013	DP			
	>A>	7342117	Nov 04, 2023	DS			
	>A>	7750029	Dec 18, 2023	U-913			
	>A>	7982049	Nov 04, 2023	DP			
MITOMYCIN - MITOSOL							
N022572 001		7806265	Feb 01, 2029	DP		ODE	Feb 07, 2019
		8186511	Jul 19, 2026	DP			
MOMETASONE FUROATE - ASMANEX TWISTHALER							
N021067 001		8173172	Mar 17, 2018	DP			
		8173172*PED	Sep 17, 2018				
MOMETASONE FUROATE - ASMANEX TWISTHALER							
N021067 002		8173172	Mar 17, 2018	DP			
		8173172*PED	Sep 17, 2018				
MONTELUKAST SODIUM - SINGULAIR							
N020829 002						NPP	Mar 26, 2015
MONTELUKAST SODIUM - SINGULAIR							
N020830 001						NPP	Mar 26, 2015
MONTELUKAST SODIUM - SINGULAIR							
N020830 002						NPP	Mar 26, 2015
MONTELUKAST SODIUM - SINGULAIR							
N021409 001						NPP	Mar 26, 2015
MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA							
N022321 001		8158156	Jun 19, 2027	U-1241			
MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA							
N022321 002		8158156	Jun 19, 2027	U-1241			
MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA							
N022321 003		8158156	Jun 19, 2027	U-1241			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA						
N022321 004	8158156	Jun 19, 2027	U-1241			
MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA						
N022321 005	8158156	Jun 19, 2027	U-1241			
MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA						
N022321 006	8158156	Jun 19, 2027	U-1241			
NAFTIFINE HYDROCHLORIDE - NAFTIN						
N019599 002					NS	Jan 13, 2015
NICOTINE - NICODERM CQ						
N020165 004	8075911	May 22, 2021	DP			
NICOTINE - NICODERM CQ						
N020165 005	8075911	May 22, 2021	DP			
NICOTINE - NICODERM CQ						
N020165 006	8075911	May 22, 2021	DP			
NILOTINIB HYDROCHLORIDE MONOHYDRATE - TASIGNA						
N022068 001	8163904	Aug 23, 2028	DS DP			
NILOTINIB HYDROCHLORIDE MONOHYDRATE - TASIGNA						
N022068 002	8163904	Aug 23, 2028	DS DP			
NITRIC OXIDE - INOMAX						
N020845 002	5558083	Nov 22, 2013	DP U-1226			
	5558083*PED	May 22, 2014				
	5732693	Dec 13, 2016	DP U-1230			
	5732693*PED	Jun 13, 2017				
	5752504	Dec 13, 2016	DP U-1230			
	5752504*PED	Jun 13, 2017				
NITRIC OXIDE - INOMAX						
N020845 003	5558083	Nov 22, 2013	DP U-1226			
	5558083*PED	May 22, 2014				
	5732693	Dec 13, 2016	DP U-1230			
	5732693*PED	Jun 13, 2017				
	5752504	Dec 13, 2016	DP U-1230			
	5752504*PED	Jun 13, 2017				
NITROGLYCERIN - NITROLINGUAL PUMPSPRAY						
N018705 002	7872049	Mar 14, 2028	DP U-39			
OXCARBAZEPINE - TRILEPTAL						
N021285 001	8119148	Dec 19, 2020	DP U-724			
	8119148*PED	Jun 19, 2021				
OXYBUTYNIN - ANTUROL						
N202513 001	7029694	Apr 26, 2020	DP U-318			
	7179483	Apr 26, 2020	U-318			
	7198801	Jun 25, 2022	DP			
OXYCODONE HYDROCHLORIDE - OXYCONTIN						
N022272 001	8114383	Oct 10, 2024	DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
OXYCODONE HYDROCHLORIDE - OXYCONTIN						
N022272 002	8114383	Oct 10, 2024	DP			
OXYCODONE HYDROCHLORIDE - OXYCONTIN						
N022272 003	8114383	Oct 10, 2024	DP			
OXYCODONE HYDROCHLORIDE - OXYCONTIN						
N022272 004	8114383	Oct 10, 2024	DP			
OXYCODONE HYDROCHLORIDE - OXYCONTIN						
N022272 005	8114383	Oct 10, 2024	DP			
OXYCODONE HYDROCHLORIDE - OXYCONTIN						
N022272 006	8114383	Oct 10, 2024	DP			
OXYCODONE HYDROCHLORIDE - OXYCONTIN						
N022272 007	8114383	Oct 10, 2024	DP			
OXYMORPHONE HYDROCHLORIDE - OPANA ER						
N201655 001	7851482	Jul 10, 2029	DS			
	8114383	Aug 08, 2024	DP			
	8192722	Sep 15, 2025	DP			
OXYMORPHONE HYDROCHLORIDE - OPANA ER						
N201655 002	7851482	Jul 10, 2029	DS			
	8114383	Aug 08, 2024	DP			
	8192722	Sep 15, 2025	DP			
OXYMORPHONE HYDROCHLORIDE - OPANA ER						
N201655 003	7851482	Jul 10, 2029	DS			
	8114383	Aug 08, 2024	DP			
	8192722	Sep 15, 2025	DP			
OXYMORPHONE HYDROCHLORIDE - OPANA ER						
N201655 004	7851482	Jul 10, 2029	DS			
	8114383	Aug 08, 2024	DP			
	8192722	Sep 15, 2025	DP			
OXYMORPHONE HYDROCHLORIDE - OPANA ER						
N201655 005	7851482	Jul 10, 2029	DS			
	8114383	Aug 08, 2024	DP			
	8192722	Sep 15, 2025	DP			
OXYMORPHONE HYDROCHLORIDE - OPANA ER						
N201655 006	7851482	Jul 10, 2029	DS			
	8114383	Aug 08, 2024	DP			
	8192722	Sep 15, 2025	DP			
OXYMORPHONE HYDROCHLORIDE - OPANA ER						
N201655 007	7851482	Jul 10, 2029	DS			
	8114383	Aug 08, 2024	DP			
	8192722	Sep 15, 2025	DP			
PACLITAXEL - ABRAXANE						
N021660 001	8138229	Dec 09, 2023	DP		U-1092	

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - CREON						
N020725 004					I-625	Apr 30, 2013
					M-93	Jul 29, 2019
					NCE	Apr 30, 2014
PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - PERTZYE						
N022175 001					NCE	May 17, 2017
PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - PERTZYE						
N022175 002					NCE	May 17, 2017
PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ULTRESA						
N022222 001					NCE	Mar 01, 2017
PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ULTRESA						
N022222 002					NCE	Mar 01, 2017
PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ULTRESA						
N022222 003					NCE	Mar 01, 2017
PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - VIOKACE						
N022542 001					NCE	Mar 01, 2017
PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - VIOKACE						
N022542 002					NCE	Mar 01, 2017
PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP						
N022210 005					NCE	Aug 27, 2014
PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP						
N022210 006					NCE	Aug 27, 2014
PAZOPANIB HYDROCHLORIDE - VOTRIENT						
N022465 001	8114885	Dec 19, 2021	DS DP		I-649	Apr 26, 2015
					ODE	Apr 26, 2019
PAZOPANIB HYDROCHLORIDE - VOTRIENT						
N022465 002	8114885	Dec 19, 2021	DS DP		I-649	Apr 26, 2015
					ODE	Apr 26, 2019
PEGINESATIDE ACETATE - OMONTYS						
N202799 007	7084245	May 12, 2024	DS DP U-1238			
	7414105	May 12, 2024	DS DP U-1238			
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026	U-1238			
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026	U-1238			
PEGINESATIDE ACETATE - OMONTYS						
N202799 008	7084245	May 12, 2024	DS DP U-1238			
	7414105	May 12, 2024	DS DP U-1238			
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026	U-1238			
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026	U-1238			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE						
N202799 001	7084245	May 12, 2024	DS DP U-1238		NCE	Mar 27, 2017
	7414105	May 12, 2024	DS DP U-1238			
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026	U-1238			
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026	U-1238			
PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE						
N202799 002	7084245	May 12, 2024	DS DP U-1238		NCE	Mar 27, 2017
	7414105	May 12, 2024	DS DP U-1238			
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026	U-1238			
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026	U-1238			
PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE						
N202799 003	7084245	May 12, 2024	DS DP U-1238		NCE	Mar 27, 2017
	7414105	May 12, 2024	DS DP U-1238			
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026	U-1238			
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026	U-1238			
PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE						
N202799 004	7084245	May 12, 2024	DS DP U-1238		NCE	Mar 27, 2017
	7414105	May 12, 2024	DS DP U-1238			
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026	U-1238			
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026	U-1238			
PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE						
N202799 005	7084245	May 12, 2024	DS DP U-1238		NCE	Mar 27, 2017
	7414105	May 12, 2024	DS DP U-1238			
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026	U-1238			
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026	U-1238			
PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE						
N202799 006	7084245	May 12, 2024	DS DP U-1238		NCE	Mar 27, 2017
	7414105	May 12, 2024	DS DP U-1238			
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026	U-1238			
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026	U-1238			
PHENTERMINE HYDROCHLORIDE - SUPRENZA						
N202088 003	6149938	Jul 23, 2018	DP U-1243			
PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA						
N022580 001					**>A>** NC	Jul 17, 2015
PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA						
N022580 002					**>A>** NC	Jul 17, 2015

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA						
N022580 003					**>A>** NC	Jul 17, 2015
PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA						
N022580 004					**>A>** NC	Jul 17, 2015
PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN						
N050684 001	8133883	Apr 14, 2023	DP U-282			
PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN						
N050684 002	8133883	Apr 14, 2023	DP U-282			
PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN						
N050684 003	8133883	Apr 14, 2023	DP U-282			
PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN						
N050684 004	8133883	Apr 14, 2023	DP U-282			
PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN IN PLASTIC CONTAINER						
N050750 001	8133883	Apr 14, 2023	DP U-282			
PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN IN PLASTIC CONTAINER						
N050750 002	8133883	Apr 14, 2023	DP U-282			
PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN IN PLASTIC CONTAINER						
N050750 003	8133883	Apr 14, 2023	DP U-282			
PREDNISOLONE ACETATE - FLO-PRED						
N022067 001	7799331	Oct 11, 2028	DP U-139			
	7799331	Oct 11, 2028	DP U-1068			
PREDNISOLONE ACETATE - FLO-PRED						
N022067 002	7799331	Oct 11, 2028	DP U-139			
	7799331	Oct 11, 2028	DP U-1068			
PREGABALIN - LYRICA						
N021446 001	**>A>** 6001876	Dec 30, 2018	U-819	Y	I-651	Jun 20, 2015
	>A> 6001876	Dec 30, 2018	U-55	Y		
	>A> RE41920	Dec 30, 2018	U-1250			
PREGABALIN - LYRICA						
N021446 002	**>A>** 6001876	Dec 30, 2018	U-819	Y	I-651	Jun 20, 2015
	>A> 6001876	Dec 30, 2018	U-55	Y		
	>A> RE41920	Dec 30, 2018	U-1250			
PREGABALIN - LYRICA						
N021446 003	**>A>** 6001876	Dec 30, 2018	U-819	Y	I-651	Jun 20, 2015
	>A> 6001876	Dec 30, 2018	U-55	Y		
	>A> RE41920	Dec 30, 2018	U-1250			
PREGABALIN - LYRICA						
N021446 004	**>A>** 6001876	Dec 30, 2018	U-819	Y	I-651	Jun 20, 2015
	>A> 6001876	Dec 30, 2018	U-55	Y		
	>A> RE41920	Dec 30, 2018	U-1250			
PREGABALIN - LYRICA						
N021446 005	**>A>** 6001876	Dec 30, 2018	U-819	Y	I-651	Jun 20, 2015
	>A> 6001876	Dec 30, 2018	U-55	Y		
	>A> RE41920	Dec 30, 2018	U-1250			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PREGABALIN - LYRICA						
N021446 006	**>A>** 6001876	Dec 30, 2018	U-819	Y	I-651	Jun 20, 2015
	>A> 6001876	Dec 30, 2018	U-55	Y		
	>A> RE41920	Dec 30, 2018	U-1250			
PREGABALIN - LYRICA						
N021446 007	**>A>** 6001876	Dec 30, 2018	U-819	Y	I-651	Jun 20, 2015
	>A> 6001876	Dec 30, 2018	U-55	Y		
	>A> RE41920	Dec 30, 2018	U-1250			
PREGABALIN - LYRICA						
N021446 008	**>A>** 6001876	Dec 30, 2018	U-819	Y	I-651	Jun 20, 2015
	>A> 6001876	Dec 30, 2018	U-55	Y		
	>A> RE41920	Dec 30, 2018	U-1250			
PREGABALIN - LYRICA						
N022488 001	**>A>** 6001876	Dec 30, 2018	U-819	Y		
	>A> 6001876	Dec 30, 2018	U-55	Y		
	>A> RE41920	Dec 30, 2018	U-1250			
PROPRANOLOL HYDROCHLORIDE - INNOPRAN XL						
N021438 001	6500454	Oct 04, 2021	DP			
PROPRANOLOL HYDROCHLORIDE - INNOPRAN XL						
N021438 002	6500454	Oct 04, 2021	DP			
RALTEGRAVIR POTASSIUM - ISENTRESS						
N022145 001					M-114	Mar 28, 2015
RALTEGRAVIR POTASSIUM - ISENTRESS						
N203045 001	7169780	Oct 03, 2023	DS DP		M-114	Mar 28, 2015
	7217713	Oct 21, 2022	U-257			
	7435734	Oct 21, 2022	U-257			
	7754731	Mar 11, 2029	DS DP U-257			
RALTEGRAVIR POTASSIUM - ISENTRESS						
N203045 002	7169780	Oct 03, 2023	DS DP		M-114	Mar 28, 2015
	7217713	Oct 21, 2022	U-257			
	7435734	Oct 21, 2022	U-257			
	7754731	Mar 11, 2029	DS DP U-257			
REGADENOSON - LEXISCAN						
N022161 001	8106029	Jun 22, 2019	U-1042			
	8106183	Feb 02, 2027	DS			
	8133879	Jun 22, 2019	DP			
	8183226	Jun 22, 2019	U-116			
RETAPAMULIN - ALTABAX						
N022055 001	RE43390	Apr 12, 2021	DS DP U-805			
RIFAXIMIN - XIFAXAN						
N021361 001	8158644	Jun 19, 2024	DP			
	8158781	Jun 19, 2024	DS			
	8193196	Sep 02, 2027	DS DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2012

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
RIFAXIMIN - XIFAXAN							
N022554 001		8158644	Jun 19, 2024	DP			
		8158781	Jun 19, 2024	DS			
		8193196	Sep 02, 2027	DS DP			
RILPIVIRINE HYDROCHLORIDE - EDURANT							
N202022 001		8080551	Apr 11, 2023	DS DP			
		8101629	Aug 09, 2022	DP			
RIZATRIPTAN BENZOATE - MAXALT							
N020864 001		5602162	Jan 28, 2012		Y		
		5602162*PED	Jul 28, 2012				
RIZATRIPTAN BENZOATE - MAXALT							
N020864 002		5602162	Jan 28, 2012		Y		
		5602162*PED	Jul 28, 2012				
RIZATRIPTAN BENZOATE - MAXALT-MLT							
N020865 001		5602162	Jan 28, 2012	U-240	Y		
		5602162*PED	Jul 28, 2012				
RIZATRIPTAN BENZOATE - MAXALT-MLT							
N020865 002		5602162	Jan 28, 2012	U-240	Y		
		5602162*PED	Jul 28, 2012				
ROMIDEPSIN - ISTODAX							
N022393 001	**>A>**	4977138	Aug 22, 2013	DS DP			
ROTIGOTINE - NEUPRO							
N021829 001						I-647	Apr 02, 2015
						I-646	Apr 02, 2015
ROTIGOTINE - NEUPRO							
N021829 002						I-647	Apr 02, 2015
						I-646	Apr 02, 2015
ROTIGOTINE - NEUPRO							
N021829 003						I-647	Apr 02, 2015
						I-646	Apr 02, 2015
ROTIGOTINE - NEUPRO							
N021829 004		6699498	Nov 27, 2020	DP		I-647	Apr 02, 2015
		6884434	Mar 30, 2021	DP		I-646	Apr 02, 2015
		7413747	Mar 18, 2019	DP			
ROTIGOTINE - NEUPRO							
N021829 005		6699498	Nov 27, 2020	DP		I-647	Apr 02, 2015
		6884434	Mar 30, 2021	DP		I-646	Apr 02, 2015
		7413747	Mar 18, 2019	DP			
ROTIGOTINE - NEUPRO							
N021829 006		6699498	Nov 27, 2020	DP		I-647	Apr 02, 2015
		6884434	Mar 30, 2021	DP		I-646	Apr 02, 2015
		7413747	Mar 18, 2019	DP			
RUFINAMIDE - BANZEL							
N201367 001	**>A>**	6740669	Nov 14, 2022	DS DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SILDENAFIL CITRATE - REVATIO						
N021845 001	5250534	Mar 27, 2012	DS DP		I-598	May 07, 2012
	5250534*PED	Sep 27, 2012			PED	Nov 07, 2012
SILDENAFIL CITRATE - REVATIO						
N022473 001	5250534	Mar 27, 2012	DS DP		NDF	Nov 20, 2012
	5250534*PED	Sep 27, 2012			PED	May 20, 2013
SILDENAFIL CITRATE - VIAGRA						
N020895 001	5250534	Mar 27, 2012				
	5250534*PED	Sep 27, 2012				
	6469012	Oct 22, 2019	U-155			
	6469012*PED	Apr 22, 2020				
SILDENAFIL CITRATE - VIAGRA						
N020895 002	5250534	Mar 27, 2012				
	5250534*PED	Sep 27, 2012				
	6469012	Oct 22, 2019	U-155			
	6469012*PED	Apr 22, 2020				
SILDENAFIL CITRATE - VIAGRA						
N020895 003	5250534	Mar 27, 2012				
	5250534*PED	Sep 27, 2012				
	6469012	Oct 22, 2019	U-155			
	6469012*PED	Apr 22, 2020				
SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC						
N202343 001	8168637	Jun 26, 2022	DP U-1188			
SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC						
N202343 002	8168637	Jun 26, 2022	DP U-1188			
SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC						
N202343 003	8168637	Jun 26, 2022	DP U-1188			
SODIUM NITRITE - SODIUM NITRITE						
N203922 001					ODE	Jan 14, 2018
SODIUM THIOSULFATE - SODIUM THIOSULFATE						
N203923 001					ODE	Jan 14, 2018
SUMATRIPTAN SUCCINATE - SUMAVEL DOSEPRO						
N022239 001	8118771	Aug 10, 2023	DP			
TAFLUPROST - ZIOPTAN						
N202514 001	5886035	Dec 18, 2017	DS DP U-778		NCE	Feb 10, 2017
TALIGLUCERASE ALFA - ELELYSO						
N022458 001					NCE	May 01, 2017
TAPENTADOL HYDROCHLORIDE - NUCYNTA ER						
N200533 001	8114383	Oct 10, 2024	DP			
TAPENTADOL HYDROCHLORIDE - NUCYNTA ER						
N200533 002	8114383	Oct 10, 2024	DP			
TAPENTADOL HYDROCHLORIDE - NUCYNTA ER						
N200533 003	8114383	Oct 10, 2024	DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TAPENTADOL HYDROCHLORIDE - NUCYNTA ER						
N200533 004	8114383	Oct 10, 2024	DP			
TAPENTADOL HYDROCHLORIDE - NUCYNTA ER						
N200533 005	8114383	Oct 10, 2024	DP			
TAZAROTENE - FABIOR						
N202428 001					NDF	May 11, 2015
TELAVANCIN HYDROCHLORIDE - VIBATIV						
N022110 001	8101575	May 01, 2021	DP			
	8158580	May 01, 2021	DP			
TELAVANCIN HYDROCHLORIDE - VIBATIV						
N022110 002	8101575	May 01, 2021	DP			
	8158580	May 01, 2021	DP			
TELBIVUDINE - TYZEKA						
N022154 001	7858594	Sep 11, 2023	DS DP U-999			
TEMSIROLIMUS - TORISEL						
N022088 001	5362718	Apr 18, 2014	DS DP		M-92	Jul 09, 2013
	5362718*PED	Oct 18, 2014			M-91	Apr 26, 2013
	8026276	Jan 20, 2026	DP		ODE	May 30, 2014
	8026276*PED	Jul 20, 2026			PED	Nov 30, 2014
					PED	Jan 09, 2014
					PED	Oct 26, 2013
TENOFOVIR DISOPROXIL FUMARATE - VIREAD						
N021356 001					NPP	Jan 18, 2015
					PED	Jul 18, 2015
TENOFOVIR DISOPROXIL FUMARATE - VIREAD						
N021356 002	5922695	Jul 25, 2017	DS U-250		M-95	Oct 01, 2013
	5922695	Jul 25, 2017	DS U-256		NPP	Jan 18, 2015
	5922695	Jul 25, 2017	DS U-999		NPP	Mar 24, 2013
	5922695	Jul 25, 2017	DS U-248		ODE	Mar 24, 2017
	5922695*PED	Jan 25, 2018			PED	Sep 24, 2017
	5935946	Jul 25, 2017	DS DP U-999		PED	Jul 18, 2015
	5935946	Jul 25, 2017	DS DP U-248		PED	Apr 01, 2014
	5935946	Jul 25, 2017	DS DP U-250		PED	Sep 24, 2013
	5935946	Jul 25, 2017	DS DP U-256			
	5935946*PED	Jan 25, 2018				
	5977089	Jul 25, 2017	DS DP U-250			
	5977089	Jul 25, 2017	DS DP U-256			
	5977089	Jul 25, 2017	DS DP U-999			
	5977089	Jul 25, 2017	DS DP U-248			
	5977089*PED	Jan 25, 2018				
	6043230	Jul 25, 2017	U-248			
	6043230	Jul 25, 2017	U-250			
	6043230	Jul 25, 2017	U-256			
	6043230	Jul 25, 2017	U-999			
	6043230*PED	Jan 25, 2018				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TENOFOVIR DISOPROXIL FUMARATE - VIREAD						
N021356 003	5922695	Jul 25, 2017	DS U-250		M-95	Oct 01, 2013
	5922695	Jul 25, 2017	DS U-256		NPP	Jan 18, 2015
	5922695	Jul 25, 2017	DS U-999		NPP	Mar 24, 2013
	5922695	Jul 25, 2017	DS U-248		ODE	Mar 24, 2017
	5922695*PED	Jan 25, 2018			PED	Sep 24, 2017
	5935946	Jul 25, 2017	DS DP U-999		PED	Jul 18, 2015
	5935946	Jul 25, 2017	DS DP U-248		PED	Apr 01, 2014
	5935946	Jul 25, 2017	DS DP U-250		PED	Sep 24, 2013
	5935946	Jul 25, 2017	DS DP U-256			
	5935946*PED	Jan 25, 2018				
	5977089	Jul 25, 2017	DS DP U-250			
	5977089	Jul 25, 2017	DS DP U-256			
	5977089	Jul 25, 2017	DS DP U-999			
	5977089	Jul 25, 2017	DS DP U-248			
	5977089*PED	Jan 25, 2018				
	6043230	Jul 25, 2017	U-248			
	6043230	Jul 25, 2017	U-250			
	6043230	Jul 25, 2017	U-256			
	6043230	Jul 25, 2017	U-999			
	6043230*PED	Jan 25, 2018				
TENOFOVIR DISOPROXIL FUMARATE - VIREAD						
N021356 004	5922695	Jul 25, 2017	DS U-250		M-95	Oct 01, 2013
	5922695	Jul 25, 2017	DS U-256		NPP	Jan 18, 2015
	5922695	Jul 25, 2017	DS U-999		NPP	Mar 24, 2013
	5922695	Jul 25, 2017	DS U-248		ODE	Mar 24, 2017
	5922695*PED	Jan 25, 2018			PED	Sep 24, 2017
	5935946	Jul 25, 2017	DS DP U-999		PED	Jul 18, 2015
	5935946	Jul 25, 2017	DS DP U-248		PED	Apr 01, 2014
	5935946	Jul 25, 2017	DS DP U-250		PED	Sep 24, 2013
	5935946	Jul 25, 2017	DS DP U-256			
	5935946*PED	Jan 25, 2018				
	5977089	Jul 25, 2017	DS DP U-250			
	5977089	Jul 25, 2017	DS DP U-256			
	5977089	Jul 25, 2017	DS DP U-999			
	5977089	Jul 25, 2017	DS DP U-248			
	5977089*PED	Jan 25, 2018				
	6043230	Jul 25, 2017	U-248			
	6043230	Jul 25, 2017	U-250			
	6043230	Jul 25, 2017	U-256			
	6043230	Jul 25, 2017	U-999			
	6043230*PED	Jan 25, 2018				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TENOFOVIR DISOPROXIL FUMARATE - VIREAD						
N022577 001	5922695	Jul 25, 2017	DS U-250		M-95	Oct 01, 2013
	5922695	Jul 25, 2017	DS U-256		NPP	Mar 24, 2013
	5922695	Jul 25, 2017	DS U-999		NDF	Jan 18, 2015
	5922695	Jul 25, 2017	DS U-248		ODE	Mar 24, 2017
	5922695*PED	Jan 25, 2018			PED	Sep 24, 2017
	5935946	Jul 25, 2017	DP U-999	Y	PED	Jul 18, 2015
	5935946	Jul 25, 2017	DP U-248	Y	PED	Apr 01, 2014
	5935946	Jul 25, 2017	DP U-250	Y	PED	Sep 24, 2013
	5935946	Jul 25, 2017	DP U-256	Y		
	5935946*PED	Jan 25, 2018				
	5977089	Jul 25, 2017	DS DP U-250			
	5977089	Jul 25, 2017	DS DP U-256			
	5977089	Jul 25, 2017	DS DP U-999			
	5977089	Jul 25, 2017	DS DP U-248			
	5977089*PED	Jan 25, 2018				
	6043230	Jul 25, 2017	U-248			
	6043230	Jul 25, 2017	U-250			
	6043230	Jul 25, 2017	U-256			
	6043230	Jul 25, 2017	U-999			
	6043230*PED	Jan 25, 2018				
TESAMORELIN ACETATE - EGRIFTA						
N022505 002					NCE	Nov 10, 2015
TESTOSTERONE - TESTIM						
N021454 001	8178518	Apr 21, 2023	DP			
TESTOSTERONE - TESTOSTERONE						
N202763 001					NP	Feb 14, 2015
THALIDOMIDE - THALOMID						
N020785 001	8143283	Mar 01, 2013	U-1236			
	8204763	Aug 28, 2018	U-1249			
THALIDOMIDE - THALOMID						
N020785 002	8143283	Mar 01, 2013	U-1236			
	8204763	Aug 28, 2018	U-1249			
THALIDOMIDE - THALOMID						
N020785 003	8143283	Mar 01, 2013	U-1236			
	8204763	Aug 28, 2018	U-1249			
THALIDOMIDE - THALOMID						
N020785 004	8143283	Mar 01, 2013	U-1236			
	8204763	Aug 28, 2018	U-1249			
TIZANIDINE HYDROCHLORIDE - ZANAFLEX						
N021447 001	**>A>** 6455557	Nov 28, 2021		Y		
TIZANIDINE HYDROCHLORIDE - ZANAFLEX						
N021447 002	**>A>** 6455557	Nov 28, 2021		Y		
TIZANIDINE HYDROCHLORIDE - ZANAFLEX						
N021447 003	**>A>** 6455557	Nov 28, 2021		Y		

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TOPIRAMATE - TOPAMAX						
N020505 001					NPP	Jul 15, 2014
TOPIRAMATE - TOPAMAX						
N020505 002					NPP	Jul 15, 2014
TOPIRAMATE - TOPAMAX						
N020505 004					NPP	Jul 15, 2014
TOPIRAMATE - TOPAMAX						
N020505 005					NPP	Jul 15, 2014
TOPIRAMATE - TOPAMAX						
N020844 001					NPP	Jul 15, 2014
TOPIRAMATE - TOPAMAX						
N020844 002					NPP	Jul 15, 2014
TOPOTECAN HYDROCHLORIDE - HYCAMTIN						
N020981 001	8158645	Dec 10, 2024	DP			
TOPOTECAN HYDROCHLORIDE - HYCAMTIN						
N020981 002	8158645	Dec 10, 2024	DP			
TRAMADOL HYDROCHLORIDE - TRAMADOL HYDROCHLORIDE						
A091607 001					PC	Jun 27, 2012
TRAMADOL HYDROCHLORIDE - TRAMADOL HYDROCHLORIDE						
A091607 002					PC	Jun 27, 2012
TRAMADOL HYDROCHLORIDE - TRAMADOL HYDROCHLORIDE						
A091607 003					PC	Jun 27, 2012
TRAZODONE HYDROCHLORIDE - OLEPTRO						
N022411 001	8133893	Mar 13, 2029	DS DP			
TRAZODONE HYDROCHLORIDE - OLEPTRO						
N022411 002	8133893	Mar 13, 2029	DS DP			
TRIAMCINOLONE ACETONIDE - TRIESENCE						
N022048 001	8128960	Dec 17, 2029	DP			
	>A> 8211880	Mar 10, 2029	U-1258			
	>A> 8211880	Mar 10, 2029	U-1257			
TRYPAN BLUE - MEMBRANEBLUE						
N022278 001					**>A>** ODE	Feb 20, 2016
VEMURAFENIB - ZELBORAF						
N202429 001	8143271	Jun 21, 2026	DS DP			
VILAZODONE HYDROCHLORIDE - VIIBRYD						
N022567 001	8193195	Jun 05, 2022	U-839			
	>A> 8236804	Jun 05, 2022	U-839			
VILAZODONE HYDROCHLORIDE - VIIBRYD						
N022567 002	8193195	Jun 05, 2022	U-839			
	>A> 8236804	Jun 05, 2022	U-839			
VILAZODONE HYDROCHLORIDE - VIIBRYD						
N022567 003	8193195	Jun 05, 2022	U-839			
	>A> 8236804	Jun 05, 2022	U-839			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
VISMODEGIB - ERIVEDGE						
N203388 001					NCE	Jan 30, 2017
VORINOSTAT - ZOLINZA						
N021991 001	8093295	May 16, 2026	DP			
	8101663	Mar 04, 2023	U-892			
ZIPRASIDONE HYDROCHLORIDE - ZIPRASIDONE HYDROCHLORIDE						
A077560 001					PC	Aug 29, 2012
ZIPRASIDONE HYDROCHLORIDE - ZIPRASIDONE HYDROCHLORIDE						
A077560 002					PC	Aug 29, 2012
ZIPRASIDONE HYDROCHLORIDE - ZIPRASIDONE HYDROCHLORIDE						
A077560 003					PC	Aug 29, 2012
ZIPRASIDONE HYDROCHLORIDE - ZIPRASIDONE HYDROCHLORIDE						
A077560 004					PC	Aug 29, 2012

Footnote:

1. Patents are published upon receipt by the Orange Book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).
2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 31st Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/docs/pattermsall.cfm

The current complete list of patent terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/docs/excltermsall.cfm